

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview for Request: cder_mpl1r_wp256

Request ID: cder_mpl1r_wp256_nsdv_v01

Request Description: In this report we characterized dispensing and administration patterns of 23 New Molecular Entities (NMEs) approved from July 1, 2021 to December 31, 2021, stratified by age and sex in the Sentinel Distributed Database (SDD).

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis module (CIDA), version 12.1.2.

Data Source: We distributed this request to 13 Sentinel Data Partners on November 20, 2023. The study year included data from January 1, 2021 to most recent data available. Please see Appendix A for a list of dates of available data for each Data Partner.

Study Design: We identified individuals initiating any of the 23 NMEs drugs. We described demographic and clinical characteristics for individuals initiating each NME based on history recorded in the six months prior to initiation of treatment with NME. The analyses characterized dispensing patterns by examining cumulative exposure episode durations, first exposure episode durations, all exposure episode durations, days supplied per dispensing, and lengths of gaps between episodes, overall and stratified by age and sex. This was a Type 5 analysis in the Query Request Package (QRP) documentation.¹

Exposures of Interest: Our exposures of interest were NMEs approved between July 1, 2021 to December 31, 2021, administered or dispensed in any care setting. These were defined using Healthcare Common Procedure Coding System (HCPCS) procedure codes and National Drug Codes (NDCs). Please see Appendix B for a list of non-proprietary and proprietary names of medical products and Appendix C for a list of procedure codes used to define exposures in this request. All valid exposure episodes were included.

Cohort Eligibility Criteria: We defined index exposure as the first qualifying administration or dispensing of a given NME to an individual during the query year. We required individuals to be enrolled in health plans with both medical and drug coverage for at least 183 days prior to their index exposure, during which gaps in coverage of up to 45 days were allowed. The following age groups were included: 0-17, 18-24, 25-40, 41-64, 65+ years.

Baseline Characteristics: We described demographic characteristics such as sex, age, and calendar year on the day of each index NME exposure. We also described 31 clinical characteristics based on history recorded in the six months prior to the index exposure. The set of clinical characteristics included 24 chronic conditions and seven lifestyle-related conditions. Chronic conditions were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse² (CCW) algorithms and included: acute myocardial infarction, Alzheimer's disease and related conditions, atrial fibrillation, diabetes mellitus, heart failure, hyperlipidemia, hypertension, depression, ischemic heart disease, rheumatoid arthritis/osteoarthritis, stroke/transient ischemic attack (TIA), breast cancer, colorectal cancer, prostate cancer, lung cancer, endometrial cancer, acquired hypothyroidism, anemia, asthma, benign prostatic hyperplasia, chronic kidney disease, chronic obstructive pulmonary disease (COPD) and bronchiectasis, glaucoma, and osteoporosis. Lifestyle-related conditions included: obesity, overweight, smoking, alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, and history of coronary angioplasty or bypass. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes, International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) procedure codes, HCPCS procedure codes, Current Procedural Terminology, Fourth Edition (CPT-4) procedure codes, and NDCs were used to define the clinical characteristics. Please see Appendix D for a list of diagnosis and procedure codes, Appendix E for a list of non-proprietary and proprietary names of medical products used to define baseline characteristics in this request.

Please refer to Appendices F, G, and H for the specifications of parameters used in this request, baseline characteristics used in this request, and a design diagram.

Limitations: Algorithms used to define exposures and inclusion criteria are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

Overview for Request: cder_mpl1r_wp256

Notes: Please contact the Sentinel Operations Center (info@sentinelssystem.org) for questions and to provide comments/suggestions for future enhancements to this document.

¹For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinelssystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse>).

²Chronic Conditions Data Warehouse. Condition Categories -Chronic Conditions Data Warehouse. (<https://www.ccwdata.org/web/guest/condition-categories>)

Table of Contents

<u>Glossary (CIDA)</u>	List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report
<u>Table 1a</u>	Aggregated Characteristics of Finerenone in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 1b</u>	Aggregated Characteristics of Fexinidazole in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 1c</u>	Aggregated Characteristics of Belumosudil in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 1d</u>	Aggregated Characteristics of Odevixibat in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 1e</u>	Aggregated Characteristics of Anifrolumab-Fnia in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 1f</u>	Aggregated Characteristics of Avalglucosidase Alfa-Ngpt in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 1g</u>	Aggregated Characteristics of Belzutifan in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 1h</u>	Aggregated Characteristics of Difelikefalin in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 1i</u>	Aggregated Characteristics of Lonapegsomatropin-Tcgd in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 1j</u>	Aggregated Characteristics of Mobocertinib in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 1k</u>	Aggregated Characteristics of Tisotumab Vedotin-Tftv in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 1l</u>	Aggregated Characteristics of Atogepant in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 1m</u>	Aggregated Characteristics of Maralixibat in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 1n</u>	Aggregated Characteristics of Avacopan in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 1o</u>	Aggregated Characteristics of Asciminib in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 1p</u>	Aggregated Characteristics of Ropeginterferon Alfa-2b-Njft in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 1q</u>	Aggregated Characteristics of Vosoritide in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 1r</u>	Aggregated Characteristics of Maribavir in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 1s</u>	Aggregated Characteristics of Pafolacianine in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 1t</u>	Aggregated Characteristics of Tezepelumab-Ekko in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 1u</u>	Aggregated Characteristics of Efgartigimod Alfa-Fcab in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 1v</u>	Aggregated Characteristics of Inclisiran in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 1w</u>	Aggregated Characteristics of Tralokinumab-Ldrm in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 2a</u>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Table of Contents

<u>Table 2b</u>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 2c</u>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex
<u>Table 2d</u>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex
<u>Table 2e</u>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group
<u>Table 2f</u>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group
<u>Table 3a</u>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 3b</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 3c</u>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex
<u>Table 3d</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex
<u>Table 3e</u>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group
<u>Table 3f</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group
<u>Table 4a</u>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 4b</u>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 4c</u>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex
<u>Table 4d</u>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex
<u>Table 4e</u>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group
<u>Table 4f</u>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group
<u>Table 5a</u>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 5b</u>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 5c</u>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex
<u>Table 5d</u>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex
<u>Table 5e</u>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group
<u>Table 5f</u>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group
<u>Table 6a</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Table of Contents

<u>Table 6b</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 6c</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex
<u>Table 6d</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex
<u>Table 6e</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group
<u>Table 6f</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group
<u>Table 7a</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 7b</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex
<u>Table 7c</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group
<u>Table 8a</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 8b</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex
<u>Table 8c</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group
<u>Table 9</u>	Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Table 10</u>	Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Figure 1a</u>	Patient Entry into Study by Month for Finerenone in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Figure 1b</u>	Patient Entry into Study by Month for Fexinidazole in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Figure 1c</u>	Patient Entry into Study by Month for Belumosudil in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Figure 1d</u>	Patient Entry into Study by Month for Odevixibat in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Figure 1e</u>	Patient Entry into Study by Month for Anifrolumab-Fnia in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Figure 1f</u>	Patient Entry into Study by Month for Avalglucosidase Alfa-Ngpt in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Figure 1g</u>	Patient Entry into Study by Month for Belzutifan in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Figure 1h</u>	Patient Entry into Study by Month for Difelikefalin in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Figure 1i</u>	Patient Entry into Study by Month for Lonapegsomatropin-Tcgd in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Figure 1j</u>	Patient Entry into Study by Month for Mobocertinib in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Figure 1k</u>	Patient Entry into Study by Month for Tisotumab Vedotin-Tftv in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Table of Contents

<u>Figure 1l</u>	Patient Entry into Study by Month for Atogepant in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Figure 1m</u>	Patient Entry into Study by Month for Maralixibat in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Figure 1n</u>	Patient Entry into Study by Month for Avacopan in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Figure 1o</u>	Patient Entry into Study by Month for Asciminib in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Figure 1p</u>	Patient Entry into Study by Month for Ropeginterferon Alfa-2b-Njft in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Figure 1q</u>	Patient Entry into Study by Month for Vosoritide in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Figure 1r</u>	Patient Entry into Study by Month for Maribavir in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Figure 1s</u>	Patient Entry into Study by Month for Pafolacianine in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Figure 1t</u>	Patient Entry into Study by Month for Tezepelumab-Ekko in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Figure 1u</u>	Patient Entry into Study by Month for Efgartigimod Alfa-Fcab in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Figure 1v</u>	Patient Entry into Study by Month for Inclisiran in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Figure 1w</u>	Patient Entry into Study by Month for Tralokinumab-Ldrm in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023
<u>Appendix A</u>	Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (November 20, 2023)
<u>Appendix B</u>	List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Exposures in this Request
<u>Appendix C</u>	List of Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Exposures in this Request
<u>Appendix D</u>	List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request
<u>Appendix E</u>	List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request
<u>Appendix F</u>	Specifications Defining Parameters for this Request
<u>Appendix G</u>	Specifications Defining Parameters for Baseline Characteristics in this Request
<u>Appendix H</u>	Query Design Diagram for this Request

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout year - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout year, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded.

Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation year in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query year; 02: Cohort includes all valid treatment episodes during the query year; 03: Cohort includes all valid treatment episodes during the query year until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout years) with drug and medical coverage during the query year.

Enrollment Gap - number of days allowed between two consecutive enrollment years without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension year - number of days post treatment year in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback year - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Member-Years - Number of all days of enrollment with medical and drug coverage in the query year preceded by an exposure washout year all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring year - used to define time years of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query year - year in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout year (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout year (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension years all divided by 365.25.

*all terms may not be used in this report

Table 1a. Aggregated Characteristics of Finerenone in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	19,188	N/A
Demographic Characteristics		
Age (years)	71.7	9.5
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	3,585	18.7%
≥ 65 years	15,413	80.3%
Sex		
Female	8,625	44.9%
Male	10,563	55.1%
Race ²		
American Indian or Alaska Native	50	0.3%
Asian	1,987	10.4%
Black or African American	2,400	12.5%
Multi-racial	89	0.5%
Native Hawaiian or Other Pacific Islander	49	0.3%
Unknown	4,505	23.5%
White	10,108	52.7%
Hispanic origin		
Yes	958	5.0%
No	13,102	68.3%
Unknown	5,128	26.7%
Year		
2021	1,113	5.8%
2022	12,754	66.5%
2023	5,321	27.7%
Health Characteristics		
Acute Myocardial Infarction	193	1.0%
Alzheimer's Disease and related conditions	911	4.7%
Atrial Fibrillation	2,263	11.8%
Diabetes Mellitus	16,893	88.0%
Heart Failure	4,404	23.0%
Hyperlipidemia	13,609	70.9%
Hypertension	16,433	85.6%
Depression	3,119	16.3%

Table 1a. Aggregated Characteristics of Finerenone in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Ischemic Heart Disease	6,813	35.5%
Rheumatoid Arthritis/Osteoarthritis	3,717	19.4%
Stroke/TIA	751	3.9%
Breast Cancer	366	1.9%
Colorectal Cancer	165	0.9%
Prostate Cancer	527	2.7%
Lung Cancer	120	0.6%
Endometrial Cancer	40	0.2%
Acquired Hypothyroidism	3,180	16.6%
Anemia	7,297	38.0%
Asthma	796	4.1%
Benign Prostatic Hyperplasia	1,909	9.9%
Chronic Kidney Disease	13,693	71.4%
COPD and Bronchiectasis	1,958	10.2%
Glaucoma	3,154	16.4%
Osteoporosis	953	5.0%
Obesity: diagnosed or identified by weight management procedures	7,141	37.2%
Obesity: identified by weight management-related prescriptions	504	2.6%
Overweight	2,568	13.4%
Smoking: diagnosed or identified by smoking cessation procedures	1,368	7.1%
Smoking: identified by smoking-related prescriptions	65	0.3%
Alcohol Abuse or Dependence	217	1.1%
Drug Abuse or Dependence	408	2.1%
History of Cardiac Arrest	30	0.2%
History of Coronary Angioplasty or Bypass	2,007	10.5%

Table 1a. Aggregated Characteristics of Finerenone in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.1	11.0
Mean number of emergency room encounters	0.3	1.0
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	4.7	8.2
Mean number of filled prescriptions	31.2	23.5
Mean number of generics dispensed	12.4	5.7
Mean number of unique drug classes dispensed	11.1	5.0

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1b. Aggregated Characteristics of Fexinidazole in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	.	.
Age		
0-17 years	.	.
18-24 years	.	.
25-40 years	.	.
41-64 years	.	.
≥ 65 years	.	.
Sex		
Female	.	.
Male	.	.
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	.	.
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	.	.
Year		
2021	.	.
2022	.	.
2023	.	.
Health Characteristics		
Acute Myocardial Infarction	.	.
Alzheimer’s Disease and related conditions	.	.
Atrial Fibrillation	.	.
Diabetes Mellitus	.	.
Heart Failure	.	.
Hyperlipidemia	.	.
Hypertension	.	.
Depression	.	.

Table 1b. Aggregated Characteristics of Fexinidazole in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Ischemic Heart Disease	.	.
Rheumatoid Arthritis/Osteoarthritis	.	.
Stroke/TIA	.	.
Breast Cancer	.	.
Colorectal Cancer	.	.
Prostate Cancer	.	.
Lung Cancer	.	.
Endometrial Cancer	.	.
Acquired Hypothyroidism	.	.
Anemia	.	.
Asthma	.	.
Benign Prostatic Hyperplasia	.	.
Chronic Kidney Disease	.	.
COPD and Bronchiectasis	.	.
Glaucoma	.	.
Osteoporosis	.	.
Obesity: diagnosed or identified by weight management procedures	.	.
Obesity: identified by weight management-related prescriptions	.	.
Overweight	.	.
Smoking: diagnosed or identified by smoking cessation procedures	.	.
Smoking: identified by smoking-related prescriptions	.	.
Alcohol Abuse or Dependence	.	.
Drug Abuse or Dependence	.	.
History of Cardiac Arrest	.	.
History of Coronary Angioplasty or Bypass	.	.

Table 1b. Aggregated Characteristics of Fexinidazole in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	.	.
Mean number of emergency room encounters	.	.
Mean number of inpatient hospital encounters	.	.
Mean number of non-acute institutional encounters	.	.
Mean number of other ambulatory encounters	.	.
Mean number of filled prescriptions	.	.
Mean number of generics dispensed	.	.
Mean number of unique drug classes dispensed	.	.

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

N/A: Not Applicable

Table 1c. Aggregated Characteristics of Belumosudil in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	810	N/A
Demographic Characteristics		
Age (years)	58.9	14.5
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	114	14.1%
41-64 years	290	35.8%
≥ 65 years	388	47.9%
Sex		
Female	340	42.0%
Male	470	58.0%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	35	4.3%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	252	31.1%
White	502	62.0%
Hispanic origin		
Yes	35	4.3%
No	522	64.4%
Unknown	253	31.2%
Year		
2021	293	36.2%
2022	431	53.2%
2023	86	10.6%
Health Characteristics		
Acute Myocardial Infarction	11	1.4%
Alzheimer's Disease and related conditions	20	2.5%
Atrial Fibrillation	82	10.1%
Diabetes Mellitus	196	24.2%
Heart Failure	109	13.5%
Hyperlipidemia	276	34.1%
Hypertension	389	48.0%
Depression	231	28.5%

Table 1c. Aggregated Characteristics of Belumosudil in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Ischemic Heart Disease	159	19.6%
Rheumatoid Arthritis/Osteoarthritis	100	12.3%
Stroke/TIA	20	2.5%
Breast Cancer	15	1.9%
Colorectal Cancer	*****	*****
Prostate Cancer	21	2.6%
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	119	14.7%
Anemia	498	61.5%
Asthma	51	6.3%
Benign Prostatic Hyperplasia	61	7.5%
Chronic Kidney Disease	230	28.4%
COPD and Bronchiectasis	152	18.8%
Glaucoma	89	11.0%
Osteoporosis	109	13.5%
Obesity: diagnosed or identified by weight management procedures	82	10.1%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	64	7.9%
Smoking: diagnosed or identified by smoking cessation procedures	32	4.0%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	13	1.6%
Drug Abuse or Dependence	31	3.8%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	22	2.7%

Table 1c. Aggregated Characteristics of Belumosudil in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	28.8	19.5
Mean number of emergency room encounters	0.5	2.0
Mean number of inpatient hospital encounters	0.7	1.3
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	11.2	17.8
Mean number of filled prescriptions	40.0	23.3
Mean number of generics dispensed	15.2	7.3
Mean number of unique drug classes dispensed	14.1	6.4

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1d. Aggregated Characteristics of Odevixibat in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	11	N/A
Demographic Characteristics		
Age (years)	14.4	10.7
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	0	0.0%
≥ 65 years	0	0.0%
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	*****	*****
Year		
2021	*****	*****
2022	*****	*****
2023	*****	*****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	0	0.0%
Heart Failure	0	0.0%
Hyperlipidemia	0	0.0%
Hypertension	0	0.0%
Depression	*****	*****

Table 1d. Aggregated Characteristics of Odevixibat in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/TIA	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	0	0.0%
Asthma	0	0.0%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	0	0.0%
COPD and Bronchiectasis	0	0.0%
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	0	0.0%
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	0	0.0%
Smoking: diagnosed or identified by smoking cessation procedures	0	0.0%
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%

Table 1d. Aggregated Characteristics of Odevixibat in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	10.7	7.3
Mean number of emergency room encounters	0.6	0.8
Mean number of inpatient hospital encounters	0.2	0.6
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	17.5	19.6
Mean number of filled prescriptions	20.7	18.5
Mean number of generics dispensed	5.7	3.6
Mean number of unique drug classes dispensed	5.2	3.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1e. Aggregated Characteristics of Anifrolumab-Fnia in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	1,539	N/A
Demographic Characteristics		
Age (years)	53.6	13.3
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	293	19.0%
41-64 years	761	49.4%
≥ 65 years	446	29.0%
Sex		
Female	1,444	93.8%
Male	95	6.2%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	233	15.1%
Multi-racial	26	1.7%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	557	36.2%
White	699	45.4%
Hispanic origin		
Yes	87	5.7%
No	799	51.9%
Unknown	653	42.4%
Year		
2021	66	4.3%
2022	1,181	76.7%
2023	292	19.0%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	19	1.2%
Atrial Fibrillation	56	3.6%
Diabetes Mellitus	193	12.5%
Heart Failure	124	8.1%
Hyperlipidemia	345	22.4%
Hypertension	594	38.6%

Table 1e. Aggregated Characteristics of Anifrolumab-Fnia in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Depression	520	33.8%
Ischemic Heart Disease	192	12.5%
Rheumatoid Arthritis/Osteoarthritis	624	40.5%
Stroke/TIA	43	2.8%
Breast Cancer	21	1.4%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	270	17.5%
Anemia	497	32.3%
Asthma	156	10.1%
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	251	16.3%
COPD and Bronchiectasis	93	6.0%
Glaucoma	98	6.4%
Osteoporosis	194	12.6%
Obesity: diagnosed or identified by weight management procedures	441	28.7%
Obesity: identified by weight management-related prescriptions	12	0.8%
Overweight	161	10.5%
Smoking: diagnosed or identified by smoking cessation procedures	128	8.3%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	26	1.7%
Drug Abuse or Dependence	114	7.4%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	22	1.4%

Table 1e. Aggregated Characteristics of Anifrolumab-Fnia in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.9	15.8
Mean number of emergency room encounters	0.6	1.4
Mean number of inpatient hospital encounters	0.1	0.5
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	5.2	7.8
Mean number of filled prescriptions	29.9	23.3
Mean number of generics dispensed	12.1	7.0
Mean number of unique drug classes dispensed	11.3	6.3

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1f. Aggregated Characteristics of Avalglucosidase Alfa-Ngpt in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	137	N/A
Demographic Characteristics		
Age (years)	57.1	14.8
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	50	36.5%
≥ 65 years	62	45.3%
Sex		
Female	73	53.3%
Male	64	46.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	96	70.1%
Hispanic origin		
Yes	0	0.0%
No	91	66.4%
Unknown	46	33.6%
Year		
2021	*****	*****
2022	112	81.8%
2023	*****	*****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	12	8.8%
Heart Failure	12	8.8%
Hyperlipidemia	26	19.0%
Hypertension	42	30.7%

Table 1f. Aggregated Characteristics of Avalglucosidase Alfa-Ngpt in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Depression	31	22.6%
Ischemic Heart Disease	14	10.2%
Rheumatoid Arthritis/Osteoarthritis	11	8.0%
Stroke/TIA	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	14	10.2%
Anemia	15	10.9%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	*****	*****
COPD and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	12	8.8%
Obesity: diagnosed or identified by weight management procedures	19	13.9%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	22.0	16.3
Mean number of emergency room encounters	0.2	0.5
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	6.2	7.5
Mean number of filled prescriptions	13.9	12.7
Mean number of generics dispensed	5.6	4.4
Mean number of unique drug classes dispensed	5.3	4.1

Table 1f. Aggregated Characteristics of Avalglucosidase Alfa-Ngpt in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
--------------------------------	--------------------	--

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

N/A: Not Applicable

Table 1g. Aggregated Characteristics of Belzutifan in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	276	N/A
Demographic Characteristics		
Age (years)	56.6	15.6
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	109	39.5%
≥ 65 years	108	39.1%
Sex		
Female	90	32.6%
Male	186	67.4%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	15	5.4%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	90	32.6%
White	158	57.2%
Hispanic origin		
Yes	13	4.7%
No	166	60.1%
Unknown	97	35.1%
Year		
2021	68	24.6%
2022	152	55.1%
2023	56	20.3%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	18	6.5%
Diabetes Mellitus	63	22.8%
Heart Failure	28	10.1%
Hyperlipidemia	80	29.0%
Hypertension	134	48.6%
Depression	60	21.7%

Table 1g. Aggregated Characteristics of Belzutifan in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Ischemic Heart Disease	39	14.1%
Rheumatoid Arthritis/Osteoarthritis	29	10.5%
Stroke/TIA	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	11	4.0%
Lung Cancer	12	4.3%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	72	26.1%
Anemia	97	35.1%
Asthma	11	4.0%
Benign Prostatic Hyperplasia	20	7.2%
Chronic Kidney Disease	203	73.6%
COPD and Bronchiectasis	16	5.8%
Glaucoma	24	8.7%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	39	14.1%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	28	10.1%
Smoking: diagnosed or identified by smoking cessation procedures	20	7.2%
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	11	4.0%

Table 1g. Aggregated Characteristics of Belzutifan in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	22.1	16.3
Mean number of emergency room encounters	0.5	0.9
Mean number of inpatient hospital encounters	0.5	0.9
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	6.6	8.1
Mean number of filled prescriptions	22.6	17.6
Mean number of generics dispensed	9.6	6.1
Mean number of unique drug classes dispensed	8.9	5.5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

N/A: Not Applicable

Table 1h. Aggregated Characteristics of Difelikefalin in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	1,909	N/A
Demographic Characteristics		
Age (years)	65.1	14.0
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	718	37.6%
≥ 65 years	1,068	55.9%
Sex		
Female	893	46.8%
Male	1,016	53.2%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	76	4.0%
Black or African American	624	32.7%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	269	14.1%
White	914	47.9%
Hispanic origin		
Yes	121	6.3%
No	1,528	80.0%
Unknown	260	13.6%
Year		
2021	0	0.0%
2022	1,195	62.6%
2023	714	37.4%
Health Characteristics		
Acute Myocardial Infarction	80	4.2%
Alzheimer's Disease and related conditions	163	8.5%
Atrial Fibrillation	454	23.8%
Diabetes Mellitus	1,193	62.5%
Heart Failure	1,029	53.9%
Hyperlipidemia	1,053	55.2%
Hypertension	1,610	84.3%
Depression	527	27.6%

Table 1h. Aggregated Characteristics of Difelikefalin in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Ischemic Heart Disease	894	46.8%
Rheumatoid Arthritis/Osteoarthritis	364	19.1%
Stroke/TIA	146	7.6%
Breast Cancer	33	1.7%
Colorectal Cancer	22	1.2%
Prostate Cancer	45	2.4%
Lung Cancer	15	0.8%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	334	17.5%
Anemia	1,851	97.0%
Asthma	116	6.1%
Benign Prostatic Hyperplasia	127	6.7%
Chronic Kidney Disease	1,907	99.9%
COPD and Bronchiectasis	371	19.4%
Glaucoma	200	10.5%
Osteoporosis	59	3.1%
Obesity: diagnosed or identified by weight management procedures	559	29.3%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	204	10.7%
Smoking: diagnosed or identified by smoking cessation procedures	251	13.1%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	50	2.6%
Drug Abuse or Dependence	95	5.0%
History of Cardiac Arrest	29	1.5%
History of Coronary Angioplasty or Bypass	338	17.7%

Table 1h. Aggregated Characteristics of Difelikefalin in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	82.8	16.2
Mean number of emergency room encounters	1.3	2.2
Mean number of inpatient hospital encounters	0.8	1.3
Mean number of non-acute institutional encounters	0.2	0.6
Mean number of other ambulatory encounters	19.3	22.1
Mean number of filled prescriptions	26.2	22.5
Mean number of generics dispensed	10.8	6.1
Mean number of unique drug classes dispensed	10.1	5.4

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

N/A: Not Applicable

Table 1i. Aggregated Characteristics of Lonapegsomatropin-Tcgd in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	211	N/A
Demographic Characteristics		
Age (years)	11.6	3.2
Age		
0-17 years	211	100.0%
18-24 years	0	0.0%
25-40 years	0	0.0%
41-64 years	0	0.0%
≥ 65 years	0	0.0%
Sex		
Female	62	29.4%
Male	149	70.6%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	0	0.0%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	176	83.4%
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	*****	*****
Year		
2021	*****	*****
2022	144	68.2%
2023	*****	*****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	0	0.0%
Heart Failure	0	0.0%
Hyperlipidemia	0	0.0%
Hypertension	0	0.0%

Table 1i. Aggregated Characteristics of Lonapegsomatropin-Tcgd in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Depression	11	5.2%
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/TIA	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	*****	*****
Asthma	*****	*****
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	0	0.0%
COPD and Bronchiectasis	*****	*****
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	0	0.0%
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%

Table 1i. Aggregated Characteristics of Lonapegsomatropin-Tcgd in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	8.1	7.6
Mean number of emergency room encounters	0.1	0.3
Mean number of inpatient hospital encounters	0.0	0.1
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	3.5	14.7
Mean number of filled prescriptions	8.3	9.8
Mean number of generics dispensed	2.8	2.7
Mean number of unique drug classes dispensed	2.7	2.5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1j. Aggregated Characteristics of Mobocertinib in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	113	N/A
Demographic Characteristics		
Age (years)	71.7	8.8
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	93	82.3%
Sex		
Female	68	60.2%
Male	45	39.8%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	72	63.7%
Hispanic origin		
Yes	*****	*****
No	77	68.1%
Unknown	*****	*****
Year		
2021	20	17.7%
2022	80	70.8%
2023	13	11.5%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	13	11.5%
Diabetes Mellitus	14	12.4%
Heart Failure	17	15.0%
Hyperlipidemia	39	34.5%
Hypertension	59	52.2%
Depression	14	12.4%

Table 1j. Aggregated Characteristics of Mobocertinib in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Ischemic Heart Disease	29	25.7%
Rheumatoid Arthritis/Osteoarthritis	17	15.0%
Stroke/TIA	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	112	99.1%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	26	23.0%
Anemia	57	50.4%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	30	26.5%
COPD and Bronchiectasis	17	15.0%
Glaucoma	12	10.6%
Osteoporosis	11	9.7%
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	*****	*****
Smoking: diagnosed or identified by smoking cessation procedures	*****	*****
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****

Table 1j. Aggregated Characteristics of Mobocertinib in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	28.7	13.7
Mean number of emergency room encounters	0.5	0.8
Mean number of inpatient hospital encounters	0.5	0.9
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	9.7	10.3
Mean number of filled prescriptions	27.4	26.0
Mean number of generics dispensed	11.6	6.1
Mean number of unique drug classes dispensed	10.5	5.0

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

******Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

N/A: Not Applicable

Table 1k. Aggregated Characteristics of Tisotumab Vedotin-Tftv in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	171	N/A
Demographic Characteristics		
Age (years)	60.5	12.0
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	16	9.4%
41-64 years	77	45.0%
≥ 65 years	78	45.6%
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	68	39.8%
White	81	47.4%
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	82	48.0%
Year		
2021	12	7.0%
2022	128	74.9%
2023	31	18.1%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	*****	*****
Diabetes Mellitus	15	8.8%
Heart Failure	*****	*****
Hyperlipidemia	40	23.4%
Hypertension	69	40.4%

Table 1k. Aggregated Characteristics of Tisotumab Vedotin-Tftv in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Depression	46	26.9%
Ischemic Heart Disease	14	8.2%
Rheumatoid Arthritis/Osteoarthritis	18	10.5%
Stroke/TIA	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	0	0.0%
Lung Cancer	*****	*****
Endometrial Cancer	11	6.4%
Acquired Hypothyroidism	37	21.6%
Anemia	94	55.0%
Asthma	*****	*****
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	75	43.9%
COPD and Bronchiectasis	*****	*****
Glaucoma	19	11.1%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	24	14.0%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	12	7.0%
Smoking: diagnosed or identified by smoking cessation procedures	24	14.0%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	16	9.4%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****

Table 1k. Aggregated Characteristics of Tisotumab Vedotin-Tftv in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	29.1	12.9
Mean number of emergency room encounters	1.0	1.6
Mean number of inpatient hospital encounters	0.6	0.9
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	7.5	9.2
Mean number of filled prescriptions	20.8	13.0
Mean number of generics dispensed	10.4	5.0
Mean number of unique drug classes dispensed	9.5	4.3

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

N/A: Not Applicable

Table 1I. Aggregated Characteristics of Atogepant in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	20,012	N/A
Demographic Characteristics		
Age (years)	49.5	13.4
Age		
0-17 years	55	0.3%
18-24 years	1,125	5.6%
25-40 years	4,582	22.9%
41-64 years	10,950	54.7%
≥ 65 years	3,300	16.5%
Sex		
Female	17,049	85.2%
Male	2,963	14.8%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	149	0.7%
Black or African American	711	3.6%
Multi-racial	377	1.9%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	11,119	55.6%
White	7,619	38.1%
Hispanic origin		
Yes	434	2.2%
No	5,715	28.6%
Unknown	13,863	69.3%
Year		
2021	1,063	5.3%
2022	14,969	74.8%
2023	3,980	19.9%
Health Characteristics		
Acute Myocardial Infarction	35	0.2%
Alzheimer's Disease and related conditions	334	1.7%
Atrial Fibrillation	407	2.0%
Diabetes Mellitus	2,230	11.1%
Heart Failure	647	3.2%
Hyperlipidemia	4,243	21.2%
Hypertension	5,003	25.0%
Depression	7,278	36.4%

Table 1I. Aggregated Characteristics of Atogepant in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Ischemic Heart Disease	1,421	7.1%
Rheumatoid Arthritis/Osteoarthritis	4,121	20.6%
Stroke/TIA	518	2.6%
Breast Cancer	278	1.4%
Colorectal Cancer	40	0.2%
Prostate Cancer	56	0.3%
Lung Cancer	54	0.3%
Endometrial Cancer	24	0.1%
Acquired Hypothyroidism	2,286	11.4%
Anemia	2,842	14.2%
Asthma	1,475	7.4%
Benign Prostatic Hyperplasia	235	1.2%
Chronic Kidney Disease	1,041	5.2%
COPD and Bronchiectasis	937	4.7%
Glaucoma	1,001	5.0%
Osteoporosis	626	3.1%
Obesity: diagnosed or identified by weight management procedures	4,933	24.7%
Obesity: identified by weight management-related prescriptions	344	1.7%
Overweight	1,854	9.3%
Smoking: diagnosed or identified by smoking cessation procedures	1,423	7.1%
Smoking: identified by smoking-related prescriptions	116	0.6%
Alcohol Abuse or Dependence	245	1.2%
Drug Abuse or Dependence	1,010	5.0%
History of Cardiac Arrest	13	0.1%
History of Coronary Angioplasty or Bypass	246	1.2%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.8	12.6
Mean number of emergency room encounters	0.5	1.6
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	3.4	6.8
Mean number of filled prescriptions	29.9	24.2
Mean number of generics dispensed	11.5	7.0
Mean number of unique drug classes dispensed	10.5	6.1

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the

Table 1I. Aggregated Characteristics of Atogepant in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
--------------------------------	--------------------	--

cells presented.

N/A: Not Applicable

Table 1m. Aggregated Characteristics of Maralixibat in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	24	N/A
Demographic Characteristics		
Age (years)	11.2	6.4
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	0	0.0%
≥ 65 years	0	0.0%
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	*****	*****
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	*****	*****
Year		
2021	*****	*****
2022	*****	*****
2023	*****	*****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	0	0.0%
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	*****	*****
Heart Failure	0	0.0%
Hyperlipidemia	*****	*****
Hypertension	*****	*****
Depression	*****	*****

Table 1m. Aggregated Characteristics of Maralixibat in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/TIA	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	*****	*****
Asthma	*****	*****
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	*****	*****
COPD and Bronchiectasis	*****	*****
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	0	0.0%
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	0	0.0%
Smoking: diagnosed or identified by smoking cessation procedures	0	0.0%
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	13.0	11.9
Mean number of emergency room encounters	0.4	0.8
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	4.4	7.5
Mean number of filled prescriptions	21.0	12.9
Mean number of generics dispensed	6.9	3.5
Mean number of unique drug classes dispensed	6.3	3.1

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the

Table 1m. Aggregated Characteristics of Maralixibat in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
--------------------------------	--------------------	--

cells presented.

N/A: Not Applicable

Table 1n. Aggregated Characteristics of Avacopan in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	222	N/A
Demographic Characteristics		
Age (years)	62.5	13.2
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	78	35.1%
≥ 65 years	121	54.5%
Sex		
Female	106	47.7%
Male	116	52.3%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	11	5.0%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	78	35.1%
White	122	55.0%
Hispanic origin		
Yes	*****	*****
No	122	55.0%
Unknown	*****	*****
Year		
2021	*****	*****
2022	142	64.0%
2023	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	33	14.9%
Diabetes Mellitus	69	31.1%
Heart Failure	56	25.2%
Hyperlipidemia	112	50.5%
Hypertension	154	69.4%
Depression	50	22.5%

Table 1n. Aggregated Characteristics of Avacopan in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Ischemic Heart Disease	59	26.6%
Rheumatoid Arthritis/Osteoarthritis	54	24.3%
Stroke/TIA	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	34	15.3%
Anemia	141	63.5%
Asthma	26	11.7%
Benign Prostatic Hyperplasia	22	9.9%
Chronic Kidney Disease	161	72.5%
COPD and Bronchiectasis	40	18.0%
Glaucoma	24	10.8%
Osteoporosis	17	7.7%
Obesity: diagnosed or identified by weight management procedures	69	31.1%
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	38	17.1%
Smoking: diagnosed or identified by smoking cessation procedures	17	7.7%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	16	7.2%

Table 1n. Aggregated Characteristics of Avacopan in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	26.3	20.2
Mean number of emergency room encounters	1.2	2.5
Mean number of inpatient hospital encounters	1.0	1.2
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	12.1	13.7
Mean number of filled prescriptions	27.9	16.6
Mean number of generics dispensed	13.1	6.2
Mean number of unique drug classes dispensed	12.2	5.5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1o. Aggregated Characteristics of Asciminib in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	402	N/A
Demographic Characteristics		
Age (years)	62.8	14.8
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	145	36.1%
≥ 65 years	211	52.5%
Sex		
Female	210	52.2%
Male	192	47.8%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	31	7.7%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	112	27.9%
White	247	61.4%
Hispanic origin		
Yes	15	3.7%
No	267	66.4%
Unknown	120	29.9%
Year		
2021	61	15.2%
2022	269	66.9%
2023	72	17.9%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	17	4.2%
Atrial Fibrillation	51	12.7%
Diabetes Mellitus	105	26.1%
Heart Failure	99	24.6%
Hyperlipidemia	158	39.3%
Hypertension	229	57.0%
Depression	108	26.9%

Table 1o. Aggregated Characteristics of Asciminib in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Ischemic Heart Disease	109	27.1%
Rheumatoid Arthritis/Osteoarthritis	89	22.1%
Stroke/TIA	15	3.7%
Breast Cancer	17	4.2%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	11	2.7%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	62	15.4%
Anemia	222	55.2%
Asthma	33	8.2%
Benign Prostatic Hyperplasia	28	7.0%
Chronic Kidney Disease	127	31.6%
COPD and Bronchiectasis	46	11.4%
Glaucoma	32	8.0%
Osteoporosis	23	5.7%
Obesity: diagnosed or identified by weight management procedures	79	19.7%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	56	13.9%
Smoking: diagnosed or identified by smoking cessation procedures	45	11.2%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	40	10.0%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	37	9.2%

Table 1o. Aggregated Characteristics of Asciminib in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	22.0	14.7
Mean number of emergency room encounters	0.9	2.0
Mean number of inpatient hospital encounters	0.6	1.2
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	9.5	14.4
Mean number of filled prescriptions	26.3	20.2
Mean number of generics dispensed	11.1	7.0
Mean number of unique drug classes dispensed	10.2	6.1

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1p. Aggregated Characteristics of Ropeginterferon Alfa-2b-Njft in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	276	N/A
Demographic Characteristics		
Age (years)	64.0	10.6
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	22	8.0%
41-64 years	82	29.7%
≥ 65 years	172	62.3%
Sex		
Female	146	52.9%
Male	130	47.1%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	175	63.4%
Hispanic origin		
Yes	*****	*****
No	152	55.1%
Unknown	*****	*****
Year		
2021	*****	*****
2022	224	81.2%
2023	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	*****	*****
Atrial Fibrillation	16	5.8%
Diabetes Mellitus	24	8.7%
Heart Failure	*****	*****
Hyperlipidemia	72	26.1%
Hypertension	102	37.0%

Table 1p. Aggregated Characteristics of Ropeginterferon Alfa-2b-Njft in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Depression	49	17.8%
Ischemic Heart Disease	50	18.1%
Rheumatoid Arthritis/Osteoarthritis	35	12.7%
Stroke/TIA	*****	*****
Breast Cancer	12	4.3%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	28	10.1%
Anemia	102	37.0%
Asthma	16	5.8%
Benign Prostatic Hyperplasia	22	8.0%
Chronic Kidney Disease	25	9.1%
COPD and Bronchiectasis	*****	*****
Glaucoma	24	8.7%
Osteoporosis	*****	*****
Obesity: diagnosed or identified by weight management procedures	30	10.9%
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	31	11.2%
Smoking: diagnosed or identified by smoking cessation procedures	14	5.1%
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	13	4.7%

Table 1p. Aggregated Characteristics of Ropeginterferon Alfa-2b-Njft in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	18.5	12.0
Mean number of emergency room encounters	0.3	0.7
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	4.6	6.7
Mean number of filled prescriptions	16.0	12.3
Mean number of generics dispensed	7.5	5.1
Mean number of unique drug classes dispensed	7.2	4.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1q. Aggregated Characteristics of Vosoritide in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	36	N/A
Demographic Characteristics		
Age (years)	9.1	3.4
Age		
0-17 years	36	100.0%
18-24 years	0	0.0%
25-40 years	0	0.0%
41-64 years	0	0.0%
≥ 65 years	0	0.0%
Sex		
Female	21	58.3%
Male	15	41.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	*****	*****
Year		
2021	0	0.0%
2022	*****	*****
2023	*****	*****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease and related conditions	0	0.0%

Table 1q. Aggregated Characteristics of Vosoritide in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Atrial Fibrillation	0	0.0%
Diabetes Mellitus	0	0.0%
Heart Failure	0	0.0%
Hyperlipidemia	0	0.0%
Hypertension	0	0.0%
Depression	0	0.0%
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/TIA	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	0	0.0%
Anemia	0	0.0%
Asthma	0	0.0%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	0	0.0%
COPD and Bronchiectasis	0	0.0%
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity: diagnosed or identified by weight management procedures	*****	*****
Obesity: identified by weight management-related prescriptions	0	0.0%
Overweight	0	0.0%
Smoking: diagnosed or identified by smoking cessation procedures	0	0.0%
Smoking: identified by smoking-related prescriptions	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Health Service Utilization Intensity Metrics		

Table 1q. Aggregated Characteristics of Vosoritide in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Mean number of ambulatory encounters	7.3	7.6
Mean number of emergency room encounters	0.0	0.2
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0.0	NaN
Mean number of other ambulatory encounters	1.6	1.6
Mean number of filled prescriptions	2.4	4.0
Mean number of generics dispensed	1.3	1.7
Mean number of unique drug classes dispensed	1.1	1.5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

¹Data presented by a dash, period, or NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

N/A: Not Applicable

Table 1r. Aggregated Characteristics of Maribavir in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	273	N/A
Demographic Characteristics		
Age (years)	54.9	14.2
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	136	49.8%
≥ 65 years	84	30.8%
Sex		
Female	115	42.1%
Male	158	57.9%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	56	20.5%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	94	34.4%
White	112	41.0%
Hispanic origin		
Yes	11	4.0%
No	159	58.2%
Unknown	103	37.7%
Year		
2021	15	5.5%
2022	208	76.2%
2023	50	18.3%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	14	5.1%
Atrial Fibrillation	45	16.5%
Diabetes Mellitus	129	47.3%
Heart Failure	76	27.8%

Table 1r. Aggregated Characteristics of Maribavir in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Hyperlipidemia	131	48.0%
Hypertension	225	82.4%
Depression	69	25.3%
Ischemic Heart Disease	78	28.6%
Rheumatoid Arthritis/Osteoarthritis	19	7.0%
Stroke/TIA	15	5.5%
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	51	18.7%
Anemia	236	86.4%
Asthma	18	6.6%
Benign Prostatic Hyperplasia	22	8.1%
Chronic Kidney Disease	233	85.3%
COPD and Bronchiectasis	29	10.6%
Glaucoma	21	7.7%
Osteoporosis	21	7.7%
Obesity: diagnosed or identified by weight management procedures	78	28.6%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	27	9.9%
Smoking: diagnosed or identified by smoking cessation procedures	11	4.0%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	12	4.4%
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	20	7.3%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	35.7	23.5
Mean number of emergency room encounters	1.2	4.0
Mean number of inpatient hospital encounters	1.7	1.5
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	25.5	28.7

Table 1r. Aggregated Characteristics of Maribavir in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	35.4	16.2
Mean number of generics dispensed	14.5	6.1
Mean number of unique drug classes dispensed	13.4	5.4

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

N/A: Not Applicable

Table 1s. Aggregated Characteristics of Pafolacianine in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	0	N/A
Demographic Characteristics		
Age (years)	.	.
Age		
0-17 years	.	.
18-24 years	.	.
25-40 years	.	.
41-64 years	.	.
≥ 65 years	.	.
Sex		
Female	.	.
Male	.	.
Race ²		
American Indian or Alaska Native	.	.
Asian	.	.
Black or African American	.	.
Multi-racial	.	.
Native Hawaiian or Other Pacific Islander	.	.
Unknown	.	.
White	.	.
Hispanic origin		
Yes	.	.
No	.	.
Unknown	.	.
Year		
2021	.	.
2022	.	.
2023	.	.
Health Characteristics		
Acute Myocardial Infarction	.	.
Alzheimer’s Disease and related conditions	.	.
Atrial Fibrillation	.	.
Diabetes Mellitus	.	.
Heart Failure	.	.

Table 1s. Aggregated Characteristics of Pafolacianine in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Hyperlipidemia	.	.
Hypertension	.	.
Depression	.	.
Ischemic Heart Disease	.	.
Rheumatoid Arthritis/Osteoarthritis	.	.
Stroke/TIA	.	.
Breast Cancer	.	.
Colorectal Cancer	.	.
Prostate Cancer	.	.
Lung Cancer	.	.
Endometrial Cancer	.	.
Acquired Hypothyroidism	.	.
Anemia	.	.
Asthma	.	.
Benign Prostatic Hyperplasia	.	.
Chronic Kidney Disease	.	.
COPD and Bronchiectasis	.	.
Glaucoma	.	.
Osteoporosis	.	.
Obesity: diagnosed or identified by weight management procedures	.	.
Obesity: identified by weight management-related prescriptions	.	.
Overweight	.	.
Smoking: diagnosed or identified by smoking cessation procedures	.	.
Smoking: identified by smoking-related prescriptions	.	.
Alcohol Abuse or Dependence	.	.
Drug Abuse or Dependence	.	.
History of Cardiac Arrest	.	.
History of Coronary Angioplasty or Bypass	.	.
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	.	.
Mean number of emergency room encounters	.	.
Mean number of inpatient hospital encounters	.	.
Mean number of non-acute institutional encounters	.	.
Mean number of other ambulatory encounters	.	.

Table 1s. Aggregated Characteristics of Pafolacianine in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Mean number of filled prescriptions	.	.
Mean number of generics dispensed	.	.
Mean number of unique drug classes dispensed	.	.

¹Value represents standard deviation where no % follows the value.

~ N/A: Not Applicable

Table 1t. Aggregated Characteristics of Tezepelumab-Ekko in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	4,842	N/A
Demographic Characteristics		
Age (years)	64.6	11.8
Age		
0-17 years	26	0.5%
18-24 years	34	0.7%
25-40 years	280	5.8%
41-64 years	1,506	31.1%
≥ 65 years	2,996	61.9%
Sex		
Female	3,275	67.6%
Male	1,567	32.4%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	61	1.3%
Black or African American	349	7.2%
Multi-racial	41	0.8%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	1,335	27.6%
White	3,045	62.9%
Hispanic origin		
Yes	92	1.9%
No	3,072	63.4%
Unknown	1,678	34.7%
Year		
2021	0	0.0%
2022	3,613	74.6%
2023	1,229	25.4%
Health Characteristics		
Acute Myocardial Infarction	27	0.6%
Alzheimer's Disease and related conditions	100	2.1%
Atrial Fibrillation	430	8.9%

Table 1t. Aggregated Characteristics of Tezepelumab-Ekko in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Diabetes Mellitus	1,169	24.1%
Heart Failure	632	13.1%
Hyperlipidemia	1,911	39.5%
Hypertension	2,457	50.7%
Depression	1,273	26.3%
Ischemic Heart Disease	1,064	22.0%
Rheumatoid Arthritis/Osteoarthritis	1,210	25.0%
Stroke/TIA	93	1.9%
Breast Cancer	130	2.7%
Colorectal Cancer	16	0.3%
Prostate Cancer	77	1.6%
Lung Cancer	57	1.2%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	744	15.4%
Anemia	972	20.1%
Asthma	4,412	91.1%
Benign Prostatic Hyperplasia	227	4.7%
Chronic Kidney Disease	565	11.7%
COPD and Bronchiectasis	1,915	39.5%
Glaucoma	460	9.5%
Osteoporosis	392	8.1%
Obesity: diagnosed or identified by weight management procedures	1,856	38.3%
Obesity: identified by weight management-related prescriptions	46	1.0%
Overweight	507	10.5%
Smoking: diagnosed or identified by smoking cessation procedures	347	7.2%
Smoking: identified by smoking-related prescriptions	35	0.7%
Alcohol Abuse or Dependence	79	1.6%
Drug Abuse or Dependence	212	4.4%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	229	4.7%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	21.2	14.1

Table 1t. Aggregated Characteristics of Tezepelumab-Ekko in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Mean number of emergency room encounters	0.5	1.3
Mean number of inpatient hospital encounters	0.2	0.7
Mean number of non-acute institutional encounters	0.0	0.2
Mean number of other ambulatory encounters	5.0	7.6
Mean number of filled prescriptions	31.9	22.9
Mean number of generics dispensed	13.5	7.2
Mean number of unique drug classes dispensed	12.5	6.4

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 1u. Aggregated Characteristics of Efgartigimod Alfa-Fcab in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	1,592	N/A
Demographic Characteristics		
Age (years)	70.0	11.5
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	273	17.1%
≥ 65 years	1,250	78.5%
Sex		
Female	703	44.2%
Male	889	55.8%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	13	0.8%
Black or African American	64	4.0%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	259	16.3%
White	1,242	78.0%
Hispanic origin		
Yes	11	0.7%
No	1,206	75.8%
Unknown	375	23.6%
Year		
2021	0	0.0%
2022	1,237	77.7%
2023	355	22.3%
Health Characteristics		
Acute Myocardial Infarction	21	1.3%
Alzheimer's Disease and related conditions	49	3.1%

Table 1u. Aggregated Characteristics of Efgartigimod Alfa-Fcab in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Atrial Fibrillation	232	14.6%
Diabetes Mellitus	519	32.6%
Heart Failure	247	15.5%
Hyperlipidemia	752	47.2%
Hypertension	959	60.2%
Depression	383	24.1%
Ischemic Heart Disease	426	26.8%
Rheumatoid Arthritis/Osteoarthritis	382	24.0%
Stroke/TIA	90	5.7%
Breast Cancer	40	2.5%
Colorectal Cancer	22	1.4%
Prostate Cancer	69	4.3%
Lung Cancer	15	0.9%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	297	18.7%
Anemia	512	32.2%
Asthma	122	7.7%
Benign Prostatic Hyperplasia	166	10.4%
Chronic Kidney Disease	319	20.0%
COPD and Bronchiectasis	191	12.0%
Glaucoma	231	14.5%
Osteoporosis	134	8.4%
Obesity: diagnosed or identified by weight management procedures	585	36.7%
Obesity: identified by weight management-related prescriptions	*****	*****
Overweight	202	12.7%
Smoking: diagnosed or identified by smoking cessation procedures	70	4.4%
Smoking: identified by smoking-related prescriptions	*****	*****
Alcohol Abuse or Dependence	19	1.2%
Drug Abuse or Dependence	55	3.5%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	104	6.5%
Health Service Utilization Intensity Metrics		

Table 1u. Aggregated Characteristics of Efgartigimod Alfa-Fcab in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Mean number of ambulatory encounters	21.0	13.9
Mean number of emergency room encounters	0.5	1.3
Mean number of inpatient hospital encounters	0.5	0.9
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	8.0	12.3
Mean number of filled prescriptions	26.3	19.4
Mean number of generics dispensed	10.7	6.0
Mean number of unique drug classes dispensed	10.1	5.4

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

N/A: Not Applicable

Table 1v. Aggregated Characteristics of Inclisiran in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	10,247	N/A
Demographic Characteristics		
Age (years)	73.1	6.8
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	611	6.0%
≥ 65 years	9,614	93.8%
Sex		
Female	5,442	53.1%
Male	4,805	46.9%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	173	1.7%
Black or African American	386	3.8%
Multi-racial	21	0.2%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	912	8.9%
White	8,738	85.3%
Hispanic origin		
Yes	69	0.7%
No	8,995	87.8%
Unknown	1,183	11.5%
Year		
2021	0	0.0%
2022	6,625	64.7%
2023	3,622	35.3%
Health Characteristics		
Acute Myocardial Infarction	198	1.9%
Alzheimer's Disease and related conditions	284	2.8%
Atrial Fibrillation	1,379	13.5%
Diabetes Mellitus	3,137	30.6%
Heart Failure	1,770	17.3%

Table 1v. Aggregated Characteristics of Inclisiran in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Hyperlipidemia	8,694	84.8%
Hypertension	7,500	73.2%
Depression	1,654	16.1%
Ischemic Heart Disease	7,831	76.4%
Rheumatoid Arthritis/Osteoarthritis	2,634	25.7%
Stroke/TIA	524	5.1%
Breast Cancer	294	2.9%
Colorectal Cancer	75	0.7%
Prostate Cancer	357	3.5%
Lung Cancer	85	0.8%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	1,692	16.5%
Anemia	2,132	20.8%
Asthma	494	4.8%
Benign Prostatic Hyperplasia	702	6.9%
Chronic Kidney Disease	1,792	17.5%
COPD and Bronchiectasis	967	9.4%
Glaucoma	1,211	11.8%
Osteoporosis	623	6.1%
Obesity: diagnosed or identified by weight management procedures	2,584	25.2%
Obesity: identified by weight management-related prescriptions	53	0.5%
Overweight	1,357	13.2%
Smoking: diagnosed or identified by smoking cessation procedures	679	6.6%
Smoking: identified by smoking-related prescriptions	19	0.2%
Alcohol Abuse or Dependence	97	0.9%
Drug Abuse or Dependence	204	2.0%
History of Cardiac Arrest	22	0.2%
History of Coronary Angioplasty or Bypass	2,862	27.9%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	16.2	13.1
Mean number of emergency room encounters	0.3	0.7
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	3.6	4.8

Table 1v. Aggregated Characteristics of Inclisiran in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Mean number of filled prescriptions	19.1	16.8
Mean number of generics dispensed	8.9	5.3
Mean number of unique drug classes dispensed	8.4	4.8

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

N/A: Not Applicable

Table 1w. Aggregated Characteristics of Tralokinumab-Ldrm in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Unique patients	1,234	N/A
Demographic Characteristics		
Age (years)	53.8	15.8
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	239	19.4%
41-64 years	468	37.9%
≥ 65 years	414	33.5%
Sex		
Female	637	51.6%
Male	597	48.4%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	47	3.8%
Black or African American	75	6.1%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	667	54.1%
White	424	34.4%
Hispanic origin		
Yes	17	1.4%
No	417	33.8%
Unknown	800	64.8%
Year		
2021	0	0.0%
2022	949	76.9%
2023	285	23.1%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease and related conditions	14	1.1%
Atrial Fibrillation	55	4.5%

Table 1w. Aggregated Characteristics of Tralokinumab-Ldrm in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Diabetes Mellitus	175	14.2%
Heart Failure	75	6.1%
Hyperlipidemia	303	24.6%
Hypertension	361	29.3%
Depression	231	18.7%
Ischemic Heart Disease	136	11.0%
Rheumatoid Arthritis/Osteoarthritis	157	12.7%
Stroke/TIA	18	1.5%
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	17	1.4%
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	90	7.3%
Anemia	151	12.2%
Asthma	93	7.5%
Benign Prostatic Hyperplasia	51	4.1%
Chronic Kidney Disease	106	8.6%
COPD and Bronchiectasis	80	6.5%
Glaucoma	87	7.1%
Osteoporosis	34	2.8%
Obesity: diagnosed or identified by weight management procedures	215	17.4%
Obesity: identified by weight management-related prescriptions	12	1.0%
Overweight	97	7.9%
Smoking: diagnosed or identified by smoking cessation procedures	109	8.8%
Smoking: identified by smoking-related prescriptions	18	1.5%
Alcohol Abuse or Dependence	38	3.1%
Drug Abuse or Dependence	31	2.5%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	37	3.0%
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	12.7	11.3

Table 1w. Aggregated Characteristics of Tralokinumab-Ldrm in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Patient Characteristics	Number/Mean	Percent/ Standard Deviation¹
Mean number of emergency room encounters	0.3	0.9
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.0	0.1
Mean number of other ambulatory encounters	2.6	4.9
Mean number of filled prescriptions	21.5	18.4
Mean number of generics dispensed	9.4	6.0
Mean number of unique drug classes dispensed	8.6	5.3

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

N/A: Not Applicable

Table 2a. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

	Number of Dispensings by Days Supplied								
	1-30 Days		31-60 Days		61-90 Days		91+ Days		
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<i>Finerenone</i>	67,661	54,148	80.0%	*****	*****	10,743	15.9%	*****	*****
<i>Fexinidazole</i>	0
<i>Belumosudil</i>	5,303	5,265	99.3%	21	0.4%	17	0.3%	0	0.0%
<i>Odevixibat</i>	66	66	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Anifrolumab-Fnia</i>	8,023	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Avalglucosidase Alfa-Ngpt</i>	2,189	2,189	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Belzutifan</i>	1,545	*****	*****	0	0.0%	*****	*****	*****	*****
<i>Difelikefalin</i>	48,955	48,955	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Lonapegsomatropin-Tcgd</i>	1,063	1,052	99.0%	*****	*****	*****	*****	0	0.0%
<i>Mobocertinib</i>	418	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Tisotumab Vedotin-Tftv</i>	642	642	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Atogepant</i>	78,901	73,585	93.3%	*****	*****	4,242	5.4%	*****	*****
<i>Maralixibat</i>	195	195	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Avacopan</i>	1,023	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Asciminib</i>	2,273	2,248	98.9%	*****	*****	*****	*****	0	0.0%
<i>Ropeginterferon Alfa-2b-Njft</i>	2,107	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Vosoritide</i>	280	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Maribavir</i>	924	*****	*****	0	0.0%	*****	*****	0	0.0%
<i>Pafolacianine</i>	0

Table 2a. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<i>Tezepelumab-Ekko</i>	22,948	22,901	99.8%	17	0.1%	30	0.1%	0	0.0%
<i>Efgartigimod Alfa-Fcab</i>	11,078	10,947	98.8%	*****	*****	*****	*****	0	0.0%
<i>Inclisiran</i>	15,443	14,670	95.0%	112	0.7%	504	3.3%	157	1.0%
<i>Tralokinumab-Ldrm</i>	5,048	4,986	98.8%	36	0.7%	*****	*****	*****	*****

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2b. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

	Distribution of Days Supplied by Dispensing							
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Finerenone</i>	67,661	1	30	30	30	180	37.4	23.4
<i>Fexinidazole</i>	0
<i>Belumosudil</i>	5,303	1	30	30	30	90	29.0	6.2
<i>Odevixibat</i>	66	1	30	30	30	30	28.0	6.2
<i>Anifrolumab-Fnia</i>	8,023	1	1	1	1	84	3.3	7.5
<i>Avalglucosidase Alfa-Ngpt</i>	2,189	1	1	1	1	28	2.9	6.7
<i>Belzutifan</i>	1,545	1	30	30	30	180	28.6	7.4
<i>Difelikefalin</i>	48,955	1	1	1	1	1	1.0	0.0
<i>Lonapegsomatropin-Tcgd</i>	1,063	1	28	28	28	84	26.0	8.3
<i>Mobocertinib</i>	418	1	30	30	30	40	28.9	4.6
<i>Tisotumab Vedotin-Tftv</i>	642	1	1	1	1	21	1.0	0.8
<i>Atogepant</i>	78,901	1	30	30	30	270	31.2	15.1
<i>Maralixibat</i>	195	1	30	30	30	30	28.7	5.3
<i>Avacopan</i>	1,023	1	30	30	30	70	28.0	6.4
<i>Asciminib</i>	2,273	1	30	30	30	90	28.5	6.3
<i>Ropeginterferon Alfa-2b-Njft</i>	2,107	1	28	28	28	90	24.5	8.5
<i>Vosoritide</i>	280	1	30	30	30	90	29.3	8.3
<i>Maribavir</i>	924	1	28	28	28	84	26.4	6.1
<i>Pafolacianine</i>	0
<i>Tezepelumab-Ekko</i>	22,948	1	1	1	1	84	6.2	10.9
<i>Efgartigimod Alfa-Fcab</i>	11,078	1	1	1	1	70	3.6	8.4
<i>Inclisiran</i>	15,443	1	1	1	1	180	6.0	22.4
<i>Tralokinumab-Ldrm</i>	5,048	1	18	28	28	112	24.2	8.6

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Finerenone	67,661	54,148	100.0%	*****	*****	10,743	100.0%	*****	*****
<i>Female</i>	30,484	24,706	45.6%	*****	*****	4,524	42.1%	*****	*****
<i>Male</i>	37,177	29,442	54.4%	*****	*****	6,219	57.9%	*****	*****
Fexinidazole	0
<i>Female</i>	0
<i>Male</i>	0
Belumosudil	5,303	5,265	100.0%	21	100.0%	17	100.0%	0	NaN
<i>Female</i>	2,268	2,250	42.7%	*****	*****	*****	*****	0	NaN
<i>Male</i>	3,035	3,015	57.3%	*****	*****	*****	*****	0	NaN
Odevixibat	66	66	100.0%	0	NaN	0	NaN	0	NaN
<i>Female</i>	23	23	34.8%	0	NaN	0	NaN	0	NaN
<i>Male</i>	43	43	65.2%	0	NaN	0	NaN	0	NaN
Anifrolumab-Fria	8,023	*****	*****	*****	*****	*****	*****	0	NaN
<i>Female</i>	7,550	*****	*****	*****	*****	*****	*****	0	NaN
<i>Male</i>	473	*****	*****	*****	*****	*****	*****	0	NaN
Avalglucosidase Alfa-Ngpt	2,189	2,189	100.0%	0	NaN	0	NaN	0	NaN
<i>Female</i>	1,154	1,154	52.7%	0	NaN	0	NaN	0	NaN
<i>Male</i>	1,035	1,035	47.3%	0	NaN	0	NaN	0	NaN
Belzutifan	1,545	*****	*****	0	NaN	*****	*****	*****	*****
<i>Female</i>	606	*****	*****	0	NaN	*****	*****	*****	*****
<i>Male</i>	939	*****	*****	0	NaN	*****	*****	*****	*****
Difelikefalin	48,955	48,955	100.0%	0	NaN	0	NaN	0	NaN

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

		Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
	Total Number of Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Female	22,029	22,029	45.0%	0	NaN	0	NaN	0	NaN
Male									
Lonapegsomatropin-Tcgd	1,063	1,052	100.0%	*****	*****	*****	*****	0	NaN
Female	288	*****	*****	*****	*****	*****	*****	0	NaN
Male	775	*****	*****	*****	*****	*****	*****	0	NaN
Mobocertinib	418	*****	*****	*****	*****	0	NaN	0	NaN
Female	258	*****	*****	*****	*****	0	NaN	0	NaN
Male	160	*****	*****	*****	*****	0	NaN	0	NaN
Tisotumab Vedotin-Tftv	642	642	100.0%	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN
Atogepant	78,901	73,585	100.0%	*****	*****	4,242	100.0%	*****	*****
Female	67,716	63,204	85.9%	*****	*****	3,618	85.3%	*****	*****
Male	11,185	10,381	14.1%	*****	*****	624	14.7%	*****	*****
Maralixibat	195	195	100.0%	0	NaN	0	NaN	0	NaN
Female	73	73	37.4%	0	NaN	0	NaN	0	NaN
Male	122	122	62.6%	0	NaN	0	NaN	0	NaN
Avacopan	1,023	*****	*****	*****	*****	*****	*****	0	NaN
Female	449	*****	*****	*****	*****	0	0.0%	0	NaN
Male	574	*****	*****	0	0.0%	*****	*****	0	NaN
Asciminib	2,273	2,248	100.0%	*****	*****	*****	*****	0	NaN
Female	1,214	1,199	53.3%	*****	*****	*****	*****	0	NaN

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Number of Dispensings by Days Supplied									
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Male	1,059	1,049	46.7%	*****	*****	*****	*****	0	NaN
Ropeginterferon Alfa-2b-Njft	2,107	*****	*****	*****	*****	*****	*****	0	NaN
Female	1,086	*****	*****	0	0.0%	*****	*****	0	NaN
Male	1,021	*****	*****	*****	*****	*****	*****	0	NaN
Vosoritide	280	*****	*****	*****	*****	*****	*****	0	NaN
Female	159	*****	*****	*****	*****	*****	*****	0	NaN
Male	121	*****	*****	0	0.0%	*****	*****	0	NaN
Maribavir	924	*****	*****	0	NaN	*****	*****	0	NaN
Female	405	*****	*****	0	NaN	*****	*****	0	NaN
Male	519	*****	*****	0	NaN	*****	*****	0	NaN
Pafolacianine	0
Female	0
Male	0
Tezepelumab-Ekko	22,948	22,901	100.0%	17	100.0%	30	100.0%	0	NaN
Female	15,569	15,536	67.8%	*****	*****	*****	*****	0	NaN
Male	7,379	7,365	32.2%	*****	*****	*****	*****	0	NaN
Efgartigimod Alfa-Fcab	11,078	10,947	100.0%	*****	*****	*****	*****	0	NaN
Female	4,622	4,557	41.6%	*****	*****	*****	*****	0	NaN
Male	6,456	6,390	58.4%	*****	*****	*****	*****	0	NaN
Inclisiran	15,443	14,670	100.0%	112	100.0%	504	100.0%	157	100.0%
Female	8,195	7,697	52.5%	67	59.8%	319	63.3%	112	71.3%
Male	7,248	6,973	47.5%	45	40.2%	185	36.7%	45	28.7%

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Number of Dispensings by Days Supplied									
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Tralokinumab-Ldrm	5,048	4,986	100.0%	36	100.0%	*****	*****	*****	*****
Female	2,514	2,477	49.7%	24	66.7%	*****	*****	*****	*****
Male	2,534	2,509	50.3%	12	33.3%	*****	*****	*****	*****

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Distribution of Days Supplied by Dispensing								
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Finerenone	67,661	1	30	30	30	180	37.4	23.4
Female	30,484	1	30	30	30	180	36.7	22.9
Male	37,177	1	30	30	30	120	37.9	23.8
Fexinidazole	0
Female	0
Male	0
Belumosudil	5,303	1	30	30	30	90	29.0	6.2
Female	2,268	1	30	30	30	90	29.0	6.0
Male	3,035	1	30	30	30	90	28.9	6.4
Odevixibat	66	1	30	30	30	30	28.0	6.2
Female	23	11	30	30	30	30	27.5	5.9
Male	43	1	30	30	30	30	28.3	6.3
Anifrolumab-Fnia	8,023	1	1	1	1	84	3.3	7.5
Female	7,550	1	1	1	1	84	3.3	7.5
Male	473	1	1	1	1	30	3.2	7.4
Avalglucosidase Alfa-Ngpt	2,189	1	1	1	1	28	2.9	6.7
Female	1,154	1	1	1	1	28	2.9	6.7
Male	1,035	1	1	1	1	28	2.9	6.8
Belzutifan	1,545	1	30	30	30	180	28.6	7.4
Female	606	1	30	30	30	30	28.5	5.1
Male	939	1	30	30	30	180	28.6	8.6
Difelikefalin	48,955	1	1	1	1	1	1.0	0.0
Female	22,029	1	1	1	1	1	1.0	0.0
Male	26,926	1	1	1	1	1	1.0	0.0
Lonapegsomatropin-Tcgd	1,063	1	28	28	28	84	26.0	8.3
Female	288	1	28	28	28	84	24.9	8.8
Male	775	1	28	28	28	84	26.4	8.0
Mobocertinib	418	1	30	30	30	40	28.9	4.6
Female	258	1	30	30	30	40	29.1	4.1
Male	160	2	30	30	30	30	28.4	5.3
Tisotumab Vedotin-Tftv	642	1	1	1	1	21	1.0	0.8
Female	*****	1	1	1	1	21	1.0	0.8
Male	*****	*****	*****	*****	*****	*****	*****	*****
Atogepant	78,901	1	30	30	30	270	31.2	15.1
Female	67,716	1	30	30	30	270	31.2	15.1
Male	11,185	1	30	30	30	120	31.5	15.3

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Distribution of Days Supplied by Dispensing								
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Maralixibat	195	1	30	30	30	30	28.7	5.3
Female	73	1	30	30	30	30	28.8	4.8
Male	122	2	30	30	30	30	28.6	5.6
Avacopan	1,023	1	30	30	30	70	28.0	6.4
Female	449	1	30	30	30	60	27.7	6.8
Male	574	1	30	30	30	70	28.2	6.1
Asciminib	2,273	1	30	30	30	90	28.5	6.3
Female	1,214	1	30	30	30	60	28.4	6.3
Male	1,059	1	30	30	30	90	28.6	6.3
Ropeginterferon Alfa-2b-Njft	2,107	1	28	28	28	90	24.5	8.5
Female	1,086	1	28	28	28	90	25.2	7.9
Male	1,021	1	22	28	28	84	23.7	9.0
Vosoritide	280	1	30	30	30	90	29.3	8.3
Female	159	2	30	30	30	90	29.2	7.3
Male	121	1	30	30	30	90	29.5	9.5
Maribavir	924	1	28	28	28	84	26.4	6.1
Female	405	1	28	28	28	84	26.3	6.3
Male	519	1	28	28	28	84	26.4	6.0
Pafolacianine	0
Female	0
Male	0
Tezepelumab-Ekko	22,948	1	1	1	1	84	6.2	10.9
Female	15,569	1	1	1	1	84	6.6	11.2
Male	7,379	1	1	1	1	84	5.4	10.2
Efgartigimod Alfa-Fcab	11,078	1	1	1	1	70	3.6	8.4
Female	4,622	1	1	1	1	64	4.0	8.8
Male	6,456	1	1	1	1	70	3.4	8.1
Inclisiran	15,443	1	1	1	1	180	6.0	22.4
Female	8,195	1	1	1	1	180	7.2	25.0
Male	7,248	1	1	1	1	180	4.7	18.8

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

	Distribution of Days Supplied by Dispensing							
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Tralokinumab-Ldrm	5,048	1	18	28	28	112	24.2	8.6
Female	2,514	1	19	28	28	112	24.4	8.8
Male	2,534	1	16	28	28	84	24.0	8.5

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age by Group

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Finerenone	67,661	54,148	100.0%	*****	*****	10,743	100.0%	*****	*****
<i>0-17 years</i>	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>18-24 years</i>	12	*****	*****	*****	*****	*****	*****	0	0.0%
<i>25-40 years</i>	519	*****	*****	18	0.7%	*****	*****	0	0.0%
<i>41-64 years</i>	12,930	10,625	19.6%	425	15.4%	1,880	17.5%	0	0.0%
<i>≥ 65 years</i>	54,200	43,095	79.6%	*****	*****	8,779	81.7%	*****	*****
Fexinidazole	0
<i>0-17 years</i>	0
<i>18-24 years</i>	0
<i>25-40 years</i>	0
<i>41-64 years</i>	0
<i>≥ 65 years</i>	0
Belumosudil	5,303	5,265	100.0%	21	100.0%	17	100.0%	0	NaN
<i>0-17 years</i>	44	44	0.8%	0	0.0%	0	0.0%	0	NaN
<i>18-24 years</i>	53	53	1.0%	0	0.0%	0	0.0%	0	NaN
<i>25-40 years</i>	775	*****	*****	0	0.0%	*****	*****	0	NaN
<i>41-64 years</i>	1,817	*****	*****	*****	*****	0	0.0%	0	NaN
<i>≥ 65 years</i>	2,614	2,587	49.1%	*****	*****	*****	*****	0	NaN
Odevixibat	66	66	100.0%	0	NaN	0	NaN	0	NaN
<i>0-17 years</i>	54	54	81.8%	0	NaN	0	NaN	0	NaN
<i>18-24 years</i>	*****	*****	*****	0	NaN	0	NaN	0	NaN
<i>25-40 years</i>	*****	*****	*****	0	NaN	0	NaN	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age by Group

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years									
Anifrolumab-Fnia	8,023	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	1,570	1,570	19.6%	0	0.0%	0	0.0%	0	NaN
41-64 years	3,950	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	2,312	2,312	28.8%	0	0.0%	0	0.0%	0	NaN
Avalglucosidase Alfa-Ngpt	2,189	2,189	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	218	218	10.0%	0	NaN	0	NaN	0	NaN
41-64 years	727	727	33.2%	0	NaN	0	NaN	0	NaN
≥ 65 years	1,130	1,130	51.6%	0	NaN	0	NaN	0	NaN
Belzutifan	1,545	*****	*****	0	NaN	*****	*****	*****	*****
0-17 years	*****	*****	*****	0	NaN	0	0.0%	0	0.0%
18-24 years	57	57	3.7%	0	NaN	0	0.0%	0	0.0%
25-40 years	350	350	22.7%	0	NaN	0	0.0%	0	0.0%
41-64 years	*****	*****	*****	0	NaN	*****	*****	*****	*****
≥ 65 years	413	413	26.8%	0	NaN	0	0.0%	0	0.0%
Difelikefalin	48,955	48,955	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	137	137	0.3%	0	NaN	0	NaN	0	NaN
25-40 years	2,757	2,757	5.6%	0	NaN	0	NaN	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age by Group

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
41-64 years	18,864	18,864	38.5%	0	NaN	0	NaN	0	NaN
≥ 65 years	27,197	27,197	55.6%	0	NaN	0	NaN	0	NaN
Lonapegsomatropin-Tcgd	1,063	1,052	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	1,063	1,052	100.0%	*****	*****	*****	*****	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
Mobocertinib	418	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	71	71	17.1%	0	0.0%	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	0	NaN	0	NaN
Tisotumab Vedotin-Tftv	642	642	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	67	67	10.4%	0	NaN	0	NaN	0	NaN
41-64 years	321	321	50.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	254	254	39.6%	0	NaN	0	NaN	0	NaN
Atogepant	78,901	73,585	100.0%	*****	*****	4,242	100.0%	*****	*****
0-17 years	192	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	4,188	*****	*****	63	5.9%	*****	*****	0	0.0%

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age by Group

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
25-40 years	17,782	16,673	22.7%	*****	*****	886	20.9%	*****	*****
41-64 years	44,501	41,347	56.2%	*****	*****	2,550	60.1%	*****	*****
≥ 65 years	12,238	11,490	15.6%	180	16.9%	568	13.4%	0	0.0%
Maralixibat	195	195	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	148	148	75.9%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
Avacopan	1,023	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	23	23	2.3%	0	0.0%	0	0.0%	0	NaN
25-40 years	89	89	8.7%	0	0.0%	0	0.0%	0	NaN
41-64 years	423	*****	*****	0	0.0%	*****	*****	0	NaN
≥ 65 years	488	*****	*****	*****	*****	0	0.0%	0	NaN
Asciminib	2,273	2,248	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	830	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	1,165	1,151	51.2%	*****	*****	*****	*****	0	NaN
Rpeginterferon Alfa-2b-Njft	2,107	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age by Group

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	198	198	9.4%	0	0.0%	0	0.0%	0	NaN
41-64 years	639	*****	*****	0	0.0%	*****	*****	0	NaN
≥ 65 years	1,270	*****	*****	*****	*****	*****	*****	0	NaN
Vosoritide	280	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	280	*****	*****	*****	*****	*****	*****	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
Maribavir	924	*****	*****	0	NaN	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	0.0%	0	NaN
25-40 years	211	*****	*****	0	NaN	*****	*****	0	NaN
41-64 years	448	448	48.6%	0	NaN	0	0.0%	0	NaN
≥ 65 years	249	*****	*****	0	NaN	*****	*****	0	NaN
Pafolacianine	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0
Tezepelumab-Ekko	22,948	22,901	100.0%	17	100.0%	30	100.0%	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age by Group

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
0-17 years	102	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	163	*****	*****	0	0.0%	*****	*****	0	NaN
25-40 years	1,299	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	6,960	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	14,424	*****	*****	*****	*****	14	46.7%	0	NaN
Efgartigimod Alfa-Fcab	11,078	10,947	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	59	59	0.5%	0	0.0%	0	0.0%	0	NaN
25-40 years	515	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	2,078	*****	*****	26	21.1%	*****	*****	0	NaN
≥ 65 years	8,426	8,327	76.1%	*****	*****	*****	*****	0	NaN
Inclisiran	15,443	14,670	100.0%	112	100.0%	504	100.0%	157	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
41-64 years	905	809	5.5%	16	14.3%	63	12.5%	17	10.8%
≥ 65 years	14,504	13,827	94.3%	96	85.7%	441	87.5%	140	89.2%

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age by Group

	Number of Dispensings by Days Supplied								
	Total Number of Dispensings	1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Tralokinumab-Ldrm	5,048	4,986	100.0%	36	100.0%	*****	*****	*****	*****
0-17 years	12	12	0.2%	0	0.0%	0	0.0%	0	0.0%
18-24 years	399	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	895	*****	*****	*****	*****	0	0.0%	*****	*****
41-64 years	2,052	2,028	40.7%	*****	*****	*****	*****	0	0.0%
≥ 65 years	1,690	1,665	33.4%	*****	*****	*****	*****	0	0.0%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of Days Supplied by Dispensing								
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Finerenone	67,661	1	30	30	30	180	37.4	23.4
<i>0-17 years</i>	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>18-24 years</i>	12	6	22	30	68	90	41.1	31.3
<i>25-40 years</i>	519	1	30	30	30	90	37.8	22.9
<i>41-64 years</i>	12,930	1	30	30	30	90	36.2	22.7
<i>≥ 65 years</i>	54,200	1	30	30	30	180	37.6	23.5
Fexinidazole	0
<i>0-17 years</i>	0
<i>18-24 years</i>	0
<i>25-40 years</i>	0
<i>41-64 years</i>	0
<i>≥ 65 years</i>	0
Belumosudil	5,303	1	30	30	30	90	29.0	6.2
<i>0-17 years</i>	44	3	30	30	30	30	27.5	7.3
<i>18-24 years</i>	53	8	30	30	30	30	28.6	4.6
<i>25-40 years</i>	775	1	30	30	30	90	29.0	6.1
<i>41-64 years</i>	1,817	1	30	30	30	60	28.7	5.3
<i>≥ 65 years</i>	2,614	1	30	30	30	90	29.2	6.8
Odevixibat	66	1	30	30	30	30	28.0	6.2
<i>0-17 years</i>	54	6	30	30	30	30	28.7	4.9
<i>18-24 years</i>	*****	11	18	30	30	30	24.8	8.3
<i>25-40 years</i>	*****	1	30	30	30	30	25.2	11.8
<i>41-64 years</i>	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
<i>≥ 65 years</i>	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Anifrolumab-Fnia	8,023	1	1	1	1	84	3.3	7.5
<i>0-17 years</i>	*****	1	1	1	1	1	1.0	0.0
<i>18-24 years</i>	*****	1	1	1	1	30	1.2	2.1
<i>25-40 years</i>	1,570	1	1	1	1	30	3.4	7.6
<i>41-64 years</i>	3,950	1	1	1	1	84	4.0	8.6
<i>≥ 65 years</i>	2,312	1	1	1	1	30	2.0	5.2
Avalglucosidase Alfa-Ngpt	2,189	1	1	1	1	28	2.9	6.7
<i>0-17 years</i>	*****	1	1	1	1	1	1.0	0.0
<i>18-24 years</i>	*****	1	1	1	1	1	1.0	0.0
<i>25-40 years</i>	218	1	1	1	1	28	5.1	9.4
<i>41-64 years</i>	727	1	1	1	1	28	3.8	8.1

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of Days Supplied by Dispensing								
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	1,130	1	1	1	1	28	2.0	5.1
Belzutifan	1,545	1	30	30	30	180	28.6	7.4
0-17 years	*****	27	30	30	30	30	29.7	1.0
18-24 years	*****	7	30	30	30	30	27.9	6.1
25-40 years	350	1	30	30	30	30	28.2	5.6
41-64 years	716	2	30	30	30	180	29.0	9.0
≥ 65 years	413	1	30	30	30	30	28.1	5.8
Difelikefalin	48,955	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	137	1	1	1	1	1	1.0	0.0
25-40 years	2,757	1	1	1	1	1	1.0	0.0
41-64 years	18,864	1	1	1	1	1	1.0	0.0
≥ 65 years	27,197	1	1	1	1	1	1.0	0.0
Lonapegsomatropin-Tcgd	1,063	1	28	28	28	84	26.0	8.3
0-17 years	1,063	1	28	28	28	84	26.0	8.3
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mobocertinib	418	1	30	30	30	40	28.9	4.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	30	30	30	30	30.0	0.0
41-64 years	*****	2	30	30	30	30	28.3	5.5
≥ 65 years	341	1	30	30	30	40	29.0	4.4
Tisotumab Vedotin-Tftv	642	1	1	1	1	21	1.0	0.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	67	1	1	1	1	1	1.0	0.0
41-64 years	321	1	1	1	1	21	1.1	1.1
≥ 65 years	254	1	1	1	1	1	1.0	0.0
Atogepant	78,901	1	30	30	30	270	31.2	15.1
0-17 years	192	1	30	30	30	90	28.5	12.0
18-24 years	4,188	1	30	30	30	90	31.4	15.3
25-40 years	17,782	1	30	30	30	270	30.9	14.8
≥ 65 years	12,238	1	30	30	30	90	30.9	14.3

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of Days Supplied by Dispensing								
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Maralixibat	195	1	30	30	30	30	28.7	5.3
0-17 years	148	3	30	30	30	30	28.8	4.9
18-24 years	*****	1	30	30	30	30	28.2	6.6
25-40 years	*****	19	30	30	30	30	27.8	4.9
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Avacopan	1,023	1	30	30	30	70	28.0	6.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	23	8	30	30	30	30	28.5	4.7
25-40 years	89	1	30	30	30	30	28.1	5.6
41-64 years	423	2	30	30	30	70	28.1	6.4
≥ 65 years	488	1	30	30	30	60	27.8	6.6
Asciminib	2,273	1	30	30	30	90	28.5	6.3
0-17 years	*****	26	30	30	30	30	29.2	1.8
18-24 years	*****	8	18	25	30	30	22.2	9.3
25-40 years	*****	2	30	30	30	30	28.5	5.1
41-64 years	830	1	30	30	30	60	28.3	6.5
≥ 65 years	1,165	1	30	30	30	90	28.6	6.5
Ropeginterferon Alfa-2b-Njft	2,107	1	28	28	28	90	24.5	8.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	198	1	24	28	28	30	24.2	6.9
41-64 years	639	1	21	28	28	90	23.0	10.1
≥ 65 years	1,270	1	28	28	28	84	25.2	7.6
Vosoritide	280	1	30	30	30	90	29.3	8.3
0-17 years	280	1	30	30	30	90	29.3	8.3
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Maribavir	924	1	28	28	28	84	26.4	6.1
0-17 years	*****	4	16	28	28	28	22.0	12.0
18-24 years	*****	4	28	28	29	30	26.5	7.1
25-40 years	211	2	28	28	28	84	26.7	6.5
41-64 years	448	1	28	28	28	30	26.3	5.5
≥ 65 years	249	1	28	28	28	84	26.3	6.7

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

	Distribution of Days Supplied by Dispensing							
	Total Number of Dispensings	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Pafolacianine	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0
Tezepelumab-Ekko	22,948	1	1	1	1	84	6.2	10.9
0-17 years	102	1	1	1	1	56	5.9	11.6
18-24 years	163	1	1	1	28	84	9.0	13.3
25-40 years	1,299	1	1	1	28	84	9.4	12.9
41-64 years	6,960	1	1	1	28	84	8.6	12.4
≥ 65 years	14,424	1	1	1	1	84	4.7	9.5
Efgartigimod Alfa-Fcab	11,078	1	1	1	1	70	3.6	8.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	59	1	1	1	1	28	2.4	6.0
25-40 years	515	1	1	1	1	50	2.7	6.5
41-64 years	2,078	1	1	1	1	64	3.7	8.5
≥ 65 years	8,426	1	1	1	1	70	3.7	8.5
Inclisiran	15,443	1	1	1	1	180	6.0	22.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	1	1	1	1	30	2.3	5.5
41-64 years	905	1	1	1	1	180	11.9	30.1
≥ 65 years	14,504	1	1	1	1	180	5.7	21.8
Tralokinumab-Ldrm	5,048	1	18	28	28	112	24.2	8.6
0-17 years	12	1	14	28	28	28	22.3	9.1
18-24 years	399	1	16	28	28	84	24.0	8.4
25-40 years	895	1	18	28	28	112	23.9	8.2
41-64 years	2,052	1	26	28	28	84	24.6	8.7
≥ 65 years	1,690	1	14	28	28	84	23.9	8.8

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 3a. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Number of Patients by Cumulative Treatment Episode Duration											
Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	
<i>Finerenone</i>	19,188	4,239 22.1%	5,431 28.3%	8,643 45.0%	875 4.6%	0 0.0%					
<i>Fexinidazole</i>	0	
<i>Belumosudil</i>	810	134 16.5%	175 21.6%	367 45.3%	134 16.5%	0 0.0%					
<i>Odevixibat</i>	11	*****	*****	*****	*****	*****	*****	*****	*****	0 0.0%	
<i>Anifrolumab-Fnia</i>	1,539	1,427 92.7%	*****	*****	75 4.9%	*****	*****	*****	*****	0 0.0%	
<i>Avalglucosidase Alfa-Ngpt</i>	137	111 81.0%	*****	*****	12 8.8%	*****	*****	*****	*****	0 0.0%	
<i>Belzutifan</i>	276	62 22.5%	69 25.0%	113 40.9%	32 11.6%	0 0.0%					
<i>Difelikefalin</i>	1,909	1,277 66.9%	596 31.2%	36 1.9%	0 0.0%	0 0.0%					
<i>Lonapegsomatropin-Tcgd</i>	211	*****	*****	56 26.5%	106 50.2%	*****	*****	*****	*****	0 0.0%	
<i>Mobocertinib</i>	113	42 37.2%	*****	*****	33 29.2%	*****	*****	*****	*****	0 0.0%	
<i>Tisotumab Vedotin-Tftv</i>	171	171 100.0%	0 0.0%	0 0.0%	0 0.0%	0 0.0%					
<i>Atogepant</i>	20,012	5,166 25.8%	5,670 28.3%	8,448 42.2%	728 3.6%	0 0.0%					
<i>Maralixibat</i>	24	*****	*****	*****	*****	11 45.8%	*****	*****	*****	0 0.0%	
<i>Avacopan</i>	222	37 16.7%	87 39.2%	87 39.2%	11 5.0%	0 0.0%					
<i>Asciminib</i>	402	63 15.7%	99 24.6%	202 50.2%	38 9.5%	0 0.0%					
<i>Ropeginterferon Alfa-2b-Njft</i>	276	45 16.3%	58 21.0%	133 48.2%	40 14.5%	0 0.0%					
<i>Vosoritide</i>	36	*****	*****	*****	*****	*****	*****	*****	*****	0 0.0%	
<i>Maribavir</i>	273	81 29.7%	107 39.2%	*****	*****	*****	*****	*****	*****	0 0.0%	
<i>Pafolacianine</i>	0	
<i>Tezepelumab-Ekko</i>	4,842	4,038 83.4%	277 5.7%	513 10.6%	14 0.3%	0 0.0%					

Table 3a. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Number of Patients by Cumulative Treatment Episode Duration											
Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	
<i>Efgartigimod Alfa-Fcab</i>	1,592	81.6%	182	11.4%	111	7.0%	0	0.0%	0	0.0%	
<i>Inclisiran</i>	10,247	95.0%	204	2.0%	289	2.8%	15	0.1%	0	0.0%	
<i>Tralokinumab-Ldrm</i>	1,234	26.5%	364	29.5%	532	43.1%	11	0.9%	0	0.0%	

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3b. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Finerenone</i>	19,188	1	39	90	190	648	131.8	113.1
<i>Fexinidazole</i>	0
<i>Belumosudil</i>	810	1	60	150	300	600	189.7	151.7
<i>Odevixibat</i>	11	18	30	101	222	670	168.1	195.2
<i>Anifrolumab-Fnia</i>	1,539	1	2	5	8	432	16.9	49.4
<i>Avalglucosidase Alfa-Ngpt</i>	137	1	9	20	27	424	45.7	89.3
<i>Belzutifan</i>	276	1	41	105	267	564	159.9	141.1
<i>Difelikefalin</i>	1,909	1	7	20	36	135	25.6	23.0
<i>Lonapegsomatropin-Tcgd</i>	211	1	41	104	200	439	130.8	105.9
<i>Mobocertinib</i>	113	9	30	60	120	521	106.8	108.6
<i>Tisotumab Vedotin-Tftv</i>	171	1	2	3	5	21	3.9	2.9
<i>Atogepant</i>	20,012	1	30	90	180	592	123.0	106.3
<i>Maralixibat</i>	24	3	104	225	373	509	232.9	153.5
<i>Avacopan</i>	222	1	47	90	180	492	128.8	110.2
<i>Asciminib</i>	402	2	58	122	240	488	161.0	124.0
<i>Ropeginterferon Alfa-2b-Njft</i>	276	1	56	161	317	457	186.7	137.6
<i>Vosoritide</i>	36	16	128	249	328	526	228.0	123.0
<i>Maribavir</i>	273	1	28	60	112	453	89.2	81.7
<i>Pafolacianine</i>	0
<i>Tezepelumab-Ekko</i>	4,842	1	2	5	9	403	29.4	64.9
<i>Efgartigimod Alfa-Fcab</i>	1,592	1	4	8	20	342	25.2	42.6
<i>Inclisiran</i>	10,247	1	1	2	2	436	9.1	38.4
<i>Tralokinumab-Ldrm</i>	1,234	1	28	81	140	420	99.0	83.9

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Number of Patients by Cumulative Treatment Episode Duration											
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Finerenone	19,188	4,239	100.0%	5,431	100.0%	8,643	100.0%	875	100.0%	0	NaN
<i>Female</i>	8,625	1,956	46.1%	2,442	45.0%	3,863	44.7%	364	41.6%	0	NaN
<i>Male</i>	10,563	2,283	53.9%	2,989	55.0%	4,780	55.3%	511	58.4%	0	NaN
Fexinidazole	0
<i>Female</i>	0
<i>Male</i>	0
Belumosudil	810	134	100.0%	175	100.0%	367	100.0%	134	100.0%	0	NaN
<i>Female</i>	340	52	38.8%	75	42.9%	154	42.0%	59	44.0%	0	NaN
<i>Male</i>	470	82	61.2%	100	57.1%	213	58.0%	75	56.0%	0	NaN
Odevixibat	11	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
<i>Female</i>	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
<i>Male</i>	*****	*****	*****	0	0.0%	*****	*****	*****	*****	0	NaN
Anifrolumab-Fria	1,539	1,427	100.0%	*****	*****	75	100.0%	*****	*****	0	NaN
<i>Female</i>	1,444	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
<i>Male</i>	95	*****	*****	0	0.0%	*****	*****	*****	*****	0	NaN
Avalglucosidase Alfa-Ngpt	137	111	100.0%	*****	*****	12	100.0%	*****	*****	0	NaN
<i>Female</i>	73	59	53.2%	*****	*****	*****	*****	*****	*****	0	NaN
<i>Male</i>	64	52	46.8%	*****	*****	*****	*****	*****	*****	0	NaN
Belzutifan	276	62	100.0%	69	100.0%	113	100.0%	32	100.0%	0	NaN
<i>Female</i>	90	16	25.8%	18	26.1%	42	37.2%	14	43.8%	0	NaN
<i>Male</i>	186	46	74.2%	51	73.9%	71	62.8%	18	56.3%	0	NaN
Difelikefalin	1,909	1,277	100.0%	596	100.0%	36	100.0%	0	NaN	0	NaN
<i>Female</i>	893	617	48.3%	262	44.0%	14	38.9%	0	NaN	0	NaN

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Number of Patients by Cumulative Treatment Episode Duration											
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Male	1,016	660	51.7%	334	56.0%	22	61.1%	0	NaN	0	NaN
Lonapegsomatropin-Tcgd	211	*****	*****	56	100.0%	106	100.0%	*****	*****	0	NaN
Female	62	*****	*****	20	35.7%	28	26.4%	*****	*****	0	NaN
Male	149	*****	*****	36	64.3%	78	73.6%	*****	*****	0	NaN
Mobocertinib	113	42	100.0%	*****	*****	33	100.0%	*****	*****	0	NaN
Female	68	28	66.7%	*****	*****	21	63.6%	*****	*****	0	NaN
Male	45	14	33.3%	*****	*****	12	36.4%	*****	*****	0	NaN
Tisotumab Vedotin-Tftv	171	171	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Atogepant	20,012	5,166	100.0%	5,670	100.0%	8,448	100.0%	728	100.0%	0	NaN
Female	17,049	4,310	83.4%	4,887	86.2%	7,222	85.5%	630	86.5%	0	NaN
Male	2,963	856	16.6%	783	13.8%	1,226	14.5%	98	13.5%	0	NaN
Maralixibat	24	*****	*****	*****	*****	11	100.0%	*****	*****	0	NaN
Female	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Male	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Avacopan	222	37	100.0%	87	100.0%	87	100.0%	11	100.0%	0	NaN
Female	106	*****	*****	47	54.0%	37	42.5%	*****	*****	0	NaN
Male	116	*****	*****	40	46.0%	50	57.5%	*****	*****	0	NaN
Asciminib	402	63	100.0%	99	100.0%	202	100.0%	38	100.0%	0	NaN
Female	210	29	46.0%	55	55.6%	107	53.0%	19	50.0%	0	NaN
Male	192	34	54.0%	44	44.4%	95	47.0%	19	50.0%	0	NaN
Ropeginterferon Alfa-2b-Njft	276	45	100.0%	58	100.0%	133	100.0%	40	100.0%	0	NaN

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Number of Patients by Cumulative Treatment Episode Duration											
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Female	146	24	53.3%	32	55.2%	70	52.6%	20	50.0%	0	NaN
Male	130	21	46.7%	26	44.8%	63	47.4%	20	50.0%	0	NaN
Vosoritide	36	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Female	21	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Male	15	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Maribavir	273	81	100.0%	107	100.0%	*****	*****	*****	*****	0	NaN
Female	115	35	43.2%	42	39.3%	*****	*****	*****	*****	0	NaN
Male	158	46	56.8%	65	60.7%	*****	*****	*****	*****	0	NaN
Pafolacianine	0
Female	0
Male	0
Tezepelumab-Ekko	4,842	4,038	100.0%	277	100.0%	513	100.0%	14	100.0%	0	NaN
Female	3,275	2,697	66.8%	*****	*****	368	71.7%	*****	*****	0	NaN
Male	1,567	1,341	33.2%	*****	*****	145	28.3%	*****	*****	0	NaN
Efgartigimod Alfa-Fcab	1,592	1,299	100.0%	182	100.0%	111	100.0%	0	NaN	0	NaN
Female	703	568	43.7%	84	46.2%	51	45.9%	0	NaN	0	NaN
Male	889	731	56.3%	98	53.8%	60	54.1%	0	NaN	0	NaN
Inclisiran	10,247	9,739	100.0%	204	100.0%	289	100.0%	15	100.0%	0	NaN
Female	5,442	5,119	52.6%	*****	*****	179	61.9%	*****	*****	0	NaN
Male	4,805	4,620	47.4%	*****	*****	110	38.1%	*****	*****	0	NaN

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Number of Patients by Cumulative Treatment Episode Duration											
Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	
Tralokinumab-Ldrm	1,234	327	100.0%	364	100.0%	532	100.0%	11	100.0%	0	NaN
Female	637	*****	*****	198	54.4%	264	49.6%	*****	*****	0	NaN
Male	597	*****	*****	166	45.6%	268	50.4%	*****	*****	0	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Finerenone	19,188	1	39	90	190	648	131.8	113.1
Female	8,625	1	37	90	185	644	129.8	111.9
Male	10,563	1	41	91	193	648	133.4	114.1
Fexinidazole	0
Female	0
Male	0
Belumosudil	810	1	60	150	300	600	189.7	151.7
Female	340	2	60	150	302	600	193.7	153.7
Male	470	1	60	150	300	581	186.9	150.4
Odevixibat	11	18	30	101	222	670	168.1	195.2
Female	*****	18	30	81	120	222	90.3	68.6
Male	*****	30	91	259	518	670	304.3	280.6
Anifrolumab-Fnia	1,539	1	2	5	8	432	16.9	49.4
Female	1,444	1	2	5	8	432	17.0	49.0
Male	95	1	2	4	8	411	15.7	55.3
Avalglucosidase Alfa-Ngpt	137	1	9	20	27	424	45.7	89.3
Female	73	1	8	20	25	424	45.1	85.3
Male	64	1	10	22	27	393	46.4	94.3
Belzutifan	276	1	41	105	267	564	159.9	141.1
Female	90	8	49	151	330	534	192.1	153.5
Male	186	1	35	90	219	564	144.3	132.3
Difelikefalin	1,909	1	7	20	36	135	25.6	23.0
Female	893	1	7	19	35	134	24.7	22.0
Male	1,016	1	7	21	37	135	26.5	23.8
Lonapegsomatropin-Tcgd	211	1	41	104	200	439	130.8	105.9
Female	62	5	37	86	182	404	115.5	92.7
Male	149	1	48	112	209	439	137.3	110.6
Mobocertinib	113	9	30	60	120	521	106.8	108.6
Female	68	9	30	60	150	521	110.5	115.8
Male	45	19	30	63	120	390	101.1	97.8
Tisotumab Vedotin-Tftv	171	1	2	3	5	21	3.9	2.9
Female	*****	1	2	3	5	21	3.9	2.9
Male	*****	*****	*****	*****	*****	*****	*****	*****
Atogepant	20,012	1	30	90	180	592	123.0	106.3
Female	17,049	1	30	90	180	592	123.8	106.5

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	2,963	1	30	90	173	522	118.9	105.4
Maralixibat	24	3	104	225	373	509	232.9	153.5
Female	*****	30	120	196	318	431	210.2	132.0
Male	*****	3	90	272	403	509	249.1	170.2
Avacopan	222	1	47	90	180	492	128.8	110.2
Female	106	2	43	79	150	492	117.2	105.4
Male	116	1	55	90	214	437	139.4	113.8
Asciminib	402	2	58	122	240	488	161.0	124.0
Female	210	2	60	128	256	488	164.2	125.4
Male	192	5	55	120	240	466	157.5	122.7
Ropeginterferon Alfa-2b-Njft	276	1	56	161	317	457	186.7	137.6
Female	146	1	56	166	319	443	187.2	139.1
Male	130	2	56	157	309	457	186.0	136.5
Vosoritide	36	16	128	249	328	526	228.0	123.0
Female	21	30	162	231	270	376	220.9	95.8
Male	15	16	93	275	330	526	237.9	156.6
Maribavir	273	1	28	60	112	453	89.2	81.7
Female	115	1	28	56	112	420	92.5	87.4
Male	158	2	28	61	112	453	86.8	77.5
Pafolacianine	0
Female	0
Male	0
Tezepelumab-Ekko	4,842	1	2	5	9	403	29.4	64.9
Female	3,275	1	2	6	10	403	31.3	67.3
Male	1,567	1	2	5	9	388	25.4	59.3
Efgartigimod Alfa-Fcab	1,592	1	4	8	20	342	25.2	42.6
Female	703	1	4	8	24	342	26.1	45.1
Male	889	1	4	8	20	323	24.4	40.5

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Inclisiran	10,247	1	1	2	2	436	9.1	38.4
Female	5,442	1	1	2	2	436	10.8	43.0
Male	4,805	1	1	2	2	429	7.1	32.3
Tralokinumab-Ldrm	1,234	1	28	81	140	420	99.0	83.9
Female	637	1	28	76	129	392	96.2	82.1
Male	597	1	28	83	154	420	102.0	85.8

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Number of Patients by Cumulative Treatment Episode Duration											
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Finerenone	19,188	4,239	100.0%	5,431	100.0%	8,643	100.0%	875	100.0%	0	NaN
<i>0-17 years</i>	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
<i>18-24 years</i>	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	NaN
<i>25-40 years</i>	*****	66	1.6%	*****	*****	65	0.8%	*****	*****	0	NaN
<i>41-64 years</i>	3,585	766	18.1%	1,044	19.2%	*****	*****	*****	*****	0	NaN
<i>≥ 65 years</i>	15,413	3,407	80.4%	4,336	79.8%	6,957	80.5%	713	81.5%	0	NaN
Fexinidazole	0
<i>0-17 years</i>	0
<i>18-24 years</i>	0
<i>25-40 years</i>	0
<i>41-64 years</i>	0
<i>≥ 65 years</i>	0
Belumosudil	810	134	100.0%	175	100.0%	367	100.0%	134	100.0%	0	NaN
<i>0-17 years</i>	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	NaN
<i>18-24 years</i>	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
<i>25-40 years</i>	114	*****	*****	*****	*****	49	13.4%	*****	*****	0	NaN
<i>41-64 years</i>	290	47	35.1%	78	44.6%	123	33.5%	42	31.3%	0	NaN
<i>≥ 65 years</i>	388	66	49.3%	69	39.4%	183	49.9%	70	52.2%	0	NaN
Odevixibat	11	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
<i>0-17 years</i>	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
<i>18-24 years</i>	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
<i>25-40 years</i>	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	NaN
<i>41-64 years</i>	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Number of Patients by Cumulative Treatment Episode Duration											
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
Anifrolumab-Fnia	1,539	1,427	100.0%	*****	*****	75	100.0%	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	293	272	19.1%	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	761	685	48.0%	*****	*****	49	65.3%	*****	*****	0	NaN
≥ 65 years	446	431	30.2%	*****	*****	*****	*****	*****	*****	0	NaN
Avalglucosidase Alfa-Ngpt	137	111	100.0%	*****	*****	12	100.0%	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	50	39	35.1%	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	62	51	45.9%	*****	*****	*****	*****	0	0.0%	0	NaN
Belzutifan	276	62	100.0%	69	100.0%	113	100.0%	32	100.0%	0	NaN
0-17 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	*****	*****	*****	12	17.4%	*****	*****	*****	*****	0	NaN
41-64 years	109	18	29.0%	24	34.8%	49	43.4%	18	56.3%	0	NaN
≥ 65 years	108	*****	*****	*****	*****	37	32.7%	*****	*****	0	NaN
Difelikefalin	1,909	1,277	100.0%	596	100.0%	36	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Number of Patients by Cumulative Treatment Episode Duration											
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>25-40 years</i>	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	718	478	37.4%	225	37.8%	15	41.7%	0	NaN	0	NaN
≥ 65 years	1,068	710	55.6%	337	56.5%	21	58.3%	0	NaN	0	NaN
Lonapegsomatropin-Tcgd	211	*****	*****	56	100.0%	106	100.0%	*****	*****	0	NaN
0-17 years	211	*****	*****	56	100.0%	106	100.0%	*****	*****	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
<i>25-40 years</i>	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
Mobocertinib	113	42	100.0%	*****	*****	33	100.0%	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
<i>25-40 years</i>	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	93	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Tisotumab Vedotin-Tftv	171	171	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
<i>25-40 years</i>	16	16	9.4%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	77	77	45.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	78	78	45.6%	0	NaN	0	NaN	0	NaN	0	NaN
Atogepant	20,012	5,166	100.0%	5,670	100.0%	8,448	100.0%	728	100.0%	0	NaN
0-17 years	55	17	0.3%	20	0.4%	*****	*****	*****	*****	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Number of Patients by Cumulative Treatment Episode Duration											
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
18-24 years	1,125	295	5.7%	329	5.8%	*****	*****	*****	*****	0	NaN
25-40 years	4,582	1,162	22.5%	1,363	24.0%	1,903	22.5%	154	21.2%	0	NaN
41-64 years	10,950	2,597	50.3%	3,051	53.8%	4,909	58.1%	393	54.0%	0	NaN
≥ 65 years	3,300	1,095	21.2%	907	16.0%	1,151	13.6%	147	20.2%	0	NaN
Maralixibat	24	*****	*****	*****	*****	11	100.0%	*****	*****	0	NaN
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
18-24 years	*****	0	0.0%	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
Avacopan	222	37	100.0%	87	100.0%	87	100.0%	11	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	78	*****	*****	*****	*****	40	46.0%	*****	*****	0	NaN
≥ 65 years	121	*****	*****	52	59.8%	*****	*****	*****	*****	0	NaN
Asciminib	402	63	100.0%	99	100.0%	202	100.0%	38	100.0%	0	NaN
0-17 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	145	*****	*****	*****	*****	68	33.7%	*****	*****	0	NaN
≥ 65 years	211	33	52.4%	51	51.5%	110	54.5%	17	44.7%	0	NaN
Ropeginterferon Alfa-2b-Njft	276	45	100.0%	58	100.0%	133	100.0%	40	100.0%	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Number of Patients by Cumulative Treatment Episode Duration											
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	22	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	82	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	172	30	66.7%	38	65.5%	76	57.1%	28	70.0%	0	NaN
Vosoritide	36	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	36	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
Maribavir	273	*****	*****	107	100.0%	80	100.0%	*****	*****	0	NaN
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	20	25.0%	*****	*****	0	NaN
41-64 years	136	47	58.0%	46	43.0%	*****	*****	*****	*****	0	NaN
≥ 65 years	84	29	35.8%	35	32.7%	*****	*****	*****	*****	0	NaN
Pafolacianine	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Number of Patients by Cumulative Treatment Episode Duration											
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Tezepelumab-Ekko	4,842	4,038	100.0%	277	100.0%	513	100.0%	14	100.0%	0	NaN
0-17 years	26	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	34	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	280	214	5.3%	12	4.3%	*****	*****	*****	*****	0	NaN
41-64 years	1,506	1,139	28.2%	*****	*****	222	43.3%	*****	*****	0	NaN
≥ 65 years	2,996	2,639	65.4%	*****	*****	228	44.4%	*****	*****	0	NaN
Efgartigimod Alfa-Fcab	1,592	1,299	100.0%	182	100.0%	111	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	273	224	17.2%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	1,250	1,020	78.5%	145	79.7%	85	76.6%	0	NaN	0	NaN
Inclisiran	10,247	9,739	100.0%	204	100.0%	289	100.0%	15	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	611	*****	*****	*****	*****	40	13.8%	0	0.0%	0	NaN
≥ 65 years	9,614	9,182	94.3%	168	82.4%	249	86.2%	15	100.0%	0	NaN
Tralokinumab-Ldrm	1,234	327	100.0%	364	100.0%	532	100.0%	11	100.0%	0	NaN
0-17 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
18-24 years	*****	29	8.9%	38	10.4%	*****	*****	*****	*****	0	NaN
25-40 years	239	*****	*****	78	21.4%	97	18.2%	*****	*****	0	NaN
41-64 years	468	*****	*****	136	37.4%	226	42.5%	*****	*****	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Number of Patients by Cumulative Treatment Episode Duration											
Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	
≥ 65 years	414	****	****	112	30.8%	166	31.2%	****	****	0	NaN

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Finerenone	19,188	1	39	90	190	648	131.8	113.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	38	60	105	110	180	98.6	54.7
25-40 years	*****	8	30	60	150	540	106.0	103.4
41-64 years	3,585	1	43	90	185	644	130.6	111.1
≥ 65 years	15,413	1	39	90	191	648	132.4	113.6
Fexinidazole	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0
Belumosudil	810	1	60	150	300	600	189.7	151.7
0-17 years	*****	97	99	120	303	317	172.9	95.6
18-24 years	*****	19	30	107	120	420	137.9	133.1
25-40 years	114	4	60	176	320	525	197.3	155.3
41-64 years	290	1	60	131	270	600	179.9	148.7
≥ 65 years	388	3	60	150	303	581	196.7	154.1
Odevixibat	11	18	30	101	222	670	168.1	195.2
0-17 years	*****	30	60	120	366	670	221.3	229.1
18-24 years	*****	18	18	30	101	101	49.7	44.9
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Anifrolumab-Fnia	1,539	1	2	5	8	432	16.9	49.4
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	1	2	5	8	30	5.7	5.3
25-40 years	293	1	2	5	9	403	17.9	52.2
41-64 years	761	1	2	5	9	432	20.8	56.0
≥ 65 years	446	1	2	5	8	420	10.5	34.7
Avalglucosidase Alfa-Ngpt	137	1	9	20	27	424	45.7	89.3
0-17 years	*****	6	12	16	22	22	15.9	6.2
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	3	9	15	30	424	65.8	129.9
41-64 years	50	1	7	19	27	393	55.1	97.4

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	62	1	10	22	27	364	36.7	72.9
Belzutifan	276	1	41	105	267	564	159.9	141.1
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	30	95	120	220	428	176.4	136.8
25-40 years	*****	11	71	171	327	557	201.5	155.7
41-64 years	109	8	60	147	300	564	190.8	152.5
≥ 65 years	108	1	30	60	150	420	107.4	103.6
Difelikefalin	1,909	1	7	20	36	135	25.6	23.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	3	26	66	85	34.3	39.8
25-40 years	*****	1	7	16	35	84	23.2	20.2
41-64 years	718	1	8	21	37	130	26.3	23.4
≥ 65 years	1,068	1	7	20	36	135	25.5	22.9
Lonapegsomatropin-Tcgd	211	1	41	104	200	439	130.8	105.9
0-17 years	211	1	41	104	200	439	130.8	105.9
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mobocertinib	113	9	30	60	120	521	106.8	108.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	60	60	90	120	120	90.0	42.4
41-64 years	*****	19	30	62	120	371	111.7	108.1
≥ 65 years	93	9	30	60	148	521	106.2	110.3
Tisotumab Vedotin-Tftv	171	1	2	3	5	21	3.9	2.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	16	1	2	4	7	12	4.2	3.1
41-64 years	77	1	2	4	6	21	4.4	3.5
≥ 65 years	78	1	2	3	4	11	3.3	2.1
Atogepant	20,012	1	30	90	180	592	123.0	106.3
0-17 years	55	2	30	60	135	398	99.4	96.4
18-24 years	1,125	1	30	90	171	522	117.0	101.1
25-40 years	4,582	1	30	90	180	585	119.8	104.1

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	10,950	1	36	90	185	576	127.7	106.8
≥ 65 years	3,300	1	30	71	164	592	114.5	109.1
Maralixibat	24	3	104	225	373	509	232.9	153.5
0-17 years	*****	3	64	244	403	509	236.9	168.0
18-24 years	*****	90	181	210	332	373	237.2	115.1
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Avacopan	222	1	47	90	180	492	128.8	110.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	55	56	90	158	297	131.2	101.7
25-40 years	*****	1	30	75	187	437	138.9	137.5
41-64 years	78	12	60	120	240	430	152.6	111.5
≥ 65 years	121	2	38	74	150	492	111.9	103.4
Asciminib	402	2	58	122	240	488	161.0	124.0
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	25	25	26	60	60	37.0	19.9
25-40 years	*****	14	90	149	268	450	181.8	128.5
41-64 years	145	7	54	120	245	488	162.2	128.7
≥ 65 years	211	2	58	120	229	484	157.8	120.2
Ropeginterferon Alfa-2b-Njft	276	1	56	161	317	457	186.7	137.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	22	28	86	238	322	405	218.0	122.4
41-64 years	82	9	60	130	302	457	178.9	133.1
≥ 65 years	172	1	56	161	329	443	186.3	141.7
Vosoritide	36	16	128	249	328	526	228.0	123.0
0-17 years	36	16	128	249	328	526	228.0	123.0
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Maribavir	273	1	28	60	112	453	89.2	81.7
0-17 years	*****	4	4	28	56	56	29.3	26.0

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	*****	88	88	90	140	140	106.0	29.5
25-40 years	*****	21	56	84	168	369	119.8	91.9
41-64 years	136	1	28	56	112	453	86.5	82.5
≥ 65 years	84	1	28	56	87	420	77.9	72.7
Pafolacianine	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0
Tezepelumab-Ekko	4,842	1	2	5	9	403	29.4	64.9
0-17 years	26	1	1	4	12	155	22.7	42.9
18-24 years	34	1	3	6	38	285	43.0	74.3
25-40 years	280	1	2	5	28	380	43.5	80.7
41-64 years	1,506	1	2	6	29	403	39.7	74.0
≥ 65 years	2,996	1	2	5	9	396	22.8	57.0
Efgartigimod Alfa-Fcab	1,592	1	4	8	20	342	25.2	42.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	2	5	7	16	84	17.5	27.4
25-40 years	*****	1	4	8	26	154	22.8	32.0
41-64 years	273	1	4	8	20	342	27.9	49.8
≥ 65 years	1,250	1	4	8	20	323	24.7	41.4
Inclisiran	10,247	1	1	2	2	436	9.1	38.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	1	1	2	2	32	3.7	7.1
41-64 years	611	1	1	2	2	337	17.6	48.7
≥ 65 years	9,614	1	1	2	2	436	8.5	37.6

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of Cumulative Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Tralokinumab-Ldrm	1,234	1	28	81	140	420	99.0	83.9
0-17 years	*****	1	15	63	119	140	66.8	63.7
18-24 years	*****	1	30	70	112	420	87.8	74.7
25-40 years	239	1	28	73	126	392	89.5	73.0
41-64 years	468	1	40	89	156	386	107.9	84.1
≥ 65 years	414	1	26	70	152	389	97.7	90.9

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 4a. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

	Number of Treatment Episodes by Duration										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Finerenone</i>	35,554	17,584	49.5%	11,567	32.5%	5,978	16.8%	425	1.2%	0	0.0%
<i>Fexinidazole</i>	0
<i>Belumosudil</i>	2,045	1,069	52.3%	573	28.0%	366	17.9%	37	1.8%	0	0.0%
<i>Odevixibat</i>	17	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Anifrolumab-Fnia</i>	7,578	7,433	98.1%	111	1.5%	34	0.4%	0	0.0%	0	0.0%
<i>Avalglucosidase Alfa-Ngpt</i>	2,088	2,058	98.6%	19	0.9%	11	0.5%	0	0.0%	0	0.0%
<i>Belzutifan</i>	656	378	57.6%	173	26.4%	91	13.9%	14	2.1%	0	0.0%
<i>Difelikefalin</i>	48,412	48,412	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Lonapegsomatropin-Tcgd</i>	395	204	51.6%	*****	*****	97	24.6%	*****	*****	0	0.0%
<i>Mobocertinib</i>	224	146	65.2%	57	25.4%	*****	*****	*****	*****	0	0.0%
<i>Tisotumab Vedotin-Tftv</i>	642	642	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Atogepant</i>	40,534	23,681	58.4%	10,892	26.9%	5,720	14.1%	241	0.6%	0	0.0%
<i>Maralixibat</i>	65	32	49.2%	19	29.2%	*****	*****	*****	*****	0	0.0%
<i>Avacopan</i>	457	240	52.5%	146	31.9%	*****	*****	*****	*****	0	0.0%
<i>Asciminib</i>	976	552	56.6%	261	26.7%	*****	*****	*****	*****	0	0.0%
<i>Ropeginterferon Alfa-2b-Njft</i>	746	421	56.4%	170	22.8%	142	19.0%	13	1.7%	0	0.0%
<i>Vosoritide</i>	64	26	40.6%	*****	*****	24	37.5%	*****	*****	0	0.0%
<i>Maribavir</i>	440	225	51.1%	156	35.5%	59	13.4%	0	0.0%	0	0.0%
<i>Pafolacianine</i>	0
<i>Tezepelumab-Ekko</i>	20,281	19,348	95.4%	652	3.2%	*****	*****	*****	*****	0	0.0%

Table 4a. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Number of Treatment Episodes by Duration											
Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	
<i>Efgartigimod Alfa-Fcab</i>	10,719	10,593	98.8%	110	1.0%	16	0.1%	0	0.0%	0	0.0%
<i>Inclisiran</i>	15,200	14,564	95.8%	408	2.7%	*****	*****	*****	*****	0	0.0%
<i>Tralokinumab-Ldrm</i>	2,424	1,484	61.2%	589	24.3%	*****	*****	*****	*****	0	0.0%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 4b. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

	Distribution of Treatment Episode Durations, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Finerenone</i>	35,554	1	30	32	90	648	71.1	74.9
<i>Fexinidazole</i>	0
<i>Belumosudil</i>	2,045	1	30	30	90	600	75.2	84.3
<i>Odevixibat</i>	17	18	30	51	90	670	108.8	165.8
<i>Anifrolumab-Fnia</i>	7,578	1	1	1	1	336	3.4	13.9
<i>Avalglucosidase Alfa-Ngpt</i>	2,088	1	1	1	1	315	3.0	16.6
<i>Belzutifan</i>	656	1	30	30	69	557	67.3	80.9
<i>Difelikefalin</i>	48,412	1	1	1	1	3	1.0	0.1
<i>Lonapegsomatropin-Tcgd</i>	395	1	28	28	84	427	69.9	75.1
<i>Mobocertinib</i>	224	8	30	30	60	521	53.9	60.1
<i>Tisotumab Vedotin-Tftv</i>	642	1	1	1	1	21	1.0	0.8
<i>Atogepant</i>	40,534	1	30	30	64	584	60.7	63.2
<i>Maralixibat</i>	65	3	30	32	90	431	86.0	98.6
<i>Avacopan</i>	457	1	30	30	60	437	62.6	61.8
<i>Asciminib</i>	976	1	30	30	61	466	66.3	73.0
<i>Ropeginterferon Alfa-2b-Njft</i>	746	1	28	28	84	443	69.1	86.0
<i>Vosoritide</i>	64	3	30	60	206	526	128.2	125.9
<i>Maribavir</i>	440	1	28	28	72	336	55.3	46.5
<i>Pafolacianine</i>	0
<i>Tezepelumab-Ekko</i>	20,281	1	1	1	1	403	7.0	23.2
<i>Efgartigimod Alfa-Fcab</i>	10,719	1	1	1	1	208	3.7	9.7
<i>Inclisiran</i>	15,200	1	1	1	1	436	6.1	27.3
<i>Tralokinumab-Ldrm</i>	2,424	1	16	28	56	420	50.4	53.5

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

	Number of Treatment Episodes by Duration										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Finerenone	35,554	17,584	100.0%	11,567	100.0%	5,978	100.0%	425	100.0%	0	NaN
<i>Female</i>	16,024	8,097	46.0%	5,135	44.4%	2,604	43.6%	188	44.2%	0	NaN
<i>Male</i>	19,530	9,487	54.0%	6,432	55.6%	3,374	56.4%	237	55.8%	0	NaN
Fexinidazole	0
<i>Female</i>	0
<i>Male</i>	0
Belumosudil	2,045	1,069	100.0%	573	100.0%	366	100.0%	37	100.0%	0	NaN
<i>Female</i>	825	413	38.6%	235	41.0%	164	44.8%	13	35.1%	0	NaN
<i>Male</i>	1,220	656	61.4%	338	59.0%	202	55.2%	24	64.9%	0	NaN
Odevixibat	17	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
<i>Female</i>	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
<i>Male</i>	*****	*****	*****	*****	*****	0	0.0%	*****	*****	0	NaN
Anifrolumab-Fria	7,578	7,433	100.0%	111	100.0%	34	100.0%	0	NaN	0	NaN
<i>Female</i>	7,133	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
<i>Male</i>	445	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Avalglucosidase Alfa-Ngpt	2,088	2,058	100.0%	19	100.0%	11	100.0%	0	NaN	0	NaN
<i>Female</i>	1,095	1,083	52.6%	*****	*****	*****	*****	0	NaN	0	NaN
<i>Male</i>	993	975	47.4%	*****	*****	*****	*****	0	NaN	0	NaN
Belzutifan	656	378	100.0%	173	100.0%	91	100.0%	14	100.0%	0	NaN
<i>Female</i>	249	139	36.8%	69	39.9%	*****	*****	*****	*****	0	NaN
<i>Male</i>	407	239	63.2%	104	60.1%	*****	*****	*****	*****	0	NaN
Difelikefalin	48,412	48,412	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
<i>Female</i>	21,783	21,783	45.0%	0	NaN	0	NaN	0	NaN	0	NaN

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Number of Treatment Episodes by Duration											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Male	26,629	26,629	55.0%	0	NaN	0	NaN	0	NaN	0	NaN
Lonapegsomatropin-Tcgd	395	204	100.0%	*****	*****	97	100.0%	*****	*****	0	NaN
Female	133	78	38.2%	*****	*****	23	23.7%	*****	*****	0	NaN
Male	262	126	61.8%	*****	*****	74	76.3%	*****	*****	0	NaN
Mobocertinib	224	146	100.0%	57	100.0%	*****	*****	*****	*****	0	NaN
Female	133	91	62.3%	*****	*****	*****	*****	*****	*****	0	NaN
Male	91	55	37.7%	*****	*****	*****	*****	0	0.0%	0	NaN
Tisotumab Vedotin-Tftv	642	642	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Atogepant	40,534	23,681	100.0%	10,892	100.0%	5,720	100.0%	241	100.0%	0	NaN
Female	34,793	20,316	85.8%	9,378	86.1%	4,900	85.7%	199	82.6%	0	NaN
Male	5,741	3,365	14.2%	1,514	13.9%	820	14.3%	42	17.4%	0	NaN
Maralixibat	65	32	100.0%	19	100.0%	*****	*****	*****	*****	0	NaN
Female	21	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Male	44	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Avacopan	457	240	100.0%	146	100.0%	*****	*****	*****	*****	0	NaN
Female	218	118	49.2%	75	51.4%	*****	*****	*****	*****	0	NaN
Male	239	122	50.8%	71	48.6%	*****	*****	*****	*****	0	NaN
Asciminib	976	552	100.0%	261	100.0%	*****	*****	*****	*****	0	NaN
Female	529	305	55.3%	135	51.7%	*****	*****	*****	*****	0	NaN
Male	447	247	44.7%	126	48.3%	*****	*****	*****	*****	0	NaN

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Number of Treatment Episodes by Duration											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Ropeginterferon Alfa-2b-Njft	746	421	100.0%	170	100.0%	142	100.0%	13	100.0%	0	NaN
Female	367	195	46.3%	84	49.4%	*****	*****	*****	*****	0	NaN
Male	379	226	53.7%	86	50.6%	*****	*****	*****	*****	0	NaN
Vosoritide	64	26	100.0%	*****	*****	24	100.0%	*****	*****	0	NaN
Female	36	13	50.0%	*****	*****	*****	*****	*****	*****	0	NaN
Male	28	13	50.0%	*****	*****	*****	*****	*****	*****	0	NaN
Maribavir	440	225	100.0%	156	100.0%	59	100.0%	0	NaN	0	NaN
Female	201	112	49.8%	62	39.7%	27	45.8%	0	NaN	0	NaN
Male	239	113	50.2%	94	60.3%	32	54.2%	0	NaN	0	NaN
Pafolacianine	0
Female	0
Male	0
Tezepelumab-Ekko	20,281	19,348	100.0%	652	100.0%	*****	*****	*****	*****	0	NaN
Female	13,617	12,939	66.9%	468	71.8%	*****	*****	*****	*****	0	NaN
Male	6,664	6,409	33.1%	184	28.2%	*****	*****	*****	*****	0	NaN
Efgartigimod Alfa-Fcab	10,719	10,593	100.0%	110	100.0%	16	100.0%	0	NaN	0	NaN
Female	4,440	4,378	41.3%	*****	*****	*****	*****	0	NaN	0	NaN
Male	6,279	6,215	58.7%	*****	*****	*****	*****	0	NaN	0	NaN
Inclisiran	15,200	14,564	100.0%	408	100.0%	*****	*****	*****	*****	0	NaN
Female	8,047	7,638	52.4%	256	62.7%	*****	*****	*****	*****	0	NaN
Male	7,153	6,926	47.6%	152	37.3%	*****	*****	*****	*****	0	NaN
Tralokinumab-Ldrm	2,424	1,484	100.0%	589	100.0%	*****	*****	*****	*****	0	NaN

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Number of Treatment Episodes by Duration											
Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	
Female	1,234	762 51.3%	298	50.6%	*****	*****	*****	*****	0	NaN	
Male	1,190	722 48.7%	291	49.4%	*****	*****	*****	*****	0	NaN	

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

	Distribution of Treatment Episode Durations, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Finerenone	35,554	1	30	32	90	648	71.1	74.9
Female	16,024	1	30	30	90	644	69.9	74.1
Male	19,530	1	30	36	90	648	72.2	75.5
Fexinidazole	0
Female	0
Male	0
Belumosudil	2,045	1	30	30	90	600	75.2	84.3
Female	825	1	30	30	90	600	79.8	89.2
Male	1,220	1	30	30	90	554	72.0	80.6
Odevixibat	17	18	30	51	90	670	108.8	165.8
Female	*****	18	30	51	90	120	57.5	33.1
Male	*****	30	30	61	366	670	202.8	263.4
Anifrolumab-Fnia	7,578	1	1	1	1	336	3.4	13.9
Female	7,133	1	1	1	1	336	3.4	14.0
Male	445	1	1	1	1	168	3.4	13.5
Avalglucosidase Alfa-Ngpt	2,088	1	1	1	1	315	3.0	16.6
Female	1,095	1	1	1	1	315	3.0	18.3
Male	993	1	1	1	1	280	3.0	14.6
Belzutifan	656	1	30	30	69	557	67.3	80.9
Female	249	2	30	30	60	534	69.4	86.4
Male	407	1	30	30	74	557	65.9	77.4
Difelikefalin	48,412	1	1	1	1	3	1.0	0.1
Female	21,783	1	1	1	1	3	1.0	0.1
Male	26,629	1	1	1	1	3	1.0	0.1
Lonapegsomatropin-Tcgd	395	1	28	28	84	427	69.9	75.1
Female	133	1	28	28	56	292	53.8	56.8
Male	262	1	28	39	112	427	78.1	81.7
Mobocertinib	224	8	30	30	60	521	53.9	60.1
Female	133	9	30	30	60	521	56.5	70.9
Male	91	8	30	30	60	240	50.0	39.4
Tisotumab Vedotin-Tftv	642	1	1	1	1	21	1.0	0.8
Female	*****	1	1	1	1	21	1.0	0.8
Male	*****	*****	*****	*****	*****	*****	*****	*****
Atogepant	40,534	1	30	30	64	584	60.7	63.2
Female	34,793	1	30	30	64	584	60.6	62.9

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	5,741	1	30	30	62	517	61.4	64.9
Maralixibat	65	3	30	32	90	431	86.0	98.6
Female	21	30	30	30	90	431	100.1	122.0
Male	44	3	30	52	90	420	79.3	86.0
Avacopan	457	1	30	30	60	437	62.6	61.8
Female	218	2	30	30	60	390	57.0	54.4
Male	239	1	30	30	74	437	67.7	67.6
Asciminib	976	1	30	30	61	466	66.3	73.0
Female	529	2	30	30	61	448	65.2	71.6
Male	447	1	30	30	60	466	67.6	74.6
Ropeginterferon Alfa-2b-Njft	746	1	28	28	84	443	69.1	86.0
Female	367	1	28	28	84	443	74.5	89.8
Male	379	1	28	28	78	410	63.8	81.9
Vosoritide	64	3	30	60	206	526	128.2	125.9
Female	36	15	30	105	206	376	128.8	106.6
Male	28	3	30	60	213	526	127.5	149.1
Maribavir	440	1	28	28	72	336	55.3	46.5
Female	201	1	28	28	58	308	52.9	45.2
Male	239	2	28	54	84	336	57.4	47.5
Pafolacianine	0
Female	0
Male	0
Tezepelumab-Ekko	20,281	1	1	1	1	403	7.0	23.2
Female	13,617	1	1	1	1	403	7.5	24.4
Male	6,664	1	1	1	1	298	6.0	20.3
Efgartigimod Alfa-Fcab	10,719	1	1	1	1	208	3.7	9.7
Female	4,440	1	1	1	1	176	4.1	10.5
Male	6,279	1	1	1	1	208	3.5	9.2
Inclisiran	15,200	1	1	1	1	436	6.1	27.3
Female	8,047	1	1	1	1	436	7.3	30.5
Male	7,153	1	1	1	1	429	4.7	23.2

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

	Distribution of Treatment Episode Durations, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Tralokinumab-Ldrm	2,424	1	16	28	56	420	50.4	53.5
Female	1,234	1	19	28	56	383	49.6	52.3
Male	1,190	1	14	28	56	420	51.2	54.7

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

	Number of Treatment Episodes by Duration										
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Finerenone	35,554	17,584	100.0%	11,567	100.0%	5,978	100.0%	425	100.0%	0	NaN
<i>0-17 years</i>	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
<i>18-24 years</i>	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
<i>25-40 years</i>	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
<i>41-64 years</i>	6,890	3,528	20.1%	2,200	19.0%	*****	*****	*****	*****	0	NaN
<i>≥ 65 years</i>	28,316	13,828	78.6%	9,287	80.3%	4,845	81.0%	356	83.8%	0	NaN
Fexinidazole	0
<i>0-17 years</i>	0
<i>18-24 years</i>	0
<i>25-40 years</i>	0
<i>41-64 years</i>	0
<i>≥ 65 years</i>	0
Belumosudil	2,045	1,069	100.0%	573	100.0%	366	100.0%	37	100.0%	0	NaN
<i>0-17 years</i>	16	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
<i>18-24 years</i>	24	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
<i>25-40 years</i>	340	198	18.5%	*****	*****	56	15.3%	*****	*****	0	NaN
<i>41-64 years</i>	696	347	32.5%	210	36.6%	*****	*****	*****	*****	0	NaN
<i>≥ 65 years</i>	969	502	47.0%	272	47.5%	172	47.0%	23	62.2%	0	NaN
Odevixibat	17	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
<i>0-17 years</i>	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
<i>18-24 years</i>	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
<i>25-40 years</i>	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
<i>41-64 years</i>	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Number of Treatment Episodes by Duration											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
Anifrolumab-Fnia	7,578	7,433	100.0%	111	100.0%	34	100.0%	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	1,474	1,449	19.5%	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	3,664	3,566	48.0%	76	68.5%	22	64.7%	0	NaN	0	NaN
≥ 65 years	2,249	2,227	30.0%	*****	*****	*****	*****	0	NaN	0	NaN
Avalglucosidase Alfa-Ngpt	2,088	2,058	100.0%	19	100.0%	11	100.0%	0	NaN	0	NaN
0-17 years	111	111	5.4%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	671	657	31.9%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	1,099	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Belzutifan	656	378	100.0%	173	100.0%	91	100.0%	14	100.0%	0	NaN
0-17 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	151	*****	*****	*****	*****	15	16.5%	*****	*****	0	NaN
41-64 years	272	155	41.0%	60	34.7%	*****	*****	*****	*****	0	NaN
≥ 65 years	214	129	34.1%	62	35.8%	*****	*****	*****	*****	0	NaN
Difelikefalin	48,412	48,412	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	137	137	0.3%	0	NaN	0	NaN	0	NaN	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Number of Treatment Episodes by Duration											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	2,681	2,681	5.5%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	18,583	18,583	38.4%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	27,011	27,011	55.8%	0	NaN	0	NaN	0	NaN	0	NaN
Lonapegsomatropin-Tcgd	395	204	100.0%	*****	*****	97	100.0%	*****	*****	0	NaN
0-17 years	395	204	100.0%	*****	*****	97	100.0%	*****	*****	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
Mobocertinib	224	146	100.0%	57	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	188	126	86.3%	*****	*****	*****	*****	*****	*****	0	NaN
Tisotumab Vedotin-Tftv	642	642	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	67	67	10.4%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	321	321	50.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	254	254	39.6%	0	NaN	0	NaN	0	NaN	0	NaN
Atogepant	40,534	23,681	100.0%	10,892	100.0%	5,720	100.0%	241	100.0%	0	NaN
0-17 years	115	73	0.3%	*****	*****	*****	*****	*****	*****	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Number of Treatment Episodes by Duration											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
18-24 years	2,348	1,455	6.1%	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	9,363	5,557	23.5%	2,526	23.2%	1,231	21.5%	49	20.3%	0	NaN
41-64 years	22,744	13,125	55.4%	6,145	56.4%	3,357	58.7%	117	48.5%	0	NaN
≥ 65 years	5,964	3,471	14.7%	1,583	14.5%	846	14.8%	64	26.6%	0	NaN
Maralixibat	65	32	100.0%	19	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	44	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
Avacopan	457	240	100.0%	146	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	11	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	43	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	207	117	48.8%	61	41.8%	29	42.0%	0	0.0%	0	NaN
≥ 65 years	196	88	36.7%	72	49.3%	*****	*****	*****	*****	0	NaN
Asciminib	976	552	100.0%	261	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	28	10.7%	*****	*****	0	0.0%	0	NaN
41-64 years	400	244	44.2%	110	42.1%	*****	*****	*****	*****	0	NaN
≥ 65 years	459	238	43.1%	123	47.1%	*****	*****	*****	*****	0	NaN
Ropeginterferon Alfa-2b-Njft	746	421	100.0%	170	100.0%	142	100.0%	13	100.0%	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Number of Treatment Episodes by Duration											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	63	33	7.8%	17	10.0%	13	9.2%	0	0.0%	0	NaN
41-64 years	225	135	32.1%	44	25.9%	*****	*****	*****	*****	0	NaN
≥ 65 years	458	253	60.1%	109	64.1%	*****	*****	*****	*****	0	NaN
Vosoritide	64	26	100.0%	*****	*****	24	100.0%	*****	*****	0	NaN
0-17 years	64	26	100.0%	*****	*****	24	100.0%	*****	*****	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
Maribavir	440	225	100.0%	156	100.0%	59	100.0%	0	NaN	0	NaN
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	210	112	49.8%	69	44.2%	29	49.2%	0	NaN	0	NaN
≥ 65 years	123	63	28.0%	44	28.2%	16	27.1%	0	NaN	0	NaN
Pafolacianine	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Number of Treatment Episodes by Duration											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Tezepelumab-Ekko	20,281	19,348	100.0%	652	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	88	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	138	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	1,078	990	5.1%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	5,748	5,348	27.6%	277	42.5%	*****	*****	*****	*****	0	NaN
≥ 65 years	13,229	12,802	66.2%	299	45.9%	128	45.9%	0	0.0%	0	NaN
Efgartigimod Alfa-Fcab	10,719	10,593	100.0%	110	100.0%	16	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	59	59	0.6%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	499	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	1,974	*****	*****	26	23.6%	*****	*****	0	NaN	0	NaN
≥ 65 years	8,187	8,096	76.4%	*****	*****	*****	*****	0	NaN	0	NaN
Inclisiran	15,200	14,564	100.0%	408	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	871	788	5.4%	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	14,295	13,742	94.4%	*****	*****	*****	*****	*****	*****	0	NaN
Tralokinumab-Ldrm	2,424	1,484	100.0%	589	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	18	5.2%	*****	*****	0	NaN
25-40 years	455	289	19.5%	110	18.7%	56	16.1%	0	0.0%	0	NaN
41-64 years	951	563	37.9%	226	38.4%	*****	*****	*****	*****	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Number of Treatment Episodes by Duration											
Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	
≥ 65 years	790	481	32.4%	196	33.3%	113	32.5%	0	0.0%	0	NaN

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

	Distribution of Treatment Episode Durations, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Finerenone	35,554	1	30	32	90	648	71.1	74.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	8	30	60	90	90	54.8	31.4
25-40 years	*****	4	30	30	60	540	57.8	69.0
41-64 years	6,890	1	30	30	90	644	67.9	70.1
≥ 65 years	28,316	1	30	35	90	648	72.1	76.1
Fexinidazole	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0
Belumosudil	2,045	1	30	30	90	600	75.2	84.3
0-17 years	16	9	30	34	92	317	75.6	80.3
18-24 years	24	10	30	30	90	300	63.2	61.6
25-40 years	340	2	30	30	60	478	66.1	73.6
41-64 years	696	1	30	31	90	600	74.9	80.7
≥ 65 years	969	1	30	30	90	558	78.8	90.5
Odevixibat	17	18	30	51	90	670	108.8	165.8
0-17 years	*****	30	30	60	120	670	140.8	200.4
18-24 years	*****	18	18	30	101	101	49.7	44.9
25-40 years	*****	30	30	31	90	90	50.3	34.4
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Anifrolumab-Fnia	7,578	1	1	1	1	336	3.4	13.9
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	30	1.2	2.1
25-40 years	1,474	1	1	1	1	336	3.6	15.7
41-64 years	3,664	1	1	1	1	252	4.3	15.3
≥ 65 years	2,249	1	1	1	1	304	2.1	10.3
Avalglucosidase Alfa-Ngpt	2,088	1	1	1	1	315	3.0	16.6
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	204	1	1	1	1	112	5.5	15.0
41-64 years	671	1	1	1	1	315	4.1	22.5

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

	Distribution of Treatment Episode Durations, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	1,099	1	1	1	1	303	2.1	13.1
Belzutifan	656	1	30	30	69	557	67.3	80.9
0-17 years	*****	30	30	30	207	207	89.0	102.2
18-24 years	*****	17	34	60	108	368	99.3	98.5
25-40 years	151	2	30	30	60	557	65.4	88.1
41-64 years	272	4	30	30	90	478	76.5	91.8
≥ 65 years	214	1	30	30	60	390	54.2	52.7
Difelikefalin	48,412	1	1	1	1	3	1.0	0.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	137	1	1	1	1	1	1.0	0.0
25-40 years	2,681	1	1	1	1	3	1.0	0.2
41-64 years	18,583	1	1	1	1	3	1.0	0.1
≥ 65 years	27,011	1	1	1	1	3	1.0	0.1
Lonapegsomatropin-Tcgd	395	1	28	28	84	427	69.9	75.1
0-17 years	395	1	28	28	84	427	69.9	75.1
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mobocertinib	224	8	30	30	60	521	53.9	60.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	30	30	60	90	45.0	30.0
41-64 years	*****	14	30	30	75	270	62.8	58.9
≥ 65 years	188	8	30	30	60	521	52.5	60.8
Tisotumab Vedotin-Tftv	642	1	1	1	1	21	1.0	0.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	67	1	1	1	1	1	1.0	0.0
41-64 years	321	1	1	1	1	21	1.1	1.1
≥ 65 years	254	1	1	1	1	1	1.0	0.0
Atogepant	40,534	1	30	30	64	584	60.7	63.2
0-17 years	115	2	30	30	60	369	47.6	46.4
18-24 years	2,348	1	30	30	60	522	56.1	57.6
25-40 years	9,363	1	30	30	60	555	58.6	60.9

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	22,744	1	30	30	70	556	61.5	63.1
≥ 65 years	5,964	1	30	30	67	584	63.4	69.3
Maralixibat	65	3	30	32	90	431	86.0	98.6
0-17 years	44	3	30	45	90	431	96.9	114.1
18-24 years	*****	30	30	38	90	180	65.9	50.1
25-40 years	*****	30	30	30	79	79	46.3	28.3
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Avacopan	457	1	30	30	60	437	62.6	61.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	11	27	30	55	90	158	59.6	40.2
25-40 years	43	1	30	30	60	437	58.1	75.9
41-64 years	207	2	30	30	60	310	57.5	53.7
≥ 65 years	196	1	30	49	89	390	69.1	67.0
Asciminib	976	1	30	30	61	466	66.3	73.0
0-17 years	*****	26	30	30	30	30	29.2	1.8
18-24 years	*****	25	26	28	30	30	27.8	2.6
25-40 years	*****	2	30	30	90	360	70.7	77.4
41-64 years	400	1	30	30	60	466	58.8	70.3
≥ 65 years	459	2	30	30	90	418	72.6	74.2
Ropeginterferon Alfa-2b-Njft	746	1	28	28	84	443	69.1	86.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	63	2	28	30	84	364	76.1	79.8
41-64 years	225	1	14	28	84	389	65.2	86.7
≥ 65 years	458	1	28	28	84	443	70.0	86.5
Vosoritide	64	3	30	60	206	526	128.2	125.9
0-17 years	64	3	30	60	206	526	128.2	125.9
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Maribavir	440	1	28	28	72	336	55.3	46.5
0-17 years	*****	4	4	28	56	56	29.3	26.0

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of Treatment Episode Durations, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	*****	4	28	42	90	112	53.0	41.3
25-40 years	*****	2	28	44	84	243	57.4	44.9
41-64 years	210	1	28	28	68	336	56.0	51.4
≥ 65 years	123	1	28	28	82	196	53.2	39.3
Pafolacianine	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0
Tezepelumab-Ekko	20,281	1	1	1	1	403	7.0	23.2
0-17 years	88	1	1	1	1	56	6.7	14.5
18-24 years	138	1	1	1	1	140	10.6	24.3
25-40 years	1,078	1	1	1	1	308	11.3	29.3
41-64 years	5,748	1	1	1	1	403	10.4	28.8
≥ 65 years	13,229	1	1	1	1	337	5.2	19.4
Efgartigimod Alfa-Fcab	10,719	1	1	1	1	208	3.7	9.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	59	1	1	1	1	28	2.4	6.0
25-40 years	499	1	1	1	1	64	2.8	7.4
41-64 years	1,974	1	1	1	1	128	3.9	10.0
≥ 65 years	8,187	1	1	1	1	208	3.8	9.8
Inclisiran	15,200	1	1	1	1	436	6.1	27.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	1	1	1	1	30	2.3	5.5
41-64 years	871	1	1	1	1	270	12.4	35.6
≥ 65 years	14,295	1	1	1	1	436	5.7	26.8

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

	Distribution of Treatment Episode Durations, days							
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Tralokinumab-Ldrm	2,424	1	16	28	56	420	50.4	53.5
0-17 years	*****	1	14	14	56	140	38.1	48.2
18-24 years	*****	1	19	28	56	420	43.3	48.3
25-40 years	455	1	20	28	56	308	47.0	47.3
41-64 years	951	1	26	28	58	383	53.1	54.4
≥ 65 years	790	1	14	28	56	365	51.2	56.9

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 5a. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

	Number of Patients by First Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>Finerenone</i>	19,188	8,888	46.3%	6,206	32.3%	3,756	19.6%	338	1.8%	0	0.0%
<i>Fexinidazole</i>	0
<i>Belumosudil</i>	810	357	44.1%	228	28.1%	196	24.2%	29	3.6%	0	0.0%
<i>Odevixibat</i>	11	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Anifrolumab-Fnia</i>	1,539	1,483	96.4%	34	2.2%	22	1.4%	0	0.0%	0	0.0%
<i>Avalglucosidase Alfa-Ngpt</i>	137	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Belzutifan</i>	276	131	47.5%	83	30.1%	*****	*****	*****	*****	0	0.0%
<i>Difelikefalin</i>	1,909	1,909	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Lonapegsomatropin-Tcgd</i>	211	109	51.7%	*****	*****	56	26.5%	*****	*****	0	0.0%
<i>Mobocertinib</i>	113	79	69.9%	22	19.5%	*****	*****	*****	*****	0	0.0%
<i>Tisotumab Vedotin-Tftv</i>	171	171	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Atogepant</i>	20,012	11,269	56.3%	5,273	26.3%	3,281	16.4%	189	0.9%	0	0.0%
<i>Maralixibat</i>	24	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Avacopan</i>	222	102	45.9%	77	34.7%	*****	*****	*****	*****	0	0.0%
<i>Asciminib</i>	402	203	50.5%	108	26.9%	*****	*****	*****	*****	0	0.0%
<i>Ropeginterferon Alfa-2b-Njft</i>	276	146	52.9%	60	21.7%	59	21.4%	11	4.0%	0	0.0%
<i>Vosoritide</i>	36	*****	*****	*****	*****	17	47.2%	*****	*****	0	0.0%
<i>Maribavir</i>	273	130	47.6%	104	38.1%	39	14.3%	0	0.0%	0	0.0%
<i>Pafolacianine</i>	0
<i>Tezepelumab-Ekko</i>	4,842	4,493	92.8%	217	4.5%	*****	*****	*****	*****	0	0.0%
<i>Efgartigimod Alfa-Fcab</i>	1,592	1,560	98.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Inclisiran</i>	10,247	9,779	95.4%	302	2.9%	*****	*****	*****	*****	0	0.0%
<i>Tralokinumab-Ldrm</i>	1,234	765	62.0%	266	21.6%	*****	*****	*****	*****	0	0.0%

Table 5a. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Number of Patients by First Treatment Episode Duration										
Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 5b. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

	Distribution of First Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Finerenone</i>	19,188	1	30	47	90	648	79.8	84.4
<i>Fexinidazole</i>	0
<i>Belumosudil</i>	810	1	30	60	120	600	95.2	103.7
<i>Odevixibat</i>	11	18	30	60	120	670	137.7	202.5
<i>Anifrolumab-Fnia</i>	1,539	1	1	1	1	336	5.8	22.0
<i>Avalglucosidase Alfa-Ngpt</i>	137	1	1	1	1	224	6.8	27.1
<i>Belzutifan</i>	276	1	30	48	90	557	82.4	95.5
<i>Difelikefalin</i>	1,909	1	1	1	1	3	1.0	0.1
<i>Lonapegsomatropin-Tcgd</i>	211	1	28	28	112	427	77.7	84.3
<i>Mobocertinib</i>	113	9	30	30	60	521	53.5	63.9
<i>Tisotumab Vedotin-Tftv</i>	171	1	1	1	1	21	1.1	1.5
<i>Atogepant</i>	20,012	1	30	30	90	584	66.9	71.4
<i>Maralixibat</i>	24	3	30	77	259	431	142.0	137.9
<i>Avacopan</i>	222	1	30	44	90	437	72.3	69.8
<i>Asciminib</i>	402	2	30	30	90	466	79.7	87.7
<i>Ropeginterferon Alfa-2b-Njft</i>	276	1	28	28	101	443	88.6	106.3
<i>Vosoritide</i>	36	16	30	153	296	526	173.7	140.9
<i>Maribavir</i>	273	1	28	54	79	336	57.6	49.0
<i>Pafolacianine</i>	0
<i>Tezepelumab-Ekko</i>	4,842	1	1	1	1	403	11.7	32.8
<i>Efgartigimod Alfa-Fcab</i>	1,592	1	1	1	1	128	7.3	13.4
<i>Inclisiran</i>	10,247	1	1	1	1	436	6.8	29.9
<i>Tralokinumab-Ldrm</i>	1,234	1	14	28	56	420	50.4	59.9

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

	Number of Patients by First Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Finerenone	19,188	8,888	100.0%	6,206	100.0%	3,756	100.0%	338	100.0%	0	NaN
<i>Female</i>	8,625	4,101	46.1%	2,739	44.1%	1,631	43.4%	154	45.6%	0	NaN
<i>Male</i>	10,563	4,787	53.9%	3,467	55.9%	2,125	56.6%	184	54.4%	0	NaN
Fexinidazole	0
<i>Female</i>	0
<i>Male</i>	0
Belumosudil	810	357	100.0%	228	100.0%	196	100.0%	29	100.0%	0	NaN
<i>Female</i>	340	145	40.6%	103	45.2%	*****	*****	*****	*****	0	NaN
<i>Male</i>	470	212	59.4%	125	54.8%	*****	*****	*****	*****	0	NaN
Odevixibat	11	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
<i>Female</i>	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
<i>Male</i>	*****	*****	*****	0	0.0%	0	0.0%	*****	*****	0	NaN
Anifrolumab-Fria	1,539	1,483	100.0%	34	100.0%	22	100.0%	0	NaN	0	NaN
<i>Female</i>	1,444	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
<i>Male</i>	95	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Avalglucosidase Alfa-Ngpt	137	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
<i>Female</i>	73	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
<i>Male</i>	64	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Belzutifan	276	131	100.0%	83	100.0%	*****	*****	*****	*****	0	NaN
<i>Female</i>	90	40	30.5%	24	28.9%	*****	*****	*****	*****	0	NaN
<i>Male</i>	186	91	69.5%	59	71.1%	*****	*****	*****	*****	0	NaN
Difelikefalin	1,909	1,909	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
<i>Female</i>	893	893	46.8%	0	NaN	0	NaN	0	NaN	0	NaN

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Number of Patients by First Treatment Episode Duration												
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	
Male	1,016	1,016	53.2%	0	NaN	0	NaN	0	NaN	0	NaN	
Lonapegsomatropin-Tcgd	211	109	100.0%	*****	*****	56	100.0%	*****	*****	0	NaN	
Female	62	37	33.9%	*****	*****	*****	*****	0	0.0%	0	NaN	
Male	149	72	66.1%	*****	*****	*****	*****	*****	*****	0	NaN	
Mobocertinib	113	79	100.0%	22	100.0%	*****	*****	*****	*****	0	NaN	
Female	68	51	64.6%	*****	*****	*****	*****	*****	*****	0	NaN	
Male	45	28	35.4%	*****	*****	*****	*****	0	0.0%	0	NaN	
Tisotumab Vedotin-Tftv	171	171	100.0%	0	NaN	0	NaN	0	NaN	0	NaN	
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN	
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN	
Atogepant	20,012	11,269	100.0%	5,273	100.0%	3,281	100.0%	189	100.0%	0	NaN	
Female	17,049	9,555	84.8%	4,539	86.1%	2,799	85.3%	156	82.5%	0	NaN	
Male	2,963	1,714	15.2%	734	13.9%	482	14.7%	33	17.5%	0	NaN	
Maralixibat	24	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN	
Female	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN	
Male	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN	
Avacopan	222	102	100.0%	77	100.0%	*****	*****	*****	*****	0	NaN	
Female	106	52	51.0%	40	51.9%	*****	*****	*****	*****	0	NaN	
Male	116	50	49.0%	37	48.1%	*****	*****	*****	*****	0	NaN	
Asciminib	402	203	100.0%	108	100.0%	*****	*****	*****	*****	0	NaN	
Female	210	111	54.7%	54	50.0%	*****	*****	*****	*****	0	NaN	
Male	192	92	45.3%	54	50.0%	*****	*****	*****	*****	0	NaN	

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

	Number of Patients by First Treatment Episode Duration										
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Ropeginterferon Alfa-2b-Njft	276	146	100.0%	60	100.0%	59	100.0%	11	100.0%	0	NaN
Female	146	74	50.7%	30	50.0%	*****	*****	*****	*****	0	NaN
Male	130	72	49.3%	30	50.0%	*****	*****	*****	*****	0	NaN
Vosoritide	36	*****	*****	*****	*****	17	100.0%	*****	*****	0	NaN
Female	21	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Male	15	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Maribavir	273	130	100.0%	104	100.0%	39	100.0%	0	NaN	0	NaN
Female	115	62	47.7%	36	34.6%	17	43.6%	0	NaN	0	NaN
Male	158	68	52.3%	68	65.4%	22	56.4%	0	NaN	0	NaN
Pafolacianine	0
Female	0
Male	0
Tezepelumab-Ekko	4,842	4,493	100.0%	217	100.0%	*****	*****	*****	*****	0	NaN
Female	3,275	3,020	67.2%	158	72.8%	*****	*****	*****	*****	0	NaN
Male	1,567	1,473	32.8%	59	27.2%	*****	*****	*****	*****	0	NaN
Efgartigimod Alfa-Fcab	1,592	1,560	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	703	686	44.0%	*****	*****	*****	*****	0	NaN	0	NaN
Male	889	874	56.0%	*****	*****	*****	*****	0	NaN	0	NaN
Inclisiran	10,247	9,779	100.0%	302	100.0%	*****	*****	*****	*****	0	NaN
Female	5,442	5,141	52.6%	194	64.2%	*****	*****	*****	*****	0	NaN
Male	4,805	4,638	47.4%	108	35.8%	*****	*****	*****	*****	0	NaN
Tralokinumab-Ldrm	1,234	765	100.0%	266	100.0%	*****	*****	*****	*****	0	NaN
Female	637	393	51.4%	142	53.4%	*****	*****	*****	*****	0	NaN

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Number of Patients by First Treatment Episode Duration											
Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	
Male	597	372	48.6%	124	46.6%	*****	*****	*****	*****	0	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

	Distribution of First Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Finerenone	19,188	1	30	47	90	648	79.8	84.4
Female	8,625	1	30	42	90	644	78.3	83.7
Male	10,563	1	30	51	90	648	81.1	85.0
Fexinidazole	0
Female	0
Male	0
Belumosudil	810	1	30	60	120	600	95.2	103.7
Female	340	2	30	60	120	600	96.5	105.0
Male	470	1	30	60	120	554	94.2	102.9
Odevixibat	11	18	30	60	120	670	137.7	202.5
Female	*****	18	30	60	101	120	59.9	38.4
Male	*****	30	30	198	518	670	274.0	307.9
Anifrolumab-Fnia	1,539	1	1	1	1	336	5.8	22.0
Female	1,444	1	1	1	1	336	5.9	22.2
Male	95	1	1	1	1	168	4.2	18.5
Avalglucosidase Alfa-Ngpt	137	1	1	1	1	224	6.8	27.1
Female	73	1	1	1	1	224	8.9	35.6
Male	64	1	1	1	1	56	4.4	11.4
Belzutifan	276	1	30	48	90	557	82.4	95.5
Female	90	8	30	54	120	534	95.6	115.8
Male	186	1	30	40	90	557	76.0	83.6
Difelikefalin	1,909	1	1	1	1	3	1.0	0.1
Female	893	1	1	1	1	3	1.0	0.1
Male	1,016	1	1	1	1	2	1.0	0.1
Lonapegsomatropin-Tcgd	211	1	28	28	112	427	77.7	84.3
Female	62	1	28	28	61	278	57.5	60.0
Male	149	1	28	37	125	427	86.1	91.4
Mobocertinib	113	9	30	30	60	521	53.5	63.9
Female	68	9	30	30	33	521	56.5	77.4
Male	45	19	30	30	60	210	49.1	35.1
Tisotumab Vedotin-Tftv	171	1	1	1	1	21	1.1	1.5
Female	*****	1	1	1	1	21	1.1	1.5
Male	*****	*****	*****	*****	*****	*****	*****	*****
Atogepant	20,012	1	30	30	90	584	66.9	71.4
Female	17,049	1	30	30	90	584	67.0	71.1

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	2,963	1	30	30	90	517	66.8	73.2
Maralixibat	24	3	30	77	259	431	142.0	137.9
Female	*****	30	30	60	318	431	145.2	161.9
Male	*****	3	60	91	247	420	139.8	124.5
Avacopan	222	1	30	44	90	437	72.3	69.8
Female	106	2	30	32	79	390	62.4	60.1
Male	116	1	30	59	105	437	81.3	76.8
Asciminib	402	2	30	30	90	466	79.7	87.7
Female	210	2	30	30	90	448	76.5	84.4
Male	192	5	30	42	90	466	83.2	91.2
Ropeginterferon Alfa-2b-Njft	276	1	28	28	101	443	88.6	106.3
Female	146	1	28	30	112	443	95.7	113.8
Male	130	1	28	28	84	392	80.7	97.1
Vosoritide	36	16	30	153	296	526	173.7	140.9
Female	21	30	30	162	242	376	157.2	113.3
Male	15	16	30	136	328	526	196.8	174.0
Maribavir	273	1	28	54	79	336	57.6	49.0
Female	115	1	28	28	79	308	54.4	47.9
Male	158	2	28	56	84	336	59.9	49.9
Pafolacianine	0
Female	0
Male	0
Tezepelumab-Ekko	4,842	1	1	1	1	403	11.7	32.8
Female	3,275	1	1	1	1	403	12.7	35.1
Male	1,567	1	1	1	1	296	9.6	27.3
Efgartigimod Alfa-Fcab	1,592	1	1	1	1	128	7.3	13.4
Female	703	1	1	1	2	128	7.9	14.3
Male	889	1	1	1	1	112	6.8	12.6
Inclisiran	10,247	1	1	1	1	436	6.8	29.9
Female	5,442	1	1	1	1	436	8.1	33.2
Male	4,805	1	1	1	1	429	5.3	25.7

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

	Distribution of First Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Tralokinumab-Ldrm	1,234	1	14	28	56	420	50.4	59.9
Female	637	1	14	28	56	383	49.4	57.8
Male	597	1	14	28	60	420	51.5	62.0

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

	Number of Patients by First Treatment Episode Duration										
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Finerenone	19,188	8,888	100.0%	6,206	100.0%	3,756	100.0%	338	100.0%	0	NaN
<i>0-17 years</i>	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
<i>18-24 years</i>	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
<i>25-40 years</i>	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
<i>41-64 years</i>	3,585	1,651	18.6%	1,196	19.3%	*****	*****	*****	*****	0	NaN
<i>≥ 65 years</i>	15,413	7,124	80.2%	4,962	80.0%	3,044	81.0%	283	83.7%	0	NaN
Fexinidazole	0
<i>0-17 years</i>	0
<i>18-24 years</i>	0
<i>25-40 years</i>	0
<i>41-64 years</i>	0
<i>≥ 65 years</i>	0
Belumosudil	810	357	100.0%	228	100.0%	196	100.0%	29	100.0%	0	NaN
<i>0-17 years</i>	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
<i>18-24 years</i>	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
<i>25-40 years</i>	114	*****	*****	*****	*****	21	10.7%	*****	*****	0	NaN
<i>41-64 years</i>	290	118	33.1%	96	42.1%	*****	*****	*****	*****	0	NaN
<i>≥ 65 years</i>	388	171	47.9%	99	43.4%	*****	*****	*****	*****	0	NaN
Odevixibat	11	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
<i>0-17 years</i>	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
<i>18-24 years</i>	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
<i>25-40 years</i>	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
<i>41-64 years</i>	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Number of Patients by First Treatment Episode Duration											
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
Anifrolumab-Fnia	1,539	1,483	100.0%	34	100.0%	22	100.0%	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	293	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	761	723	48.8%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	446	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Avalglucosidase Alfa-Ngpt	137	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
41-64 years	50	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	62	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Belzutifan	276	131	100.0%	83	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	*****	*****	*****	16	19.3%	*****	*****	*****	*****	0	NaN
41-64 years	109	46	35.1%	*****	*****	29	55.8%	*****	*****	0	NaN
≥ 65 years	108	61	46.6%	34	41.0%	*****	*****	*****	*****	0	NaN
Difelikefalin	1,909	1,909	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Number of Patients by First Treatment Episode Duration											
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	718	718	37.6%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	1,068	1,068	55.9%	0	NaN	0	NaN	0	NaN	0	NaN
Lonapegsomatropin-Tcgd	211	109	100.0%	*****	*****	56	100.0%	*****	*****	0	NaN
0-17 years	211	109	100.0%	*****	*****	56	100.0%	*****	*****	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
Mobocertinib	113	79	100.0%	22	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	93	68	86.1%	*****	*****	*****	*****	*****	*****	0	NaN
Tisotumab Vedotin-Tftv	171	171	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	16	16	9.4%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	77	77	45.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	78	78	45.6%	0	NaN	0	NaN	0	NaN	0	NaN
Atogepant	20,012	11,269	100.0%	5,273	100.0%	3,281	100.0%	189	100.0%	0	NaN
0-17 years	55	34	0.3%	*****	*****	*****	*****	*****	*****	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Number of Patients by First Treatment Episode Duration											
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
18-24 years	1,125	674	6.0%	*****	*****	148	4.5%	*****	*****	0	NaN
25-40 years	4,582	2,576	22.9%	1,256	23.8%	*****	*****	*****	*****	0	NaN
41-64 years	10,950	6,063	53.8%	2,884	54.7%	1,911	58.2%	92	48.7%	0	NaN
≥ 65 years	3,300	1,922	17.1%	820	15.6%	506	15.4%	52	27.5%	0	NaN
Maralixibat	24	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
Avacopan	222	102	100.0%	77	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
41-64 years	78	*****	*****	*****	*****	17	41.5%	0	0.0%	0	NaN
≥ 65 years	121	52	51.0%	48	62.3%	*****	*****	*****	*****	0	NaN
Asciminib	402	203	100.0%	108	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	11	13.3%	0	0.0%	0	NaN
41-64 years	145	76	37.4%	*****	*****	*****	*****	*****	*****	0	NaN
≥ 65 years	211	100	49.3%	56	51.9%	*****	*****	*****	*****	0	NaN
Ropeginterferon Alfa-2b-Njft	276	146	100.0%	60	100.0%	59	100.0%	11	100.0%	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Number of Patients by First Treatment Episode Duration											
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	22	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	82	*****	*****	*****	*****	26	44.1%	*****	*****	0	NaN
≥ 65 years	172	95	65.1%	38	63.3%	*****	*****	*****	*****	0	NaN
Vosoritide	36	*****	*****	*****	*****	17	100.0%	*****	*****	0	NaN
0-17 years	36	*****	*****	*****	*****	17	100.0%	*****	*****	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
Maribavir	273	130	100.0%	104	100.0%	39	100.0%	0	NaN	0	NaN
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	*****	*****	*****	22	21.2%	*****	*****	0	NaN	0	NaN
41-64 years	136	70	53.8%	48	46.2%	18	46.2%	0	NaN	0	NaN
≥ 65 years	84	41	31.5%	*****	*****	*****	*****	0	NaN	0	NaN
Pafolacianine	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Number of Patients by First Treatment Episode Duration											
	Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
≥ 65 years	0
Tezepelumab-Ekko	4,842	4,493	100.0%	217	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	26	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	34	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	280	250	5.6%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	1,506	1,345	29.9%	105	48.4%	*****	*****	*****	*****	0	NaN
≥ 65 years	2,996	2,844	63.3%	92	42.4%	60	46.2%	0	0.0%	0	NaN
Efgartigimod Alfa-Fcab	1,592	1,560	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	273	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	1,250	1,225	78.5%	*****	*****	*****	*****	0	NaN	0	NaN
Inclisiran	10,247	9,779	100.0%	302	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	611	546	5.6%	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	9,614	9,211	94.2%	*****	*****	*****	*****	*****	*****	0	NaN
Tralokinumab-Ldrm	1,234	765	100.0%	266	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
18-24 years	*****	*****	*****	29	10.9%	13	6.5%	*****	*****	0	NaN
25-40 years	239	149	19.5%	57	21.4%	33	16.5%	0	0.0%	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Number of Patients by First Treatment Episode Duration											
Total Number of Patients	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	
41-64 years	468	277	36.2%	101	38.0%	*****	*****	*****	*****	0	NaN
≥ 65 years	414	270	35.3%	79	29.7%	65	32.5%	0	0.0%	0	NaN

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Finerenone	19,188	1	30	47	90	648	79.8	84.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	30	60	60	90	90	66.0	25.1
25-40 years	*****	8	30	30	78	540	66.0	77.7
41-64 years	3,585	1	30	50	90	644	77.5	79.8
≥ 65 years	15,413	1	30	47	90	648	80.5	85.5
Fexinidazole	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0
Belumosudil	810	1	30	60	120	600	95.2	103.7
0-17 years	*****	30	30	60	154	317	101.6	105.2
18-24 years	*****	19	30	60	120	300	87.6	82.0
25-40 years	114	4	30	30	84	478	77.6	90.1
41-64 years	290	1	30	60	120	600	91.2	95.4
≥ 65 years	388	3	30	60	142	558	103.4	113.2
Odevixibat	11	18	30	60	120	670	137.7	202.5
0-17 years	*****	30	30	60	366	670	190.9	242.0
18-24 years	*****	18	18	30	101	101	49.7	44.9
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Anifrolumab-Fnia	1,539	1	1	1	1	336	5.8	22.0
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	1	1	1	1	30	1.8	4.7
25-40 years	293	1	1	1	1	336	6.2	28.0
41-64 years	761	1	1	1	1	252	7.4	23.6
≥ 65 years	446	1	1	1	1	168	3.2	13.8
Avalglucosidase Alfa-Ngpt	137	1	1	1	1	224	6.8	27.1
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	1	1	1	1	112	11.5	27.5
41-64 years	50	1	1	1	1	224	11.2	40.7

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	62	1	1	1	1	56	2.8	8.4
Belzutifan	276	1	30	48	90	557	82.4	95.5
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	30	60	90	95	180	83.9	47.0
25-40 years	*****	11	30	60	90	557	102.7	132.5
41-64 years	109	8	30	60	120	478	98.7	104.3
≥ 65 years	108	1	30	30	60	390	57.2	57.6
Difelikefalin	1,909	1	1	1	1	3	1.0	0.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	*****	1	1	1	1	2	1.0	0.2
41-64 years	718	1	1	1	1	3	1.0	0.1
≥ 65 years	1,068	1	1	1	1	2	1.0	0.1
Lonapegsomatropin-Tcgd	211	1	28	28	112	427	77.7	84.3
0-17 years	211	1	28	28	112	427	77.7	84.3
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mobocertinib	113	9	30	30	60	521	53.5	63.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	30	60	90	90	60.0	42.4
41-64 years	*****	19	30	30	60	210	61.8	54.0
≥ 65 years	93	9	30	30	36	521	51.8	66.3
Tisotumab Vedotin-Tftv	171	1	1	1	1	21	1.1	1.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	16	1	1	1	1	1	1.0	0.0
41-64 years	77	1	1	1	1	21	1.3	2.3
≥ 65 years	78	1	1	1	1	1	1.0	0.0
Atogepant	20,012	1	30	30	90	584	66.9	71.4
0-17 years	55	2	30	30	60	369	50.9	54.9
18-24 years	1,125	1	30	30	60	522	60.3	62.2
25-40 years	4,582	1	30	30	81	555	65.1	69.2

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	10,950	1	30	30	90	556	68.1	71.3
≥ 65 years	3,300	1	30	30	88	584	68.1	77.4
Maralixibat	24	3	30	77	259	431	142.0	137.9
0-17 years	*****	3	30	90	296	431	164.4	150.0
18-24 years	*****	30	30	60	120	180	84.0	65.0
25-40 years	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Avacopan	222	1	30	44	90	437	72.3	69.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	55	56	90	90	158	89.8	41.8
25-40 years	*****	1	30	30	60	437	82.3	107.2
41-64 years	78	12	30	30	90	251	68.9	58.3
≥ 65 years	121	2	30	54	90	390	72.3	71.2
Asciminib	402	2	30	30	90	466	79.7	87.7
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	*****	25	25	26	30	30	27.0	2.6
25-40 years	*****	14	30	30	110	360	83.5	88.5
41-64 years	145	7	30	30	61	466	75.2	92.8
≥ 65 years	211	2	30	39	103	418	83.0	84.6
Ropeginterferon Alfa-2b-Njft	276	1	28	28	101	443	88.6	106.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	22	28	28	29	84	364	73.2	82.4
41-64 years	82	1	28	56	140	389	97.9	106.6
≥ 65 years	172	1	28	28	84	443	86.2	109.0
Vosoritide	36	16	30	153	296	526	173.7	140.9
0-17 years	36	16	30	153	296	526	173.7	140.9
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Maribavir	273	1	28	54	79	336	57.6	49.0
0-17 years	*****	4	4	28	56	56	29.3	26.0

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of First Treatment Episode Duration, days								
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	*****	28	28	90	112	112	76.7	43.6
25-40 years	*****	7	28	56	84	243	66.7	50.4
41-64 years	136	1	28	28	61	336	57.0	54.9
≥ 65 years	84	1	28	46	84	168	53.6	37.6
Pafolacianine	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0
Tezepelumab-Ekko	4,842	1	1	1	1	403	11.7	32.8
0-17 years	26	1	1	1	1	56	7.6	14.6
18-24 years	34	1	1	1	28	140	15.5	30.1
25-40 years	280	1	1	1	19	308	17.5	41.7
41-64 years	1,506	1	1	1	28	403	16.6	39.3
≥ 65 years	2,996	1	1	1	1	337	8.7	27.7
Efgartigimod Alfa-Fcab	1,592	1	1	1	1	128	7.3	13.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	28	4.4	9.5
25-40 years	*****	1	1	1	1	30	5.9	10.3
41-64 years	273	1	1	1	1	128	7.4	15.3
≥ 65 years	1,250	1	1	1	1	112	7.4	13.1
Inclisiran	10,247	1	1	1	1	436	6.8	29.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	*****	1	1	1	1	30	3.0	6.9
41-64 years	611	1	1	1	1	270	13.9	39.0
≥ 65 years	9,614	1	1	1	1	436	6.4	29.2

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

	Distribution of First Treatment Episode Duration, days							
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Tralokinumab-Ldrm	1,234	1	14	28	56	420	50.4	59.9
0-17 years	*****	1	8	14	77	140	42.3	65.5
18-24 years	*****	1	14	28	56	420	49.0	62.0
25-40 years	239	1	14	28	56	255	47.0	50.4
41-64 years	468	1	14	28	62	383	54.6	62.6
≥ 65 years	414	1	14	18	56	365	48.1	61.2

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 6a. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Number of Treatment Episodes by Duration (Excluding First Treatment Episode)											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Finerenone</i>	16,366	8,696	53.1%	5,361	32.8%	2,222	13.6%	87	0.5%	0	0.0%
<i>Fexinidazole</i>	0
<i>Belumosudil</i>	1,235	712	57.7%	345	27.9%	*****	*****	*****	*****	0	0.0%
<i>Odevixibat</i>	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Anifrolumab-Fnia</i>	6,039	5,950	98.5%	77	1.3%	12	0.2%	0	0.0%	0	0.0%
<i>Avalglucosidase Alfa-Ngpt</i>	1,951	1,926	98.7%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Belzutifan</i>	380	247	65.0%	90	23.7%	*****	*****	*****	*****	0	0.0%
<i>Difelikefalin</i>	46,503	46,503	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Lonapegsomatropin-Tcgd</i>	184	95	51.6%	48	26.1%	41	22.3%	0	0.0%	0	0.0%
<i>Mobocertinib</i>	111	67	60.4%	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Tisotumab Vedotin-Tftv</i>	471	471	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Atogepant</i>	20,522	12,412	60.5%	5,619	27.4%	2,439	11.9%	52	0.3%	0	0.0%
<i>Maralixibat</i>	41	24	58.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Avacopan</i>	235	138	58.7%	69	29.4%	28	11.9%	0	0.0%	0	0.0%
<i>Asciminib</i>	574	349	60.8%	153	26.7%	*****	*****	*****	*****	0	0.0%
<i>Ropeginterferon Alfa-2b-Njft</i>	470	275	58.5%	110	23.4%	*****	*****	*****	*****	0	0.0%
<i>Vosoritide</i>	28	15	53.6%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Maribavir</i>	167	95	56.9%	52	31.1%	20	12.0%	0	0.0%	0	0.0%
<i>Pafolacianine</i>	0
<i>Tezepelumab-Ekko</i>	15,439	14,855	96.2%	435	2.8%	149	1.0%	0	0.0%	0	0.0%
<i>Efgartigimod Alfa-Fcab</i>	9,127	9,033	99.0%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Inclisiran</i>	4,953	4,785	96.6%	106	2.1%	62	1.3%	0	0.0%	0	0.0%
<i>Tralokinumab-Ldrm</i>	1,190	719	60.4%	323	27.1%	148	12.4%	0	0.0%	0	0.0%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.*

Table 6b. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Finerenone</i>	16,366	1	30	30	86	561	60.9	60.4
<i>Fexinidazole</i>	0
<i>Belumosudil</i>	1,235	1	30	30	60	487	62.0	65.4
<i>Odevixibat</i>	*****	30	31	47	90	90	55.7	27.7
<i>Anifrolumab-Fnia</i>	6,039	1	1	1	1	304	2.8	10.9
<i>Avalglucosidase Alfa-Ngpt</i>	1,951	1	1	1	1	315	2.7	15.6
<i>Belzutifan</i>	380	2	30	30	60	444	56.3	66.3
<i>Difelikefalin</i>	46,503	1	1	1	1	3	1.0	0.1
<i>Lonapegsomatropin-Tcgd</i>	184	1	28	28	84	363	61.0	61.9
<i>Mobocertinib</i>	111	8	30	30	60	370	54.2	56.2
<i>Tisotumab Vedotin-Tftv</i>	471	1	1	1	1	1	1.0	0.0
<i>Atogepant</i>	20,522	1	30	30	60	555	54.7	53.4
<i>Maralixibat</i>	41	13	30	30	60	183	53.2	40.2
<i>Avacopan</i>	235	1	30	30	60	310	53.4	51.6
<i>Asciminib</i>	574	1	30	30	60	377	56.9	58.9
<i>Ropeginterferon Alfa-2b-Njft</i>	470	1	19	28	83	410	57.6	69.0
<i>Vosoritide</i>	28	3	30	30	100	303	69.8	70.3
<i>Maribavir</i>	167	2	28	28	61	213	51.7	41.8
<i>Pafolacianine</i>	0
<i>Tezepelumab-Ekko</i>	15,439	1	1	1	1	308	5.5	19.0
<i>Efgartigimod Alfa-Fcab</i>	9,127	1	1	1	1	208	3.1	8.8
<i>Inclisiran</i>	4,953	1	1	1	1	299	4.7	21.0
<i>Tralokinumab-Ldrm</i>	1,190	1	28	28	56	308	50.4	46.0

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Number of Treatment Episodes by Duration (Excluding First Treatment Episode)											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Finerenone	16,366	8,696	100.0%	5,361	100.0%	2,222	100.0%	87	100.0%	0	NaN
<i>Female</i>	7,399	3,996	46.0%	2,396	44.7%	973	43.8%	34	39.1%	0	NaN
<i>Male</i>	8,967	4,700	54.0%	2,965	55.3%	1,249	56.2%	53	60.9%	0	NaN
Fexinidazole	0
<i>Female</i>	0
<i>Male</i>	0
Belumosudil	1,235	712	100.0%	345	100.0%	*****	*****	*****	*****	0	NaN
<i>Female</i>	485	268	37.6%	132	38.3%	*****	*****	*****	*****	0	NaN
<i>Male</i>	750	444	62.4%	213	61.7%	*****	*****	*****	*****	0	NaN
Odevixibat	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
<i>Female</i>	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
<i>Male</i>	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Anifrolumab-Fria	6,039	5,950	100.0%	77	100.0%	12	100.0%	0	NaN	0	NaN
<i>Female</i>	5,689	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
<i>Male</i>	350	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Avalglucosidase Alfa-Ngpt	1,951	1,926	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
<i>Female</i>	1,022	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
<i>Male</i>	929	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Belzutifan	380	247	100.0%	90	100.0%	*****	*****	*****	*****	0	NaN
<i>Female</i>	159	99	40.1%	45	50.0%	*****	*****	*****	*****	0	NaN
<i>Male</i>	221	148	59.9%	45	50.0%	*****	*****	*****	*****	0	NaN
Difelikefalin	46,503	46,503	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
<i>Female</i>	20,890	20,890	44.9%	0	NaN	0	NaN	0	NaN	0	NaN

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Number of Treatment Episodes by Duration (Excluding First Treatment Episode)											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Male	25,613	25,613	55.1%	0	NaN	0	NaN	0	NaN	0	NaN
Lonapegsomatropin-Tcgd	184	95	100.0%	48	100.0%	41	100.0%	0	NaN	0	NaN
Female	71	41	43.2%	17	35.4%	13	31.7%	0	NaN	0	NaN
Male	113	54	56.8%	31	64.6%	28	68.3%	0	NaN	0	NaN
Mobocertinib	111	67	100.0%	35	100.0%	*****	*****	*****	*****	0	NaN
Female	65	40	59.7%	*****	*****	*****	*****	*****	*****	0	NaN
Male	46	27	40.3%	*****	*****	*****	*****	0	0.0%	0	NaN
Tisotumab Vedotin-Tftv	471	471	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	471	471	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Atogepant	20,522	12,412	100.0%	5,619	100.0%	2,439	100.0%	52	100.0%	0	NaN
Female	17,744	10,761	86.7%	4,839	86.1%	*****	*****	*****	*****	0	NaN
Male	2,778	1,651	13.3%	780	13.9%	*****	*****	*****	*****	0	NaN
Maralixibat	41	24	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	11	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	30	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Avacopan	235	138	100.0%	69	100.0%	28	100.0%	0	NaN	0	NaN
Female	112	66	47.8%	35	50.7%	11	39.3%	0	NaN	0	NaN
Male	123	72	52.2%	34	49.3%	17	60.7%	0	NaN	0	NaN
Asciminib	574	349	100.0%	153	100.0%	*****	*****	*****	*****	0	NaN
Female	319	194	55.6%	81	52.9%	*****	*****	*****	*****	0	NaN
Male	255	155	44.4%	72	47.1%	*****	*****	*****	*****	0	NaN

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Number of Treatment Episodes by Duration (Excluding First Treatment Episode)											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Ropeginterferon Alfa-2b-Njft	470	275	100.0%	110	100.0%	*****	*****	*****	*****	0	NaN
Female	221	121	44.0%	54	49.1%	*****	*****	*****	*****	0	NaN
Male	249	154	56.0%	56	50.9%	*****	*****	*****	*****	0	NaN
Vosoritide	28	15	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	15	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	13	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Maribavir	167	95	100.0%	52	100.0%	20	100.0%	0	NaN	0	NaN
Female	86	50	52.6%	*****	*****	*****	*****	0	NaN	0	NaN
Male	81	45	47.4%	*****	*****	*****	*****	0	NaN	0	NaN
Pafolacianine	0
Female	0
Male	0
Tezepelumab-Ekko	15,439	14,855	100.0%	435	100.0%	149	100.0%	0	NaN	0	NaN
Female	10,342	9,919	66.8%	310	71.3%	113	75.8%	0	NaN	0	NaN
Male	5,097	4,936	33.2%	125	28.7%	36	24.2%	0	NaN	0	NaN
Efgartigimod Alfa-Fcab	9,127	9,033	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
Female	3,737	3,692	40.9%	*****	*****	*****	*****	0	NaN	0	NaN
Male	5,390	5,341	59.1%	*****	*****	*****	*****	0	NaN	0	NaN
Inclisiran	4,953	4,785	100.0%	106	100.0%	62	100.0%	0	NaN	0	NaN
Female	2,605	2,497	52.2%	62	58.5%	46	74.2%	0	NaN	0	NaN
Male	2,348	2,288	47.8%	44	41.5%	16	25.8%	0	NaN	0	NaN
Tralokinumab-Ldrm	1,190	719	100.0%	323	100.0%	148	100.0%	0	NaN	0	NaN
Female	597	369	51.3%	156	48.3%	72	48.6%	0	NaN	0	NaN

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Number of Treatment Episodes by Duration (Excluding First Treatment Episode)											
Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	
Male	593	350	48.7%	167	51.7%	76	51.4%	0	NaN	0	NaN

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Finerenone	16,366	1	30	30	86	561	60.9	60.4
Female	7,399	1	30	30	82	561	60.0	59.6
Male	8,967	1	30	30	88	529	61.7	61.0
Fexinidazole	0
Female	0
Male	0
Belumosudil	1,235	1	30	30	60	487	62.0	65.4
Female	485	1	30	30	90	487	68.1	74.1
Male	750	1	30	30	60	469	58.1	58.7
Odevixibat	*****	30	31	47	90	90	55.7	27.7
Female	*****	30	36	47	71	90	53.3	26.0
Male	*****	31	31	61	90	90	60.5	41.7
Anifrolumab-Fnia	6,039	1	1	1	1	304	2.8	10.9
Female	5,689	1	1	1	1	304	2.8	10.8
Male	350	1	1	1	1	155	3.1	11.8
Avalglucosidase Alfa-Ngpt	1,951	1	1	1	1	315	2.7	15.6
Female	1,022	1	1	1	1	315	2.6	16.3
Male	929	1	1	1	1	280	2.9	14.8
Belzutifan	380	2	30	30	60	444	56.3	66.3
Female	159	2	30	30	60	420	54.6	59.7
Male	221	2	30	30	60	444	57.4	70.9
Difelikefalin	46,503	1	1	1	1	3	1.0	0.1
Female	20,890	1	1	1	1	3	1.0	0.1
Male	25,613	1	1	1	1	3	1.0	0.1
Lonapegsomatropin-Tcgd	184	1	28	28	84	363	61.0	61.9
Female	71	1	20	28	56	292	50.6	54.1
Male	113	1	28	41	84	363	67.4	65.7
Mobocertinib	111	8	30	30	60	370	54.2	56.2
Female	65	17	30	30	60	370	56.5	63.9
Male	46	8	30	30	60	240	50.9	43.6
Tisotumab Vedotin-Tftv	471	1	1	1	1	1	1.0	0.0
Female	471	1	1	1	1	1	1.0	0.0
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Atogepant	20,522	1	30	30	60	555	54.7	53.4
Female	17,744	1	30	30	60	555	54.6	53.3

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	2,778	1	30	30	60	430	55.6	54.1
Maralixibat	41	13	30	30	60	183	53.2	40.2
Female	11	30	30	30	79	150	59.1	47.8
Male	30	13	30	30	60	183	51.0	37.7
Avacopan	235	1	30	30	60	310	53.4	51.6
Female	112	2	30	30	60	278	51.9	48.0
Male	123	1	30	30	60	310	54.8	54.9
Asciminib	574	1	30	30	60	377	56.9	58.9
Female	319	4	30	30	60	360	57.7	60.8
Male	255	1	30	30	60	377	55.9	56.5
Ropeginterferon Alfa-2b-Njft	470	1	19	28	83	410	57.6	69.0
Female	221	1	26	28	84	373	60.5	66.3
Male	249	1	14	28	69	410	55.0	71.3
Vosoritide	28	3	30	30	100	303	69.8	70.3
Female	15	15	30	59	148	303	89.1	84.7
Male	13	3	30	30	60	150	47.5	41.7
Maribavir	167	2	28	28	61	213	51.7	41.8
Female	86	5	28	28	56	201	51.0	41.4
Male	81	2	28	28	84	213	52.5	42.5
Pafolacianine	0
Female	0
Male	0
Tezepelumab-Ekko	15,439	1	1	1	1	308	5.5	19.0
Female	10,342	1	1	1	1	308	5.9	19.7
Male	5,097	1	1	1	1	298	4.9	17.5
Efgartigimod Alfa-Fcab	9,127	1	1	1	1	208	3.1	8.8
Female	3,737	1	1	1	1	176	3.4	9.4
Male	5,390	1	1	1	1	208	2.9	8.3
Inclisiran	4,953	1	1	1	1	299	4.7	21.0
Female	2,605	1	1	1	1	270	5.7	23.9
Male	2,348	1	1	1	1	299	3.6	17.1

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Tralokinumab-Ldrm	1,190	1	28	28	56	308	50.4	46.0
Female	597	1	28	28	56	308	49.9	45.8
Male	593	1	28	28	56	308	50.8	46.3

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Number of Treatment Episodes by Duration (Excluding First Treatment Episode)											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Finerenone	16,366	8,696	100.0%	5,361	100.0%	2,222	100.0%	87	100.0%	0	NaN
<i>0-17 years</i>	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
<i>18-24 years</i>	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
<i>25-40 years</i>	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
<i>41-64 years</i>	3,305	1,877	21.6%	1,004	18.7%	*****	*****	*****	*****	0	NaN
<i>≥ 65 years</i>	12,903	6,704	77.1%	4,325	80.7%	1,801	81.1%	73	83.9%	0	NaN
Fexinidazole	0
<i>0-17 years</i>	0
<i>18-24 years</i>	0
<i>25-40 years</i>	0
<i>41-64 years</i>	0
<i>≥ 65 years</i>	0
Belumosudil	1,235	712	100.0%	345	100.0%	*****	*****	*****	*****	0	NaN
<i>0-17 years</i>	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
<i>18-24 years</i>	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
<i>25-40 years</i>	226	138	19.4%	*****	*****	35	20.6%	*****	*****	0	NaN
<i>41-64 years</i>	406	229	32.2%	114	33.0%	*****	*****	*****	*****	0	NaN
<i>≥ 65 years</i>	581	331	46.5%	173	50.1%	*****	*****	*****	*****	0	NaN
Odevixibat	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
<i>0-17 years</i>	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
<i>18-24 years</i>	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
<i>25-40 years</i>	*****	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
<i>41-64 years</i>	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Number of Treatment Episodes by Duration (Excluding First Treatment Episode)											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
Anifrolumab-Fnia	6,039	5,950	100.0%	77	100.0%	12	100.0%	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	1,181	1,165	19.6%	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	2,903	2,843	47.8%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	1,803	1,790	30.1%	*****	*****	*****	*****	0	NaN	0	NaN
Avalglucosidase Alfa-Ngpt	1,951	1,926	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	104	104	5.4%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	621	610	31.7%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	1,037	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Belzutifan	380	247	100.0%	90	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	*****	*****	*****	28	31.1%	*****	*****	0	0.0%	0	NaN
41-64 years	163	109	44.1%	31	34.4%	*****	*****	*****	*****	0	NaN
≥ 65 years	106	68	27.5%	*****	*****	*****	*****	0	0.0%	0	NaN
Difelikefalin	46,503	46,503	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	133	133	0.3%	0	NaN	0	NaN	0	NaN	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Number of Treatment Episodes by Duration (Excluding First Treatment Episode)											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	2,562	2,562	5.5%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	17,865	17,865	38.4%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	25,943	25,943	55.8%	0	NaN	0	NaN	0	NaN	0	NaN
Lonapegsomatropin-Tcgd	184	95	100.0%	48	100.0%	41	100.0%	0	NaN	0	NaN
0-17 years	184	95	100.0%	48	100.0%	41	100.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
Mobocertinib	111	67	100.0%	*****	*****	*****	*****	*****	*****	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	95	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
Tisotumab Vedotin-Tftv	471	471	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	51	51	10.8%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	244	244	51.8%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	176	176	37.4%	0	NaN	0	NaN	0	NaN	0	NaN
Atogepant	20,522	12,412	100.0%	5,619	100.0%	2,439	100.0%	52	100.0%	0	NaN
0-17 years	60	39	0.3%	*****	*****	*****	*****	0	0.0%	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Number of Treatment Episodes by Duration (Excluding First Treatment Episode)											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
18-24 years	1,223	781	6.3%	*****	*****	131	5.4%	*****	*****	0	NaN
25-40 years	4,781	2,981	24.0%	1,270	22.6%	*****	*****	*****	*****	0	NaN
41-64 years	11,794	7,062	56.9%	3,261	58.0%	1,446	59.3%	25	48.1%	0	NaN
≥ 65 years	2,664	1,549	12.5%	763	13.6%	340	13.9%	12	23.1%	0	NaN
Maralixibat	41	24	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	26	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
Avacopan	235	138	100.0%	69	100.0%	28	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	129	77	55.8%	40	58.0%	12	42.9%	0	NaN	0	NaN
≥ 65 years	75	36	26.1%	*****	*****	*****	*****	0	NaN	0	NaN
Asciminib	574	349	100.0%	153	100.0%	*****	*****	*****	*****	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	20	13.1%	*****	*****	0	0.0%	0	NaN
41-64 years	255	168	48.1%	66	43.1%	*****	*****	*****	*****	0	NaN
≥ 65 years	248	138	39.5%	67	43.8%	43	60.6%	0	0.0%	0	NaN
Ropeginterferon Alfa-2b-Njft	470	275	100.0%	110	100.0%	*****	*****	*****	*****	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Number of Treatment Episodes by Duration (Excluding First Treatment Episode)											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	41	21	7.6%	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	143	96	34.9%	*****	*****	18	21.7%	*****	*****	0	NaN
≥ 65 years	286	158	57.5%	71	64.5%	*****	*****	*****	*****	0	NaN
Vosoritide	28	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	28	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
Maribavir	167	95	100.0%	52	100.0%	20	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	18	34.6%	*****	*****	0	NaN	0	NaN
41-64 years	74	42	44.2%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	39	22	23.2%	*****	*****	*****	*****	0	NaN	0	NaN
Pafolacianine	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Number of Treatment Episodes by Duration (Excluding First Treatment Episode)											
	Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Tezepelumab-Ekko	15,439	14,855	100.0%	435	100.0%	149	100.0%	0	NaN	0	NaN
0-17 years	62	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
18-24 years	104	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	798	740	5.0%	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	4,242	4,003	26.9%	172	39.5%	67	45.0%	0	NaN	0	NaN
≥ 65 years	10,233	9,958	67.0%	207	47.6%	68	45.6%	0	NaN	0	NaN
Efgartigimod Alfa-Fcab	9,127	9,033	100.0%	*****	*****	*****	*****	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	51	51	0.6%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	438	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	1,701	*****	*****	21	25.0%	*****	*****	0	NaN	0	NaN
≥ 65 years	6,937	6,871	76.1%	*****	*****	*****	*****	0	NaN	0	NaN
Inclisiran	4,953	4,785	100.0%	106	100.0%	62	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	12	12	0.3%	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	260	242	5.1%	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	4,681	4,531	94.7%	*****	*****	*****	*****	0	NaN	0	NaN
Tralokinumab-Ldrm	1,190	719	100.0%	323	100.0%	148	100.0%	0	NaN	0	NaN
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	27	8.4%	*****	*****	0	NaN	0	NaN
25-40 years	216	140	19.5%	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	483	286	39.8%	125	38.7%	72	48.6%	0	NaN	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Number of Treatment Episodes by Duration (Excluding First Treatment Episode)											
Total Number of Episodes	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days		
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	
≥ 65 years	376	211	29.3%	117	36.2%	48	32.4%	0	NaN	0	NaN

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Finerenone	16,366	1	30	30	86	561	60.9	60.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	8	14	33	68	90	40.8	36.3
25-40 years	*****	4	30	30	45	470	48.1	55.3
41-64 years	3,305	1	30	30	78	529	57.6	55.9
≥ 65 years	12,903	1	30	30	88	561	61.9	61.5
Fexinidazole	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0
Belumosudil	1,235	1	30	30	60	487	62.0	65.4
0-17 years	*****	9	30	30	60	180	55.4	52.5
18-24 years	*****	10	30	30	60	90	42.5	25.7
25-40 years	226	2	30	30	60	420	60.4	63.1
41-64 years	406	1	30	30	75	469	63.3	65.9
≥ 65 years	581	1	30	30	60	487	62.3	66.7
Odevixibat	*****	30	31	47	90	90	55.7	27.7
0-17 years	*****	30	36	47	71	90	53.3	26.0
18-24 years	*****	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	31	31	61	90	90	60.5	41.7
41-64 years	*****	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	*****	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Anifrolumab-Fnia	6,039	1	1	1	1	304	2.8	10.9
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	1,181	1	1	1	1	207	2.9	10.7
41-64 years	2,903	1	1	1	1	168	3.5	12.1
≥ 65 years	1,803	1	1	1	1	304	1.8	9.3
Avalglucosidase Alfa-Ngpt	1,951	1	1	1	1	315	2.7	15.6
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	1	1.0	0.0
25-40 years	187	1	1	1	1	84	4.9	13.3
41-64 years	621	1	1	1	1	315	3.5	20.3

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	1,037	1	1	1	1	303	2.0	13.3
Belzutifan	380	2	30	30	60	444	56.3	66.3
0-17 years	*****	30	30	119	207	207	118.5	125.2
18-24 years	*****	17	30	40	281	368	119.0	143.2
25-40 years	*****	2	30	30	60	338	47.5	46.8
41-64 years	163	4	30	30	60	444	61.6	79.4
≥ 65 years	106	3	30	30	60	243	51.2	47.4
Difelikefalin	46,503	1	1	1	1	3	1.0	0.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	133	1	1	1	1	1	1.0	0.0
25-40 years	2,562	1	1	1	1	3	1.0	0.2
41-64 years	17,865	1	1	1	1	3	1.0	0.1
≥ 65 years	25,943	1	1	1	1	3	1.0	0.1
Lonapegsomatropin-Tcgd	184	1	28	28	84	363	61.0	61.9
0-17 years	184	1	28	28	84	363	61.0	61.9
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mobocertinib	111	8	30	30	60	370	54.2	56.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	30	30	30	30	30.0	0.0
41-64 years	*****	14	30	32	90	270	64.1	66.8
≥ 65 years	95	8	30	30	60	370	53.2	55.3
Tisotumab Vedotin-Tftv	471	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	51	1	1	1	1	1	1.0	0.0
41-64 years	244	1	1	1	1	1	1.0	0.0
≥ 65 years	176	1	1	1	1	1	1.0	0.0
Atogepant	20,522	1	30	30	60	555	54.7	53.4
0-17 years	60	2	30	30	59	180	44.5	37.3
18-24 years	1,223	1	30	30	60	459	52.2	52.7
25-40 years	4,781	1	30	30	60	555	52.4	50.9

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>41-64 years</i>	11,794	1	30	30	60	509	55.3	53.6
<i>≥ 65 years</i>	2,664	1	30	30	60	472	57.5	57.1
Maralixibat	41	13	30	30	60	183	53.2	40.2
0-17 years	26	13	30	30	60	183	50.2	39.6
18-24 years	*****	30	30	32	61	150	58.9	44.3
25-40 years	*****	30	30	55	79	79	54.5	34.6
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Avacopan	235	1	30	30	60	310	53.4	51.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	27	30	30	30	60	34.5	12.5
25-40 years	*****	7	30	30	30	180	40.7	34.5
41-64 years	129	2	30	30	60	310	50.6	49.7
≥ 65 years	75	1	30	36	72	270	64.0	59.5
Asciminib	574	1	30	30	60	377	56.9	58.9
0-17 years	*****	26	28	30	30	30	29.0	2.0
18-24 years	*****	30	30	30	30	30	30.0	NaN
25-40 years	*****	2	30	30	60	360	62.5	69.0
41-64 years	255	1	30	30	60	377	49.5	51.4
≥ 65 years	248	4	30	30	73	360	63.7	62.8
Ropeginterferon Alfa-2b-Njft	470	1	19	28	83	410	57.6	69.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	41	2	28	30	84	349	77.7	79.4
41-64 years	143	1	1	28	56	373	46.5	66.4
≥ 65 years	286	1	26	28	84	410	60.2	68.0
Vosoritide	28	3	30	30	100	303	69.8	70.3
0-17 years	28	3	30	30	100	303	69.8	70.3
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Maribavir	167	2	28	28	61	213	51.7	41.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	*****	4	4	28	56	56	29.3	26.0
25-40 years	51	2	28	28	56	201	48.9	37.6
41-64 years	74	5	28	28	84	213	54.2	44.5
≥ 65 years	*****	5	28	28	81	196	52.4	43.3
Pafolacianine	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0
Tezepelumab-Ekko	15,439	1	1	1	1	308	5.5	19.0
0-17 years	62	1	1	1	1	56	6.4	14.6
18-24 years	104	1	1	1	1	112	9.0	22.0
25-40 years	798	1	1	1	1	224	9.1	23.1
41-64 years	4,242	1	1	1	1	308	8.2	23.6
≥ 65 years	10,233	1	1	1	1	280	4.1	16.1
Efgartigimod Alfa-Fcab	9,127	1	1	1	1	208	3.1	8.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	51	1	1	1	1	28	2.1	5.3
25-40 years	438	1	1	1	1	64	2.4	6.8
41-64 years	1,701	1	1	1	1	100	3.3	8.8
≥ 65 years	6,937	1	1	1	1	208	3.1	8.9
Inclisiran	4,953	1	1	1	1	299	4.7	21.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	12	1	1	1	1	2	1.1	0.3
41-64 years	260	1	1	1	1	180	8.8	25.5
≥ 65 years	4,681	1	1	1	1	299	4.5	20.7

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of Treatment Episode Durations Excluding First Treatment Episode, days								
	Total Number of Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Tralokinumab-Ldrm	1,190	1	28	28	56	308	50.4	46.0
0-17 years	*****	14	14	28	56	56	32.7	21.4
18-24 years	*****	2	28	28	50	140	37.7	28.7
25-40 years	216	1	28	28	56	308	47.1	43.6
41-64 years	483	1	28	28	56	273	51.6	45.2
≥ 65 years	376	1	28	28	56	308	54.5	51.7

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

NaN: Not a Number

Table 7a. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Finerenone</i>	16,366	1	3	7	19	461	18.7	34.1
<i>Fexinidazole</i>	0
<i>Belumosudil</i>	1,235	1	2	5	15	406	17.7	41.1
<i>Odevixibat</i>	6	2	4	5	9	18	7.2	5.8
<i>Anifrolumab-Fnia</i>	6,039	1	27	27	31	377	31.2	17.6
<i>Avalglucosidase Alfa-Ngpt</i>	1,951	1	13	13	13	266	14.3	10.7
<i>Belzutifan</i>	380	1	3	6	15	303	14.6	29.9
<i>Difelikefalin</i>	46,503	1	1	1	2	185	1.9	3.7
<i>Lonapegsomatropin-Tcgd</i>	184	1	3	6	15	124	13.6	20.1
<i>Mobocertinib</i>	111	1	4	9	25	293	20.8	36.4
<i>Tisotumab Vedotin-Tftv</i>	471	6	20	20	25	91	24.1	9.9
<i>Atogepant</i>	20,522	1	3	6	17	418	16.7	31.6
<i>Maralixibat</i>	41	1	5	6	12	213	20.2	41.4
<i>Avacopan</i>	235	1	2	5	10	236	9.8	22.8
<i>Asciminib</i>	574	1	3	7	20	278	16.5	26.1
<i>Ropeginterferon Alfa-2b-Njft</i>	470	1	3	8	14	161	13.0	18.1
<i>Vosoritide</i>	28	1	2	4	8	34	6.4	7.1
<i>Maribavir</i>	167	1	3	6	18	181	17.0	28.6
<i>Pafolacianine</i>	0
<i>Tezepelumab-Ekko</i>	15,439	1	27	27	29	275	28.8	14.7
<i>Efgartigimod Alfa-Fcab</i>	9,127	1	6	6	13	344	15.7	22.3
<i>Inclisiran</i>	4,953	1	90	91	101	293	105.8	39.9
<i>Tralokinumab-Ldrm</i>	1,190	1	3	7	15	173	12.1	15.9

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Finerenone	16,366	1	3	7	19	461	18.7	34.1
<i>Female</i>	7,399	1	3	7	18	415	18.1	32.7
<i>Male</i>	8,967	1	3	7	19	461	19.2	35.2
Fexinidazole	0
<i>Female</i>	0
<i>Male</i>	0
Belumosudil	1,235	1	2	5	15	406	17.7	41.1
<i>Female</i>	485	1	3	5	16	406	18.3	43.5
<i>Male</i>	750	1	2	5	14	364	17.3	39.4
Odevixibat	6	2	4	5	9	18	7.2	5.8
<i>Female</i>	4	2	3	5	12	18	7.3	7.3
<i>Male</i>	2	5	5	7	9	9	7.0	2.8
Anifrolumab-Fnia	6,039	1	27	27	31	377	31.2	17.6
<i>Female</i>	5,689	1	27	27	31	377	31.2	17.8
<i>Male</i>	350	1	27	27	30	139	30.7	14.2
Avalglucosidase Alfa-Ngpt	1,951	1	13	13	13	266	14.3	10.7
<i>Female</i>	1,022	1	13	13	13	160	14.2	8.4
<i>Male</i>	929	1	13	13	13	266	14.3	12.7
Belzutifan	380	1	3	6	15	303	14.6	29.9
<i>Female</i>	159	1	3	7	19	303	17.3	36.0
<i>Male</i>	221	1	2	5	14	248	12.5	24.5
Difelikefalin	46,503	1	1	1	2	185	1.9	3.7
<i>Female</i>	20,890	1	1	1	2	137	1.9	3.5
<i>Male</i>	25,613	1	1	1	2	185	1.9	3.8
Lonapegsomatropin-Tcgd	184	1	3	6	15	124	13.6	20.1
<i>Female</i>	71	1	4	8	23	124	17.8	26.3
<i>Male</i>	113	1	2	6	13	78	10.9	14.5
Mobocertinib	111	1	4	9	25	293	20.8	36.4
<i>Female</i>	65	1	4	9	23	293	22.2	41.9
<i>Male</i>	46	1	4	10	25	159	18.7	27.2
Tisotumab Vedotin-Tftv	471	6	20	20	25	91	24.1	9.9
<i>Female</i>	471	6	20	20	25	91	24.1	9.9
<i>Male</i>	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Atogepant	20,522	1	3	6	17	418	16.7	31.6

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	17,744	1	3	6	16	418	16.6	31.8
Male	2,778	1	3	6	18	369	17.0	30.2
Maralixibat	41	1	5	6	12	213	20.2	41.4
Female	11	1	3	5	67	213	45.2	72.7
Male	30	1	5	7	11	80	11.0	14.6
Avacopan	235	1	2	5	10	236	9.8	22.8
Female	112	1	3	5	11	236	10.2	23.8
Male	123	1	2	4	9	231	9.4	21.9
Asciminib	574	1	3	7	20	278	16.5	26.1
Female	319	1	3	8	20	230	17.0	25.5
Male	255	1	3	6	20	278	15.9	26.7
Ropeginterferon Alfa-2b-Njft	470	1	3	8	14	161	13.0	18.1
Female	221	1	2	6	13	95	10.3	12.7
Male	249	1	4	10	15	161	15.4	21.6
Vosoritide	28	1	2	4	8	34	6.4	7.1
Female	15	1	2	3	11	20	5.6	5.8
Male	13	2	3	5	7	34	7.4	8.6
Maribavir	167	1	3	6	18	181	17.0	28.6
Female	86	1	3	5	15	181	15.9	28.7
Male	81	1	3	6	20	163	18.1	28.6
Pafolacianine	0
Female	0
Male	0
Tezepelumab-Ekko	15,439	1	27	27	29	275	28.8	14.7
Female	10,342	1	27	27	29	261	28.6	14.7
Male	5,097	1	27	27	29	275	29.1	14.7
Efgartigimod Alfa-Fcab	9,127	1	6	6	13	344	15.7	22.3
Female	3,737	1	6	6	13	284	15.7	21.8
Male	5,390	1	6	6	12	344	15.7	22.7
Inclisiran	4,953	1	90	91	101	293	105.8	39.9
Female	2,605	1	90	91	102	247	105.2	40.3
Male	2,348	1	90	91	100	293	106.5	39.4

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Tralokinumab-Ldrm	1,190	1	3	7	15	173	12.1	15.9
Female	597	1	3	7	18	173	12.7	16.0
Male	593	1	3	7	13	148	11.5	15.9

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Finerenone	16,366	1	3	7	19	461	18.7	34.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	4	2	5	10	66	119	35.3	56.0
25-40 years	154	1	4	8	24	297	22.0	39.6
41-64 years	3,305	1	3	7	18	351	17.3	29.9
≥ 65 years	12,903	1	3	7	19	461	19.0	35.0
Fexinidazole	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0
Belumosudil	1,235	1	2	5	15	406	17.7	41.1
0-17 years	9	1	2	3	9	124	17.9	40.0
18-24 years	13	2	6	9	12	38	11.3	9.4
25-40 years	226	1	3	6	19	359	19.9	39.0
41-64 years	406	1	2	5	16	406	14.8	31.4
≥ 65 years	581	1	2	5	13	378	19.1	47.7
Odevixibat	6	2	4	5	9	18	7.2	5.8
0-17 years	4	2	3	5	12	18	7.3	7.3
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	2	5	5	7	9	9	7.0	2.8
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Anifrolumab-Fnia	6,039	1	27	27	31	377	31.2	17.6
0-17 years	4	27	27	27	27	27	27.0	0.0
18-24 years	148	1	27	27	31	69	29.5	8.6
25-40 years	1,181	1	27	27	31	243	31.0	17.0
41-64 years	2,903	1	27	27	31	377	31.3	20.4
≥ 65 years	1,803	1	27	27	31	202	31.2	13.0
Avalglucosidase Alfa-Ngpt	1,951	1	13	13	13	266	14.3	10.7
0-17 years	104	7	13	13	13	73	14.3	6.9
18-24 years	2	12	12	12	12	12	12.0	0.0
25-40 years	187	1	13	13	13	266	16.1	22.7
41-64 years	621	1	13	13	13	85	14.5	6.4

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	1,037	1	13	13	13	237	13.8	9.5
Belzutifan	380	1	3	6	15	303	14.6	29.9
0-17 years	2	2	2	3	3	3	2.5	0.7
18-24 years	7	1	1	5	9	22	6.9	7.2
25-40 years	102	1	3	5	13	42	9.8	10.4
41-64 years	163	1	3	6	19	303	18.9	39.2
≥ 65 years	106	1	2	6	14	248	13.2	26.2
Difelikefalin	46,503	1	1	1	2	185	1.9	3.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	133	1	1	1	2	11	1.5	1.1
25-40 years	2,562	1	1	1	2	107	2.0	3.7
41-64 years	17,865	1	1	1	2	185	2.0	4.1
≥ 65 years	25,943	1	1	1	2	177	1.9	3.4
Lonapegsomatropin-Tcgd	184	1	3	6	15	124	13.6	20.1
0-17 years	184	1	3	6	15	124	13.6	20.1
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mobocertinib	111	1	4	9	25	293	20.8	36.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	2	1	1	2	2	2	1.5	0.7
41-64 years	14	1	4	8	18	51	13.3	14.5
≥ 65 years	95	1	4	9	25	293	22.3	38.8
Tisotumab Vedotin-Tftv	471	6	20	20	25	91	24.1	9.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	51	12	20	20	27	42	23.0	6.2
41-64 years	244	6	20	20	26	91	23.9	9.8
≥ 65 years	176	19	20	20	25	91	24.7	10.9
Atogepant	20,522	1	3	6	17	418	16.7	31.6
0-17 years	60	1	2	4	9	241	11.7	31.5
18-24 years	1,223	1	3	7	19	368	18.0	31.5
25-40 years	4,781	1	3	6	16	393	16.2	29.6

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>41-64 years</i>	11,794	1	3	6	17	401	16.6	31.5
<i>≥ 65 years</i>	2,664	1	3	6	17	418	17.4	35.5
Maralixibat	41	1	5	6	12	213	20.2	41.4
0-17 years	26	1	4	6	11	213	15.4	40.7
18-24 years	13	1	6	11	30	156	32.1	44.7
25-40 years	2	4	4	5	5	5	4.5	0.7
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Avacopan	235	1	2	5	10	236	9.8	22.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	6	2	4	5	6	8	5.0	2.0
25-40 years	25	1	2	5	8	27	6.0	5.4
41-64 years	129	1	2	4	12	236	11.4	29.3
≥ 65 years	75	1	3	5	10	82	8.5	11.5
Asciminib	574	1	3	7	20	278	16.5	26.1
0-17 years	4	3	4	13	27	33	15.3	14.4
18-24 years	1	11	11	11	11	11	11.0	NaN
25-40 years	66	1	3	8	21	278	21.7	42.3
41-64 years	255	1	3	7	19	150	16.1	23.3
≥ 65 years	248	1	3	6	21	230	15.5	23.1
Ropeginterferon Alfa-2b-Njft	470	1	3	8	14	161	13.0	18.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	41	1	2	5	11	53	11.0	14.7
41-64 years	143	1	3	11	14	161	13.4	19.4
≥ 65 years	286	1	3	7	14	127	13.1	18.0
Vosoritide	28	1	2	4	8	34	6.4	7.1
0-17 years	28	1	2	4	8	34	6.4	7.1
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Maribavir	167	1	3	6	18	181	17.0	28.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	3	11	11	18	34	34	21.0	11.8
25-40 years	51	1	3	7	13	75	11.6	14.6
41-64 years	74	1	2	6	27	181	19.3	31.2
≥ 65 years	39	1	2	5	16	163	19.3	36.7
Pafolacianine	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0
Tezepelumab-Ekko	15,439	1	27	27	29	275	28.8	14.7
0-17 years	62	2	20	27	33	71	26.4	15.1
18-24 years	104	1	22	27	29	82	25.8	13.1
25-40 years	798	1	20	27	31	160	27.3	17.3
41-64 years	4,242	1	26	27	30	247	28.2	18.4
≥ 65 years	10,233	1	27	27	29	275	29.2	12.6
Efgartigimod Alfa-Fcab	9,127	1	6	6	13	344	15.7	22.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	51	1	6	6	15	94	16.8	20.8
25-40 years	438	1	6	6	9	177	12.6	17.2
41-64 years	1,701	1	6	6	18	284	15.9	22.4
≥ 65 years	6,937	1	6	6	12	344	15.8	22.6
Inclisiran	4,953	1	90	91	101	293	105.8	39.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	12	82	91	95	128	196	114.2	38.6
41-64 years	260	1	90	91	103	207	100.2	42.7
≥ 65 years	4,681	1	90	91	101	293	106.1	39.7

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of Treatment Episode Gap Durations, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Tralokinumab-Ldrm	1,190	1	3	7	15	173	12.1	15.9
0-17 years	3	41	41	77	85	85	67.7	23.4
18-24 years	112	1	4	9	21	125	16.3	20.2
25-40 years	216	1	4	7	15	103	11.2	12.1
41-64 years	483	1	3	7	15	173	11.8	16.2
≥ 65 years	376	1	3	7	13	131	11.3	15.1

NaN: Not a Number

Table 8a. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Finerenone</i>	8,398	1	3	8	23	461	22.7	40.4
<i>Fexinidazole</i>	0
<i>Belumosudil</i>	450	1	2	5	16	406	21.4	50.9
<i>Odevixibat</i>	3	2	2	5	5	5	4.0	1.7
<i>Anifrolumab-Fnia</i>	1,251	1	27	27	32	346	31.8	20.7
<i>Avalglucosidase Alfa-Ngpt</i>	128	1	13	13	13	65	14.8	8.0
<i>Belzutifan</i>	150	1	3	6	18	248	17.1	32.8
<i>Difelikefalin</i>	1,788	1	1	1	2	137	2.3	6.0
<i>Lonapegsomatropin-Tcgd</i>	94	1	2	7	14	124	14.1	22.1
<i>Mobocertinib</i>	53	1	4	14	37	293	28.2	44.9
<i>Tisotumab Vedotin-Tftv</i>	134	6	20	20	26	89	24.8	10.9
<i>Atogepant</i>	9,607	1	3	7	20	418	20.0	37.5
<i>Maralixibat</i>	14	1	3	5	8	213	26.2	57.5
<i>Avacopan</i>	109	1	2	5	11	231	10.3	23.0
<i>Asciminib</i>	218	1	3	7	21	278	17.8	31.5
<i>Ropeginterferon Alfa-2b-Njft</i>	178	1	3	7	14	127	12.5	17.9
<i>Vosoritide</i>	13	1	3	5	9	20	6.9	5.6
<i>Maribavir</i>	101	1	2	5	20	181	18.7	31.4
<i>Pafolacianine</i>	0
<i>Tezepelumab-Ekko</i>	3,764	1	27	27	30	275	30.0	19.4
<i>Efgartigimod Alfa-Fcab</i>	1,446	1	6	6	8	284	14.9	23.6
<i>Inclisiran</i>	4,842	1	90	91	100	293	105.1	38.7
<i>Tralokinumab-Ldrm</i>	633	1	3	7	17	148	13.0	16.8

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Finerenone	8,398	1	3	8	23	461	22.7	40.4
<i>Female</i>	3,809	1	3	8	22	395	22.1	38.9
<i>Male</i>	4,589	1	3	8	24	461	23.2	41.6
Fexinidazole	0
<i>Female</i>	0
<i>Male</i>	0
Belumosudil	450	1	2	5	16	406	21.4	50.9
<i>Female</i>	193	1	3	6	18	406	22.3	54.2
<i>Male</i>	257	1	2	5	15	364	20.6	48.5
Odevixibat	3	2	2	5	5	5	4.0	1.7
<i>Female</i>	2	2	2	4	5	5	3.5	2.1
<i>Male</i>	1	5	5	5	5	5	5.0	NaN
Anifrolumab-Fnia	1,251	1	27	27	32	346	31.8	20.7
<i>Female</i>	1,179	1	27	27	32	346	31.8	21.0
<i>Male</i>	72	5	27	27	32	118	32.1	16.2
Avalglucosidase Alfa-Ngpt	128	1	13	13	13	65	14.8	8.0
<i>Female</i>	69	3	13	13	14	65	16.2	9.6
<i>Male</i>	59	1	13	13	13	41	13.2	5.1
Belzutifan	150	1	3	6	18	248	17.1	32.8
<i>Female</i>	52	1	4	7	22	140	18.5	29.7
<i>Male</i>	98	1	2	6	14	248	16.4	34.4
Difelikefalin	1,788	1	1	1	2	137	2.3	6.0
<i>Female</i>	836	1	1	1	2	137	2.5	6.9
<i>Male</i>	952	1	1	1	2	107	2.2	5.0
Lonapegsomatropin-Tcgd	94	1	2	7	14	124	14.1	22.1
<i>Female</i>	35	1	4	8	15	124	17.6	29.3
<i>Male</i>	59	1	2	6	14	78	12.0	16.3
Mobocertinib	53	1	4	14	37	293	28.2	44.9
<i>Female</i>	30	1	6	16	34	293	34.2	56.8
<i>Male</i>	23	1	3	12	37	55	20.4	19.9
Tisotumab Vedotin-Tftv	134	6	20	20	26	89	24.8	10.9
<i>Female</i>	134	6	20	20	26	89	24.8	10.9
<i>Male</i>	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Atogepant	9,607	1	3	7	20	418	20.0	37.5
<i>Female</i>	8,273	1	3	7	19	418	19.9	37.7

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Sex

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	1,334	1	3	8	21	369	20.6	36.4
Maralixibat	14	1	3	5	8	213	26.2	57.5
Female	6	1	2	4	5	213	38.2	85.7
Male	8	3	5	7	16	80	17.3	26.1
Avacopan	109	1	2	5	11	231	10.3	23.0
Female	51	1	3	5	11	40	8.3	8.3
Male	58	1	2	5	12	231	12.0	30.6
Asciminib	218	1	3	7	21	278	17.8	31.5
Female	116	1	3	8	20	230	19.4	31.5
Male	102	1	3	6	22	278	16.0	31.5
Ropeginterferon Alfa-2b-Njft	178	1	3	7	14	127	12.5	17.9
Female	88	1	3	6	12	60	9.5	12.0
Male	90	1	3	8	15	127	15.4	21.9
Vosoritide	13	1	3	5	9	20	6.9	5.6
Female	8	1	3	4	9	20	6.4	6.8
Male	5	5	5	7	9	13	7.8	3.3
Maribavir	101	1	2	5	20	181	18.7	31.4
Female	51	1	2	5	11	181	18.2	35.1
Male	50	1	3	7	21	126	19.2	27.6
Pafolacianine	0
Female	0
Male	0
Tezepelumab-Ekko	3,764	1	27	27	30	275	30.0	19.4
Female	2,525	1	27	27	31	198	29.8	18.6
Male	1,239	1	27	27	30	275	30.6	20.8
Efgartigimod Alfa-Fcab	1,446	1	6	6	8	284	14.9	23.6
Female	618	1	6	6	9	284	15.4	25.6
Male	828	1	6	6	8	208	14.5	22.0
Inclisiran	4,842	1	90	91	100	293	105.1	38.7
Female	2,542	1	90	91	101	247	104.7	39.1
Male	2,300	1	90	91	98	293	105.6	38.3
Tralokinumab-Ldrm	633	1	3	7	17	148	13.0	16.8
Female	323	1	4	8	18	106	13.5	15.9
Male	310	1	3	7	14	148	12.5	17.7

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Finerenone	8,398	1	3	8	23	461	22.7	40.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	4	2	5	10	66	119	35.3	56.0
25-40 years	71	1	4	8	26	297	26.2	50.6
41-64 years	1,622	1	3	8	20	351	20.4	35.5
≥ 65 years	6,701	1	3	8	24	461	23.2	41.4
Fexinidazole	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0
Belumosudil	450	1	2	5	16	406	21.4	50.9
0-17 years	5	2	2	3	12	124	28.6	53.5
18-24 years	5	2	8	9	9	38	13.2	14.2
25-40 years	72	1	3	8	15	359	22.1	50.1
41-64 years	151	1	2	4	20	406	20.6	46.3
≥ 65 years	217	1	2	5	12	378	21.7	55.0
Odevixibat	3	2	2	5	5	5	4.0	1.7
0-17 years	2	2	2	4	5	5	3.5	2.1
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	1	5	5	5	5	5	5.0	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Anifrolumab-Fnia	1,251	1	27	27	32	346	31.8	20.7
0-17 years	1	27	27	27	27	27	27.0	NaN
18-24 years	32	6	27	27	29	51	28.3	6.7
25-40 years	244	1	27	27	33	243	32.7	23.5
41-64 years	619	1	27	27	31	346	32.2	23.9
≥ 65 years	355	1	27	27	32	133	30.8	11.9
Avalglucosidase Alfa-Ngpt	128	1	13	13	13	65	14.8	8.0
0-17 years	7	13	13	13	17	17	14.1	2.0
18-24 years	1	12	12	12	12	12	12.0	NaN
25-40 years	16	2	13	13	16	21	12.8	5.1
41-64 years	45	6	13	13	13	41	14.7	6.3

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	59	1	13	13	14	65	15.7	10.0
Belzutifan	150	1	3	6	18	248	17.1	32.8
0-17 years	1	2	2	2	2	2	2.0	NaN
18-24 years	5	1	1	4	9	22	7.4	8.8
25-40 years	30	1	3	6	15	42	10.4	10.7
41-64 years	61	1	4	6	21	168	22.8	38.7
≥ 65 years	53	1	2	7	14	248	15.6	34.7
Difelikefalin	1,788	1	1	1	2	137	2.3	6.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	3	2	2	2	2	2	2.0	0.0
25-40 years	113	1	1	2	2	107	3.2	10.3
41-64 years	664	1	1	1	2	137	2.5	6.6
≥ 65 years	1,008	1	1	1	2	104	2.1	4.8
Lonapegsomatropin-Tcgd	94	1	2	7	14	124	14.1	22.1
0-17 years	94	1	2	7	14	124	14.1	22.1
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Mobocertinib	53	1	4	14	37	293	28.2	44.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	2	1	1	2	2	2	1.5	0.7
41-64 years	8	1	5	15	30	51	19.0	17.2
≥ 65 years	43	1	6	14	39	293	31.1	48.9
Tisotumab Vedotin-Tftv	134	6	20	20	26	89	24.8	10.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	12	12	20	20	24	35	21.8	5.6
41-64 years	60	6	20	20	27	89	24.5	11.0
≥ 65 years	62	19	20	20	26	69	25.6	11.6
Atogepant	9,607	1	3	7	20	418	20.0	37.5
0-17 years	27	1	2	5	17	40	9.3	10.8
18-24 years	589	1	3	8	20	368	19.9	35.6
25-40 years	2,224	1	3	7	20	393	19.5	34.1

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
41-64 years	5,444	1	3	7	19	401	20.1	37.8
≥ 65 years	1,323	1	3	6	19	418	20.9	42.9
Maralixibat	14	1	3	5	8	213	26.2	57.5
0-17 years	8	2	3	5	8	213	30.8	73.7
18-24 years	5	1	5	7	23	80	23.2	32.8
25-40 years	1	5	5	5	5	5	5.0	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Avacopan	109	1	2	5	11	231	10.3	23.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	1	5	5	5	5	5	5.0	NaN
25-40 years	11	2	3	5	12	27	7.7	7.3
41-64 years	52	1	2	5	12	231	12.5	32.2
≥ 65 years	45	1	3	5	10	40	8.4	8.6
Asciminib	218	1	3	7	21	278	17.8	31.5
0-17 years	1	4	4	4	4	4	4.0	NaN
18-24 years	1	11	11	11	11	11	11.0	NaN
25-40 years	24	1	3	8	17	278	25.3	59.1
41-64 years	83	1	3	8	24	150	16.8	23.5
≥ 65 years	109	1	3	6	21	230	17.1	28.4
Ropeginterferon Alfa-2b-Njft	178	1	3	7	14	127	12.5	17.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	17	1	3	7	20	53	15.4	17.2
41-64 years	47	1	3	6	14	91	11.1	15.2
≥ 65 years	114	1	3	7	13	127	12.6	19.1
Vosoritide	13	1	3	5	9	20	6.9	5.6
0-17 years	13	1	3	5	9	20	6.9	5.6
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Maribavir	101	1	2	5	20	181	18.7	31.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Gaps	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
18-24 years	2	11	11	23	34	34	22.5	16.3
25-40 years	27	1	4	6	11	75	12.1	16.2
41-64 years	47	1	2	5	27	181	21.8	36.8
≥ 65 years	25	1	3	5	17	126	19.6	34.1
Pafolacianine	0
0-17 years	0
18-24 years	0
25-40 years	0
41-64 years	0
≥ 65 years	0
Tezepelumab-Ekko	3,764	1	27	27	30	275	30.0	19.4
0-17 years	16	3	11	26	30	37	21.5	11.4
18-24 years	27	2	7	27	29	82	24.3	18.2
25-40 years	211	1	22	27	35	160	30.2	20.1
41-64 years	1,112	1	25	27	33	247	30.8	24.4
≥ 65 years	2,398	1	27	27	29	275	29.8	16.5
Efgartigimod Alfa-Fcab	1,446	1	6	6	8	284	14.9	23.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	8	6	7	8	35	72	21.9	26.2
25-40 years	56	1	6	6	9	55	9.7	9.7
41-64 years	247	1	6	6	13	284	16.1	28.3
≥ 65 years	1,135	1	6	6	8	208	14.8	22.9
Inclisiran	4,842	1	90	91	100	293	105.1	38.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	12	82	91	95	128	196	114.2	38.6
41-64 years	239	1	90	91	97	201	95.4	38.1
≥ 65 years	4,591	1	90	91	100	293	105.6	38.7
Tralokinumab-Ldrm	633	1	3	7	17	148	13.0	16.8
0-17 years	2	77	77	81	85	85	81.0	5.7
18-24 years	64	1	5	8	19	80	14.5	16.4
25-40 years	119	1	4	8	17	68	11.6	11.1
41-64 years	248	1	3	7	18	148	13.3	17.6

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023, by Age Group

Distribution of First Treatment Episode Gap Duration, days								
	Total Number of Gaps	Minimu m	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	200	1	4	7	13	131	12.4	17.4

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023¹

	Censoring Reason												
	End of Exposure Episode ²		Occurrence of User-Defined Censoring Criteria ³		Evidence of Death ⁴		Disenrollment ⁵		End of Data ⁶		End of Study year ⁷		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Finerenone</i>	35,554	34,298	96.5%	0	0.0%	156	0.4%	12,208	34.3%	12,451	35.0%	0	0.0%
<i>Fexinidazole</i>	0
<i>Belumosudil</i>	2,045	1,994	97.5%	0	0.0%	40	2.0%	391	19.1%	364	17.8%	0	0.0%
<i>Odevixibat</i>	17	15	88.2%	0	0.0%	0	0.0%	*****	*****	*****	*****	0	0.0%
<i>Anifrolumab-Fnia</i>	7,578	7,575	100.0%	0	0.0%	*****	*****	76	1.0%	72	1.0%	0	0.0%
<i>Avalglucosidase Alfa-Ngpt</i>	2,088	2,086	99.9%	0	0.0%	*****	*****	14	0.7%	18	0.9%	0	0.0%
<i>Belzutifan</i>	656	630	96.0%	0	0.0%	14	2.1%	148	22.6%	141	21.5%	0	0.0%
<i>Difelikefalin</i>	48,412	48,412	100.0%	0	0.0%	*****	*****	549	1.1%	541	1.1%	0	0.0%
<i>Lonapegsomatropin-Tcgd</i>	395	371	93.9%	0	0.0%	0	0.0%	147	37.2%	146	37.0%	0	0.0%
<i>Mobocertinib</i>	224	215	96.0%	0	0.0%	*****	*****	32	14.3%	27	12.1%	0	0.0%
<i>Tisotumab Vedotin-Tftv</i>	642	642	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Atogepant</i>	40,534	38,722	95.5%	0	0.0%	26	0.1%	9,441	23.3%	9,781	24.1%	0	0.0%
<i>Maralixibat</i>	65	60	92.3%	0	0.0%	0	0.0%	*****	*****	14	21.5%	0	0.0%
<i>Avacopan</i>	457	434	95.0%	0	0.0%	*****	*****	122	26.7%	137	30.0%	0	0.0%
<i>Asciminib</i>	976	949	97.2%	0	0.0%	14	1.4%	234	24.0%	221	22.6%	0	0.0%
<i>Ropeginterferon Alfa-2b-Njft</i>	746	722	96.8%	0	0.0%	*****	*****	163	21.8%	176	23.6%	0	0.0%
<i>Vosoritide</i>	64	58	90.6%	0	0.0%	0	0.0%	25	39.1%	29	45.3%	0	0.0%
<i>Maribavir</i>	440	431	98.0%	0	0.0%	*****	*****	85	19.3%	74	16.8%	0	0.0%
<i>Pafolacianine</i>	0

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023¹

	Censoring Reason												
	End of Exposure Episode ²		Occurrence of User-Defined Censoring Criteria ³		Evidence of Death ⁴		Disenrollment ⁵		End of Data ⁶		End of Study year ⁷		
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Tezepelumab-Ekko</i>	20,281	20,210	99.6%	0	0.0%	*****	*****	654	3.2%	665	3.3%	0	0.0%
<i>Efgartigimod Alfa-Fcab</i>	10,719	10,705	99.9%	0	0.0%	*****	*****	182	1.7%	186	1.7%	0	0.0%
<i>Inclisiran</i>	15,200	15,175	99.8%	0	0.0%	*****	*****	464	3.1%	471	3.1%	0	0.0%
<i>Tralokinumab-Ldrm</i>	2,424	2,337	96.4%	0	0.0%	*****	*****	554	22.9%	582	24.0%	0	0.0%

¹An episode may be censored due to more than one reason if they occur on the same date. Therefore, the Number of the reasons for censoring may be greater than the total number of episodes.

²Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

³Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

⁴Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

⁵Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

⁶Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

⁷Represents episodes censored due to user-specified study end date.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

	Finerenone		Fexinidazole		Belumosudil		Odevixibat	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query year	153,594,516	N/A	153,594,516	N/A	153,594,516	N/A	153,594,516	N/A
Had required coverage type (medical and/or drug coverage)	97,602,815	55,991,701	97,602,815	55,991,701	97,602,815	55,991,701	97,602,815	55,991,701
Enrolled during specified age range	97,602,116	699	97,602,116	699	97,602,116	699	97,602,116	699
Had requestable medical charts	97,602,116	0	97,602,116	0	97,602,116	0	97,602,116	0
Met demographic requirements (sex, race, and Hispanic origin)	97,560,417	41,699	97,560,417	41,699	97,560,417	41,699	97,560,417	41,699
Members with a valid index event								
Had any cohort-defining claim during the query year	21,631	97,538,786	0	97,560,417	908	97,559,509	*****	*****
Claim recorded during specified age range	21,631	0	0	0	908	0	*****	0
Episode defining index claim recorded during the query year	21,631	0	0	0	908	0	*****	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	19,188	2,443	0	0	810	98	*****	*****
Met inclusion and exclusion criteria	19,188	0	0	0	810	0	*****	0
Had sufficient post-index continuous enrollment	19,188	0	0	0	810	0	*****	0
Final cohort								
Number of members	19,188	N/A	0	N/A	810	N/A	11	N/A

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

	Anifrolumab-Fnia		Avalglucosidase Alfa-Ngpt		Belzutifan		Difelikefalin	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query year	153,594,516	N/A	153,594,516	N/A	153,594,516	N/A	153,594,516	N/A
Had required coverage type (medical and/or drug coverage)	97,602,815	55,991,701	97,602,815	55,991,701	97,602,815	55,991,701	97,602,815	55,991,701
Enrolled during specified age range	97,602,116	699	97,602,116	699	97,602,116	699	97,602,116	699
Had requestable medical charts	97,602,116	0	97,602,116	0	97,602,116	0	97,602,116	0
Met demographic requirements (sex, race, and Hispanic origin)	97,560,417	41,699	97,560,417	41,699	97,560,417	41,699	97,560,417	41,699
Members with a valid index event								
Had any cohort-defining claim during the query year	1,700	97,558,717	*****	*****	313	97,560,104	2,140	97,558,277
Claim recorded during specified age range	1,700	0	*****	0	313	0	2,140	0
Episode defining index claim recorded during the query year	1,700	0	*****	0	313	0	2,140	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	1,539	161	*****	*****	276	37	1,909	231
Met inclusion and exclusion criteria	1,539	0	*****	0	276	0	1,909	0
Had sufficient post-index continuous enrollment	1,539	0	*****	0	276	0	1,909	0
Final cohort								
Number of members	1,539	N/A	137	N/A	276	N/A	1,909	N/A

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

	Lonapegsomatropin-Tcgd		Mobocertinib		Tisotumab Vedotin-Tftv		Atogepant	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query year	153,594,516	N/A	153,594,516	N/A	153,594,516	N/A	153,594,516	N/A
Had required coverage type (medical and/or drug coverage)	97,602,815	55,991,701	97,602,815	55,991,701	97,602,815	55,991,701	97,602,815	55,991,701
Enrolled during specified age range	97,602,116	699	97,602,116	699	97,602,116	699	97,602,116	699
Had requestable medical charts	97,602,116	0	97,602,116	0	97,602,116	0	97,602,116	0
Met demographic requirements (sex, race, and Hispanic origin)	97,560,417	41,699	97,560,417	41,699	97,560,417	41,699	97,560,417	41,699
Members with a valid index event								
Had any cohort-defining claim during the query year	237	97,560,180	131	97,560,286	205	97,560,212	23,088	97,537,329
Claim recorded during specified age range	237	0	131	0	205	0	23,088	0
Episode defining index claim recorded during the query year	237	0	131	0	205	0	23,088	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	211	26	113	18	171	34	20,012	3,076
Met inclusion and exclusion criteria	211	0	113	0	171	0	20,012	0
Had sufficient post-index continuous enrollment	211	0	113	0	171	0	20,012	0
Final cohort								
Number of members	211	N/A	113	N/A	171	N/A	20,012	N/A

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

	Maralixibat		Avacopan		Asciminib		Ropeginterferon Alfa-2b-Njft	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query year	153,594,516	N/A	153,594,516	N/A	153,594,516	N/A	153,594,516	N/A
Had required coverage type (medical and/or drug coverage)	97,602,815	55,991,701	97,602,815	55,991,701	97,602,815	55,991,701	97,602,815	55,991,701
Enrolled during specified age range	97,602,116	699	97,602,116	699	97,602,116	699	97,602,116	699
Had requestable medical charts	97,602,116	0	97,602,116	0	97,602,116	0	97,602,116	0
Met demographic requirements (sex, race, and Hispanic origin)	97,560,417	41,699	97,560,417	41,699	97,560,417	41,699	97,560,417	41,699
Members with a valid index event								
Had any cohort-defining claim during the query year	*****	*****	252	97,560,165	447	97,559,970	311	97,560,106
Claim recorded during specified age range	*****	0	252	0	447	0	311	0
Episode defining index claim recorded during the query year	*****	0	252	0	447	0	311	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	*****	*****	222	30	402	45	276	35
Met inclusion and exclusion criteria	*****	0	222	0	402	0	276	0
Had sufficient post-index continuous enrollment	*****	0	222	0	402	0	276	0
Final cohort								
Number of members	24	N/A	222	N/A	402	N/A	276	N/A

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

	Vosoritide		Maribavir		Pafolacianine		Tezepelumab-Ekko	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query year	153,594,516	N/A	153,594,516	N/A	153,594,516	N/A	153,594,516	N/A
Had required coverage type (medical and/or drug coverage)	97,602,815	55,991,701	97,602,815	55,991,701	97,602,815	55,991,701	97,602,815	55,991,701
Enrolled during specified age range	97,602,116	699	97,602,116	699	97,602,116	699	97,602,116	699
Had requestable medical charts	97,602,116	0	97,602,116	0	97,602,116	0	97,602,116	0
Met demographic requirements (sex, race, and Hispanic origin)	97,560,417	41,699	97,560,417	41,699	97,560,417	41,699	97,560,417	41,699
Members with a valid index event								
Had any cohort-defining claim during the query year	*****	*****	295	97,560,122	0	97,560,417	5,325	97,555,092
Claim recorded during specified age range	*****	0	295	0	0	0	5,325	0
Episode defining index claim recorded during the query year	*****	0	295	0	0	0	5,325	0
Members with required pre-index history								
Had sufficient pre-index continuous enrollment	*****	*****	273	22	0	0	4,842	483
Met inclusion and exclusion criteria	*****	0	273	0	0	0	4,842	0
Had sufficient post-index continuous enrollment	*****	0	273	0	0	0	4,842	0
Final cohort								
Number of members	36	N/A	273	N/A	0	N/A	4,842	N/A

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

N/A: Not Applicable


Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

	Efgartigimod Alfa-Fcab		Inclisiran		Tralokinumab-Ldrm	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query year	153,594,516	N/A	153,594,516	N/A	153,594,516	N/A
Had required coverage type (medical and/or drug coverage)	97,602,815	55,991,701	97,602,815	55,991,701	97,602,815	55,991,701
Enrolled during specified age range	97,602,116	699	97,602,116	699	97,602,116	699
Had requestable medical charts	97,602,116	0	97,602,116	0	97,602,116	0
Met demographic requirements (sex, race, and Hispanic origin)	97,560,417	41,699	97,560,417	41,699	97,560,417	41,699
Members with a valid index event						
Had any cohort-defining claim during the query year	1,711	97,558,706	10,692	97,549,725	1,406	97,559,011
Claim recorded during specified age range	1,711	0	10,692	0	1,406	0
Episode defining index claim recorded during the query year	1,711	0	10,692	0	1,406	0
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	1,592	119	10,247	445	1,234	172
Met inclusion and exclusion criteria	1,592	0	10,247	0	1,234	0
Had sufficient post-index continuous enrollment	1,592	0	10,247	0	1,234	0
Final cohort						
Number of members	1,592	N/A	10,247	N/A	1,234	N/A

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.


N/A: Not Applicable

Figure 1a. Patient Entry into Study by Month for Finerenone in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023




The FDA approval date for this drug was on July 9, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

Figure 1b. Patient Entry into Study by Month for Fexinidazole in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023



The FDA approval date for this drug was on July 16, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

Figure 1c. Patient Entry into Study by Month for Belumosudil in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023




The FDA approval date for this drug was on July 16, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

Figure 1d. Patient Entry into Study by Month for Odevixibat in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

The FDA approval date for this drug was on July 20, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.*

Figure 1e. Patient Entry into Study by Month for Anifrolumab-Fnia in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023




The FDA approval date for this drug was on July 30, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

Figure 1f. Patient Entry into Study by Month for Avalglucosidase Alfa-Ngpt in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

The FDA approval date for this drug was on August 6, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.*

Figure 1h. Patient Entry into Study by Month for Difelikefalin in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023



The FDA approval date for this drug was on August 23, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

Figure 1g. Patient Entry into Study by Month for Belzutifan in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

The FDA approval date for this drug was on August 13, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.*

Figure 1i. Patient Entry into Study by Month for Lonapegsomatropin-Tcgd in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

The FDA approval date for this drug was on August 25, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.*

Figure 1j. Patient Entry into Study by Month for Mobocertinib in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

The FDA approval date for this drug was on September 15, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>


****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.*

Figure 1k. Patient Entry into Study by Month for Tisotumab Vedotin-Tftv in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

The FDA approval date for this drug was on September 20, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.*

Figure 11. Patient Entry into Study by Month for Atopepant in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023



The FDA approval date for this drug was on September 28, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

Figure 1m. Patient Entry into Study by Month for Maralixibat in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

The FDA approval date for this drug was on September 29, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.*

Figure 1n. Patient Entry into Study by Month for Avacopan in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

The FDA approval date for this drug was on October 7, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.*

Figure 1o. Patient Entry into Study by Month for Asciminib in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

The FDA approval date for this drug was on October 29, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.*

Figure 1p. Patient Entry into Study by Month for Ropeginterferon Alfa-2b-Njft in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

The FDA approval date for this drug was on November 12, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.*

Figure 1q. Patient Entry into Study by Month for Vosoritide in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

The FDA approval date for this drug was on November 19, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>


****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.*

Figure 1r. Patient Entry into Study by Month for Maribavir in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023

The FDA approval date for this drug was on November 23, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>


****Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.*

Figure 1s. Patient Entry into Study by Month for Pafolacianine in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023




The FDA approval date for this drug was on November 29, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

Figure 1t. Patient Entry into Study by Month for Tezepelumab-Ekko in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023




The FDA approval date for this drug was on December 17, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

Figure 1u. Patient Entry into Study by Month for Efgartigimod Alfa-Fcab in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023




The FDA approval date for this drug was on December 17, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

Figure 1v. Patient Entry into Study by Month for Inclisiran in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023



The FDA approval date for this drug was on December 22, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

Figure 1w. Patient Entry into Study by Month for Tralokinumab-Ldrm in the Sentinel Distributed Database from January 1, 2021 to June 30, 2023



The FDA approval date for this drug was on December 27, 2021 as listed on the FDA website <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (November 20, 2023)

Masked DP ID	DP Start Date	DP End Date ¹
DP01	01/01/2000	05/31/2023
DP02	01/01/2004	11/30/2022
DP03	01/01/2008	06/30/2023
DP04	01/01/2006	02/28/2023
DP05	01/01/2000	04/30/2023
DP06	01/01/2008	12/31/2022
DP07	01/01/2005	07/31/2022
DP08	01/01/2000	08/31/2022
DP09	01/01/2000	08/31/2022
DP10	01/01/2000	12/31/2021
DP11	01/01/2007	01/31/2023
DP12	01/01/2000	10/31/2022
DP13	01/01/2010	03/31/2023

¹End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Appendix B. List of Non-Proprietary and Proprietary Medical Products Used to Define Exposures in this Request

Non-Proprietary Name	Proprietary Name
Finerenone	
Finerenone	Kerendia
Fexinidazole	
Fexinidazole	
Belumosudil mesylate	
Belumosudil mesylate	Rezurock
Odevixibat	
Odevixibat	Bylvay
Anifrolumab-Fnia	
Anifrolumab-Fnia	Saphnelo
avalglucosidase alfa-ngpt	
Avalglucosidase Alfa-Ngpt	Nexviazyme
Belzutifan	
Belzutifan	Welireg
Difelikefalin acetate	
Difelikefalin acetate	Korsuva
Lonapegsomatropin-Tcgd	
Lonapegsomatropin-Tcgd	Skytrofa
Mobocertinib succinate	
Mobocertinib succinate	Exkivity
tisotumab vedotin-tftv	
Tisotumab Vedotin-Tftv	Tivdak
Atogepant	
Atogepant	Qulipta
Maralixibat chloride	
Maralixibat chloride	Livmarli
Avacopan	
Avacopan	Tavneos
Asciminib hydrochloride	
Asciminib hydrochloride	Scemblix
ropeginterferon alfa-2b-njft	
Ropeginterferon Alfa-2b-Njft	Besremi
Vosoritide	
Vosoritide	Voxzogo
Maribavir	
Maribavir	Livtensity
Pafolacianine sodium	
Pafolacianine sodium	Cytalux

Appendix B. List of Non-Proprietary and Proprietary Medical Products Used to Define Exposures in this Request

Non-Proprietary Name	Proprietary Name
Tezepelumab-Ekko	
Tezepelumab-Ekko	Tezspire
efgartigimod	
Efgartigimod Alfa-Fcab	Vyvgart
efgartigimod alfa-hyaluronidase-qvfc	Vyvgart Hytrulo
Inclisiran sodium	
Inclisiran sodium	Leqvio
Tralokinumab-Ldrm	
Tralokinumab-Ldrm	Adbry

Appendix C. List of Healthcare Common Procedure Coding System, Level II (HCPCS) Codes Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
Anifrolumab-Fnia			
C9086	Injection, Anifrolumab-Fnia, 1 mg	Procedure	HCPCS
J0491	Injection, Anifrolumab-Fnia, 1 mg	Procedure	HCPCS
avalglucosidase alfa-ngpt			
C9085	Injection, Avalglucosidase Alfa-Ngpt, 4 mg	Procedure	HCPCS
J0219	Injection, Avalglucosidase Alfa-Ngpt, 4 mg	Procedure	HCPCS
Difelikefalin			
J0879	Injection, Difelikefalin, 0.1 mcg, (for ESRD on dialysis)	Procedure	HCPCS
tisotumab vedotin-tftv			
J9273	Injection, Tisotumab Vedotin-Tftv, 1 mg	Procedure	HCPCS
Tezepelumab-Ekko			
J2356	Injection, Tezepelumab-Ekko, 1 mg	Procedure	HCPCS
efgartigimod alfa-fcab			
J9332	Injection, Efgartigimod Alfa-Fcab, 2 mg	Procedure	HCPCS
Inclisiran			
J1306	Injection, Inclisiran, 1 mg	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
Acute Myocardial Infarction			
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.9	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
Alzheimers			
F01.50	Vascular dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F01.51	Vascular dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F02.80	Dementia in other diseases classified elsewhere without behavioral disturbance	Diagnosis	ICD-10-CM
F02.81	Dementia in other diseases classified elsewhere with behavioral disturbance	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F03.90	Unspecified dementia without behavioral disturbance	Diagnosis	ICD-10-CM
F03.91	Unspecified dementia with behavioral disturbance	Diagnosis	ICD-10-CM
F04	Amnestic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F05	Delirium due to known physiological condition	Diagnosis	ICD-10-CM
F06.1	Catatonic disorder due to known physiological condition	Diagnosis	ICD-10-CM
F06.8	Other specified mental disorders due to known physiological condition	Diagnosis	ICD-10-CM
G13.8	Systemic atrophy primarily affecting central nervous system in other diseases classified	Diagnosis	ICD-10-CM
G30.0	Alzheimer's disease with early onset	Diagnosis	ICD-10-CM
G30.1	Alzheimer's disease with late onset	Diagnosis	ICD-10-CM
G30.8	Other Alzheimer's disease	Diagnosis	ICD-10-CM
G30.9	Alzheimer's disease, unspecified	Diagnosis	ICD-10-CM
G31.01	Pick's disease	Diagnosis	ICD-10-CM
G31.09	Other frontotemporal dementia	Diagnosis	ICD-10-CM
G31.1	Senile degeneration of brain, not elsewhere classified	Diagnosis	ICD-10-CM
G31.2	Degeneration of nervous system due to alcohol	Diagnosis	ICD-10-CM
G94	Other disorders of brain in diseases classified elsewhere	Diagnosis	ICD-10-CM
R41.81	Age-related cognitive decline	Diagnosis	ICD-10-CM
R54	Age-related physical debility	Diagnosis	ICD-10-CM
Atrial Fibrillation			
I48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
I48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
I48.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
I48.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
I48.3	Typical atrial flutter	Diagnosis	ICD-10-CM
I48.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
I48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
Diabetes			
E08.00	Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E08.01	Diabetes mellitus due to underlying condition with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E08.10	Diabetes mellitus due to underlying condition with ketoacidosis without coma	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E08.11	Diabetes mellitus due to underlying condition with ketoacidosis with coma	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E08.39	Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E08.40	Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E08.41	Diabetes mellitus due to underlying condition with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E08.42	Diabetes mellitus due to underlying condition with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E08.44	Diabetes mellitus due to underlying condition with diabetic amyotrophy	Diagnosis	ICD-10-CM
E08.49	Diabetes mellitus due to underlying condition with other diabetic neurological complication	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with	Diagnosis	ICD-10-CM
E08.59	Diabetes mellitus due to underlying condition with other circulatory complications	Diagnosis	ICD-10-CM
E08.610	Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E08.618	Diabetes mellitus due to underlying condition with other diabetic arthropathy	Diagnosis	ICD-10-CM
E08.620	Diabetes mellitus due to underlying condition with diabetic dermatitis	Diagnosis	ICD-10-CM
E08.621	Diabetes mellitus due to underlying condition with foot ulcer	Diagnosis	ICD-10-CM
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer	Diagnosis	ICD-10-CM
E08.628	Diabetes mellitus due to underlying condition with other skin complications	Diagnosis	ICD-10-CM
E08.630	Diabetes mellitus due to underlying condition with yearontal disease	Diagnosis	ICD-10-CM
E08.638	Diabetes mellitus due to underlying condition with other oral complications	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E08.69	Diabetes mellitus due to underlying condition with other specified complication	Diagnosis	ICD-10-CM
E08.8	Diabetes mellitus due to underlying condition with unspecified complications	Diagnosis	ICD-10-CM
E08.9	Diabetes mellitus due to underlying condition without complications	Diagnosis	ICD-10-CM
E09.00	Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E09.01	Drug or chemical induced diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E09.10	Drug or chemical induced diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E09.11	Drug or chemical induced diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.321	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3219	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.329	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3299	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.331	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3319	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.339	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E09.3399	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.341	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3419	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.349	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3499	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.351	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3519	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.3521	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E09.3522	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3529	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3531	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3532	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3539	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3541	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E09.3542	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E09.3549	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E09.3551	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy,	Diagnosis	ICD-10-CM
E09.3552	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left	Diagnosis	ICD-10-CM
E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy,	Diagnosis	ICD-10-CM
E09.3559	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E09.359	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3599	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.36	Drug or chemical induced diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E09.37X1	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E09.37X2	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E09.37X3	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E09.37X9	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E09.39	Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E09.40	Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E09.41	Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E09.42	Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E09.43	Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E09.44	Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy	Diagnosis	ICD-10-CM
E09.49	Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication	Diagnosis	ICD-10-CM
E09.51	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without	Diagnosis	ICD-10-CM
E09.52	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with	Diagnosis	ICD-10-CM
E09.59	Drug or chemical induced diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E09.610	Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E09.618	Drug or chemical induced diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E09.620	Drug or chemical induced diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E09.622	Drug or chemical induced diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E09.628	Drug or chemical induced diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E09.630	Drug or chemical induced diabetes mellitus with yearontal disease	Diagnosis	ICD-10-CM
E09.638	Drug or chemical induced diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E09.641	Drug or chemical induced diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E09.649	Drug or chemical induced diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E09.65	Drug or chemical induced diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E09.69	Drug or chemical induced diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E09.8	Drug or chemical induced diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E09.9	Drug or chemical induced diabetes mellitus without complications	Diagnosis	ICD-10-CM
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left	Diagnosis	ICD-10-CM
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema,	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right	Diagnosis	ICD-10-CM
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with yearontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular	Diagnosis	ICD-10-CM
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular	Diagnosis	ICD-10-CM
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right	Diagnosis	ICD-10-CM
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema,	Diagnosis	ICD-10-CM
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right	Diagnosis	ICD-10-CM
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with yearontal disease	Diagnosis	ICD-10-CM
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular	Diagnosis	ICD-10-CM
E13.321	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.329	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.331	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.339	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.341	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.349	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.351	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified	Diagnosis	ICD-10-CM
E13.359	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with yearontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
Heart Failure			
I09.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I42.0	Dilated cardiomyopathy	Diagnosis	ICD-10-CM
I42.5	Other restrictive cardiomyopathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
I42.7	Cardiomyopathy due to drug and external agent	Diagnosis	ICD-10-CM
I42.8	Other cardiomyopathies	Diagnosis	ICD-10-CM
I43	Cardiomyopathy in diseases classified elsewhere	Diagnosis	ICD-10-CM
I50.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
I50.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I50.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
I50.811	Acute right heart failure	Diagnosis	ICD-10-CM
I50.812	Chronic right heart failure	Diagnosis	ICD-10-CM
I50.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
I50.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
I50.82	Biventricular heart failure	Diagnosis	ICD-10-CM
I50.83	High output heart failure	Diagnosis	ICD-10-CM
I50.84	End stage heart failure	Diagnosis	ICD-10-CM
I50.89	Other heart failure	Diagnosis	ICD-10-CM
I50.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
P29.0	Neonatal cardiac failure	Diagnosis	ICD-10-CM
Hyperlipidemia			
E78.0	Pure hypercholesterolemia	Diagnosis	ICD-10-CM
E78.00	Pure hypercholesterolemia, unspecified	Diagnosis	ICD-10-CM
E78.01	Familial hypercholesterolemia	Diagnosis	ICD-10-CM
E78.1	Pure hyperglyceridemia	Diagnosis	ICD-10-CM
E78.2	Mixed hyperlipidemia	Diagnosis	ICD-10-CM
E78.3	Hyperchylomicronemia	Diagnosis	ICD-10-CM
E78.4	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.41	Elevated Lipoprotein(a)	Diagnosis	ICD-10-CM
E78.49	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.5	Hyperlipidemia, unspecified	Diagnosis	ICD-10-CM
Hypertension			
H35.031	Hypertensive retinopathy, right eye	Diagnosis	ICD-10-CM
H35.032	Hypertensive retinopathy, left eye	Diagnosis	ICD-10-CM
H35.033	Hypertensive retinopathy, bilateral	Diagnosis	ICD-10-CM
H35.039	Hypertensive retinopathy, unspecified eye	Diagnosis	ICD-10-CM
I10	Essential (primary) hypertension	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I11.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I15.0	Renovascular hypertension	Diagnosis	ICD-10-CM
I15.1	Hypertension secondary to other renal disorders	Diagnosis	ICD-10-CM
I15.2	Hypertension secondary to endocrine disorders	Diagnosis	ICD-10-CM
I15.8	Other secondary hypertension	Diagnosis	ICD-10-CM
I15.9	Secondary hypertension, unspecified	Diagnosis	ICD-10-CM
I67.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
N26.2	Page kidney	Diagnosis	ICD-10-CM
Depression			
F06.31	Mood disorder due to known physiological condition with depressive features	Diagnosis	ICD-10-CM
F06.32	Mood disorder due to known physiological condition with major depressive-like episode	Diagnosis	ICD-10-CM
F31.0	Bipolar disorder, current episode hypomanic	Diagnosis	ICD-10-CM
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified	Diagnosis	ICD-10-CM
F31.11	Bipolar disorder, current episode manic without psychotic features, mild	Diagnosis	ICD-10-CM
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate	Diagnosis	ICD-10-CM
F31.13	Bipolar disorder, current episode manic without psychotic features, severe	Diagnosis	ICD-10-CM
F31.2	Bipolar disorder, current episode manic severe with psychotic features	Diagnosis	ICD-10-CM
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.73	Bipolar disorder, in partial remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
F31.89	Other bipolar disorder	Diagnosis	ICD-10-CM
F31.9	Bipolar disorder, unspecified	Diagnosis	ICD-10-CM
F32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
F32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
F32.2	Major depressive disorder, single episode, severe without psychotic features	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM
F32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
F32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM
F32.8	Other depressive episodes	Diagnosis	ICD-10-CM
F32.89	Other specified depressive episodes	Diagnosis	ICD-10-CM
F32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
F32.A	Depression, unspecified	Diagnosis	ICD-10-CM
F33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM
F33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM
F33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
F33.41	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM
F33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
F34.0	Cyclothymic disorder	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F43.21	Adjustment disorder with depressed mood	Diagnosis	ICD-10-CM
F43.23	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-10-CM
Ischemic Heart Disease			
I20.0	Unstable angina	Diagnosis	ICD-10-CM
I20.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I20.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I20.9	Angina pectoris, unspecified	Diagnosis	ICD-10-CM
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I24.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
I24.1	Dressler's syndrome	Diagnosis	ICD-10-CM
I24.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I24.9	Acute ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.2	Old myocardial infarction	Diagnosis	ICD-10-CM
I25.3	Aneurysm of heart	Diagnosis	ICD-10-CM
I25.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
I25.42	Coronary artery dissection	Diagnosis	ICD-10-CM
I25.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
I25.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM
I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina	Diagnosis	ICD-10-CM
I25.709	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina	Diagnosis	ICD-10-CM
I25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina	Diagnosis	ICD-10-CM
I25.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina	Diagnosis	ICD-10-CM
I25.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina	Diagnosis	ICD-10-CM
I25.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I25.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina	Diagnosis	ICD-10-CM
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina	Diagnosis	ICD-10-CM
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
I25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina	Diagnosis	ICD-10-CM
I25.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
I25.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
I25.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
I25.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I25.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
Rheumatoid Arthritis/Osteoarthritis			
L40.50	Arthropathic psoriasis, unspecified	Diagnosis	ICD-10-CM
L40.51	Distal interphalangeal psoriatic arthropathy	Diagnosis	ICD-10-CM
L40.54	Psoriatic juvenile arthropathy	Diagnosis	ICD-10-CM
L40.59	Other psoriatic arthropathy	Diagnosis	ICD-10-CM
M05.00	Felty's syndrome, unspecified site	Diagnosis	ICD-10-CM
M05.011	Felty's syndrome, right shoulder	Diagnosis	ICD-10-CM
M05.012	Felty's syndrome, left shoulder	Diagnosis	ICD-10-CM
M05.019	Felty's syndrome, unspecified shoulder	Diagnosis	ICD-10-CM
M05.021	Felty's syndrome, right elbow	Diagnosis	ICD-10-CM
M05.022	Felty's syndrome, left elbow	Diagnosis	ICD-10-CM
M05.029	Felty's syndrome, unspecified elbow	Diagnosis	ICD-10-CM
M05.031	Felty's syndrome, right wrist	Diagnosis	ICD-10-CM
M05.032	Felty's syndrome, left wrist	Diagnosis	ICD-10-CM
M05.039	Felty's syndrome, unspecified wrist	Diagnosis	ICD-10-CM
M05.041	Felty's syndrome, right hand	Diagnosis	ICD-10-CM
M05.042	Felty's syndrome, left hand	Diagnosis	ICD-10-CM
M05.049	Felty's syndrome, unspecified hand	Diagnosis	ICD-10-CM
M05.051	Felty's syndrome, right hip	Diagnosis	ICD-10-CM
M05.052	Felty's syndrome, left hip	Diagnosis	ICD-10-CM
M05.059	Felty's syndrome, unspecified hip	Diagnosis	ICD-10-CM
M05.061	Felty's syndrome, right knee	Diagnosis	ICD-10-CM
M05.062	Felty's syndrome, left knee	Diagnosis	ICD-10-CM
M05.069	Felty's syndrome, unspecified knee	Diagnosis	ICD-10-CM
M05.071	Felty's syndrome, right ankle and foot	Diagnosis	ICD-10-CM
M05.072	Felty's syndrome, left ankle and foot	Diagnosis	ICD-10-CM
M05.079	Felty's syndrome, unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.09	Felty's syndrome, multiple sites	Diagnosis	ICD-10-CM
M05.10	Rheumatoid lung disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.111	Rheumatoid lung disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.112	Rheumatoid lung disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.119	Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.121	Rheumatoid lung disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M05.122	Rheumatoid lung disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.129	Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.131	Rheumatoid lung disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.132	Rheumatoid lung disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.139	Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.141	Rheumatoid lung disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.142	Rheumatoid lung disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.149	Rheumatoid lung disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.151	Rheumatoid lung disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.152	Rheumatoid lung disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.159	Rheumatoid lung disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.161	Rheumatoid lung disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.162	Rheumatoid lung disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.169	Rheumatoid lung disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.171	Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.172	Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.179	Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.19	Rheumatoid lung disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.239	Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.241	Rheumatoid vasculitis with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.242	Rheumatoid vasculitis with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.249	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.251	Rheumatoid vasculitis with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.252	Rheumatoid vasculitis with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.259	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M05.261	Rheumatoid vasculitis with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.262	Rheumatoid vasculitis with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.269	Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.271	Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.272	Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.279	Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.29	Rheumatoid vasculitis with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.619	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.629	Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.639	Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.641	Rheumatoid arthritis of right hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.642	Rheumatoid arthritis of left hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.649	Rheumatoid arthritis of unspecified hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.651	Rheumatoid arthritis of right hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.652	Rheumatoid arthritis of left hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.659	Rheumatoid arthritis of unspecified hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.661	Rheumatoid arthritis of right knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.662	Rheumatoid arthritis of left knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.669	Rheumatoid arthritis of unspecified knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.671	Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.672	Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and	Diagnosis	ICD-10-CM
M05.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M05.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M05.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site	Diagnosis	ICD-10-CM
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder	Diagnosis	ICD-10-CM
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder	Diagnosis	ICD-10-CM
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder	Diagnosis	ICD-10-CM
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow	Diagnosis	ICD-10-CM
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow	Diagnosis	ICD-10-CM
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow	Diagnosis	ICD-10-CM
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist	Diagnosis	ICD-10-CM
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist	Diagnosis	ICD-10-CM
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist	Diagnosis	ICD-10-CM
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand	Diagnosis	ICD-10-CM
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand	Diagnosis	ICD-10-CM
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand	Diagnosis	ICD-10-CM
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip	Diagnosis	ICD-10-CM
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip	Diagnosis	ICD-10-CM
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip	Diagnosis	ICD-10-CM
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee	Diagnosis	ICD-10-CM
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee	Diagnosis	ICD-10-CM
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee	Diagnosis	ICD-10-CM
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot	Diagnosis	ICD-10-CM
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot	Diagnosis	ICD-10-CM
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites	Diagnosis	ICD-10-CM
M05.8A	Other rheumatoid arthritis with rheumatoid factor of other specified site	Diagnosis	ICD-10-CM
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified	Diagnosis	ICD-10-CM
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site	Diagnosis	ICD-10-CM
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder	Diagnosis	ICD-10-CM
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder	Diagnosis	ICD-10-CM
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder	Diagnosis	ICD-10-CM
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow	Diagnosis	ICD-10-CM
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow	Diagnosis	ICD-10-CM
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist	Diagnosis	ICD-10-CM
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist	Diagnosis	ICD-10-CM
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist	Diagnosis	ICD-10-CM
M06.041	Rheumatoid arthritis without rheumatoid factor, right hand	Diagnosis	ICD-10-CM
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand	Diagnosis	ICD-10-CM
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand	Diagnosis	ICD-10-CM
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip	Diagnosis	ICD-10-CM
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip	Diagnosis	ICD-10-CM
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip	Diagnosis	ICD-10-CM
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee	Diagnosis	ICD-10-CM
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee	Diagnosis	ICD-10-CM
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee	Diagnosis	ICD-10-CM
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot	Diagnosis	ICD-10-CM
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot	Diagnosis	ICD-10-CM
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae	Diagnosis	ICD-10-CM
M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites	Diagnosis	ICD-10-CM
M06.0A	Rheumatoid arthritis without rheumatoid factor, other specified site	Diagnosis	ICD-10-CM
M06.1	Adult-onset Still's disease	Diagnosis	ICD-10-CM
M06.20	Rheumatoid bursitis, unspecified site	Diagnosis	ICD-10-CM
M06.211	Rheumatoid bursitis, right shoulder	Diagnosis	ICD-10-CM
M06.212	Rheumatoid bursitis, left shoulder	Diagnosis	ICD-10-CM
M06.219	Rheumatoid bursitis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.221	Rheumatoid bursitis, right elbow	Diagnosis	ICD-10-CM
M06.222	Rheumatoid bursitis, left elbow	Diagnosis	ICD-10-CM
M06.229	Rheumatoid bursitis, unspecified elbow	Diagnosis	ICD-10-CM
M06.231	Rheumatoid bursitis, right wrist	Diagnosis	ICD-10-CM
M06.232	Rheumatoid bursitis, left wrist	Diagnosis	ICD-10-CM
M06.239	Rheumatoid bursitis, unspecified wrist	Diagnosis	ICD-10-CM
M06.241	Rheumatoid bursitis, right hand	Diagnosis	ICD-10-CM
M06.242	Rheumatoid bursitis, left hand	Diagnosis	ICD-10-CM
M06.249	Rheumatoid bursitis, unspecified hand	Diagnosis	ICD-10-CM
M06.251	Rheumatoid bursitis, right hip	Diagnosis	ICD-10-CM
M06.252	Rheumatoid bursitis, left hip	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
M06.259	Rheumatoid bursitis, unspecified hip	Diagnosis	ICD-10-CM
M06.261	Rheumatoid bursitis, right knee	Diagnosis	ICD-10-CM
M06.262	Rheumatoid bursitis, left knee	Diagnosis	ICD-10-CM
M06.269	Rheumatoid bursitis, unspecified knee	Diagnosis	ICD-10-CM
M06.271	Rheumatoid bursitis, right ankle and foot	Diagnosis	ICD-10-CM
M06.272	Rheumatoid bursitis, left ankle and foot	Diagnosis	ICD-10-CM
M06.279	Rheumatoid bursitis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.28	Rheumatoid bursitis, vertebrae	Diagnosis	ICD-10-CM
M06.29	Rheumatoid bursitis, multiple sites	Diagnosis	ICD-10-CM
M06.30	Rheumatoid nodule, unspecified site	Diagnosis	ICD-10-CM
M06.311	Rheumatoid nodule, right shoulder	Diagnosis	ICD-10-CM
M06.312	Rheumatoid nodule, left shoulder	Diagnosis	ICD-10-CM
M06.319	Rheumatoid nodule, unspecified shoulder	Diagnosis	ICD-10-CM
M06.321	Rheumatoid nodule, right elbow	Diagnosis	ICD-10-CM
M06.322	Rheumatoid nodule, left elbow	Diagnosis	ICD-10-CM
M06.329	Rheumatoid nodule, unspecified elbow	Diagnosis	ICD-10-CM
M06.331	Rheumatoid nodule, right wrist	Diagnosis	ICD-10-CM
M06.332	Rheumatoid nodule, left wrist	Diagnosis	ICD-10-CM
M06.339	Rheumatoid nodule, unspecified wrist	Diagnosis	ICD-10-CM
M06.341	Rheumatoid nodule, right hand	Diagnosis	ICD-10-CM
M06.342	Rheumatoid nodule, left hand	Diagnosis	ICD-10-CM
M06.349	Rheumatoid nodule, unspecified hand	Diagnosis	ICD-10-CM
M06.351	Rheumatoid nodule, right hip	Diagnosis	ICD-10-CM
M06.352	Rheumatoid nodule, left hip	Diagnosis	ICD-10-CM
M06.359	Rheumatoid nodule, unspecified hip	Diagnosis	ICD-10-CM
M06.361	Rheumatoid nodule, right knee	Diagnosis	ICD-10-CM
M06.362	Rheumatoid nodule, left knee	Diagnosis	ICD-10-CM
M06.369	Rheumatoid nodule, unspecified knee	Diagnosis	ICD-10-CM
M06.371	Rheumatoid nodule, right ankle and foot	Diagnosis	ICD-10-CM
M06.372	Rheumatoid nodule, left ankle and foot	Diagnosis	ICD-10-CM
M06.379	Rheumatoid nodule, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.38	Rheumatoid nodule, vertebrae	Diagnosis	ICD-10-CM
M06.39	Rheumatoid nodule, multiple sites	Diagnosis	ICD-10-CM
M06.80	Other specified rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M06.811	Other specified rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M06.812	Other specified rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M06.819	Other specified rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.821	Other specified rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M06.822	Other specified rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M06.829	Other specified rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M06.831	Other specified rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M06.832	Other specified rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M06.839	Other specified rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M06.841	Other specified rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M06.842	Other specified rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M06.849	Other specified rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M06.851	Other specified rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M06.852	Other specified rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M06.859	Other specified rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M06.861	Other specified rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M06.862	Other specified rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M06.869	Other specified rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M06.871	Other specified rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M06.872	Other specified rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.88	Other specified rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M06.89	Other specified rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M06.8A	Other specified rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M06.9	Rheumatoid arthritis, unspecified	Diagnosis	ICD-10-CM
M08.00	Unspecified juvenile rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M08.011	Unspecified juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.012	Unspecified juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.019	Unspecified juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.021	Unspecified juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.022	Unspecified juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.029	Unspecified juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.031	Unspecified juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.032	Unspecified juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M08.039	Unspecified juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.041	Unspecified juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.042	Unspecified juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.049	Unspecified juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.051	Unspecified juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.052	Unspecified juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.059	Unspecified juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.061	Unspecified juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.062	Unspecified juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.069	Unspecified juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.071	Unspecified juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.072	Unspecified juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.079	Unspecified juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.08	Unspecified juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.09	Unspecified juvenile rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.0A	Unspecified juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.1	Juvenile ankylosing spondylitis	Diagnosis	ICD-10-CM
M08.20	Juvenile rheumatoid arthritis with systemic onset, unspecified site	Diagnosis	ICD-10-CM
M08.211	Juvenile rheumatoid arthritis with systemic onset, right shoulder	Diagnosis	ICD-10-CM
M08.212	Juvenile rheumatoid arthritis with systemic onset, left shoulder	Diagnosis	ICD-10-CM
M08.219	Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder	Diagnosis	ICD-10-CM
M08.221	Juvenile rheumatoid arthritis with systemic onset, right elbow	Diagnosis	ICD-10-CM
M08.222	Juvenile rheumatoid arthritis with systemic onset, left elbow	Diagnosis	ICD-10-CM
M08.229	Juvenile rheumatoid arthritis with systemic onset, unspecified elbow	Diagnosis	ICD-10-CM
M08.231	Juvenile rheumatoid arthritis with systemic onset, right wrist	Diagnosis	ICD-10-CM
M08.232	Juvenile rheumatoid arthritis with systemic onset, left wrist	Diagnosis	ICD-10-CM
M08.239	Juvenile rheumatoid arthritis with systemic onset, unspecified wrist	Diagnosis	ICD-10-CM
M08.241	Juvenile rheumatoid arthritis with systemic onset, right hand	Diagnosis	ICD-10-CM
M08.242	Juvenile rheumatoid arthritis with systemic onset, left hand	Diagnosis	ICD-10-CM
M08.249	Juvenile rheumatoid arthritis with systemic onset, unspecified hand	Diagnosis	ICD-10-CM
M08.251	Juvenile rheumatoid arthritis with systemic onset, right hip	Diagnosis	ICD-10-CM
M08.252	Juvenile rheumatoid arthritis with systemic onset, left hip	Diagnosis	ICD-10-CM
M08.259	Juvenile rheumatoid arthritis with systemic onset, unspecified hip	Diagnosis	ICD-10-CM
M08.261	Juvenile rheumatoid arthritis with systemic onset, right knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M08.262	Juvenile rheumatoid arthritis with systemic onset, left knee	Diagnosis	ICD-10-CM
M08.269	Juvenile rheumatoid arthritis with systemic onset, unspecified knee	Diagnosis	ICD-10-CM
M08.271	Juvenile rheumatoid arthritis with systemic onset, right ankle and foot	Diagnosis	ICD-10-CM
M08.272	Juvenile rheumatoid arthritis with systemic onset, left ankle and foot	Diagnosis	ICD-10-CM
M08.279	Juvenile rheumatoid arthritis with systemic onset, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.28	Juvenile rheumatoid arthritis with systemic onset, vertebrae	Diagnosis	ICD-10-CM
M08.29	Juvenile rheumatoid arthritis with systemic onset, multiple sites	Diagnosis	ICD-10-CM
M08.2A	Juvenile rheumatoid arthritis with systemic onset, other specified site	Diagnosis	ICD-10-CM
M08.3	Juvenile rheumatoid polyarthritis (seronegative)	Diagnosis	ICD-10-CM
M08.40	Pauciarticular juvenile rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.411	Pauciarticular juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.412	Pauciarticular juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.419	Pauciarticular juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.421	Pauciarticular juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.422	Pauciarticular juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.429	Pauciarticular juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.431	Pauciarticular juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.432	Pauciarticular juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.439	Pauciarticular juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.441	Pauciarticular juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.442	Pauciarticular juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.449	Pauciarticular juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.451	Pauciarticular juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.452	Pauciarticular juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.459	Pauciarticular juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.461	Pauciarticular juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.462	Pauciarticular juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.469	Pauciarticular juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.471	Pauciarticular juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.472	Pauciarticular juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.479	Pauciarticular juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.48	Pauciarticular juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.4A	Pauciarticular juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.80	Other juvenile arthritis, unspecified site	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
M08.811	Other juvenile arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.812	Other juvenile arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.819	Other juvenile arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.821	Other juvenile arthritis, right elbow	Diagnosis	ICD-10-CM
M08.822	Other juvenile arthritis, left elbow	Diagnosis	ICD-10-CM
M08.829	Other juvenile arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.831	Other juvenile arthritis, right wrist	Diagnosis	ICD-10-CM
M08.832	Other juvenile arthritis, left wrist	Diagnosis	ICD-10-CM
M08.839	Other juvenile arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.841	Other juvenile arthritis, right hand	Diagnosis	ICD-10-CM
M08.842	Other juvenile arthritis, left hand	Diagnosis	ICD-10-CM
M08.849	Other juvenile arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.851	Other juvenile arthritis, right hip	Diagnosis	ICD-10-CM
M08.852	Other juvenile arthritis, left hip	Diagnosis	ICD-10-CM
M08.859	Other juvenile arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.861	Other juvenile arthritis, right knee	Diagnosis	ICD-10-CM
M08.862	Other juvenile arthritis, left knee	Diagnosis	ICD-10-CM
M08.869	Other juvenile arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.871	Other juvenile arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.872	Other juvenile arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.879	Other juvenile arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.88	Other juvenile arthritis, other specified site	Diagnosis	ICD-10-CM
M08.89	Other juvenile arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.90	Juvenile arthritis, unspecified, unspecified site	Diagnosis	ICD-10-CM
M08.911	Juvenile arthritis, unspecified, right shoulder	Diagnosis	ICD-10-CM
M08.912	Juvenile arthritis, unspecified, left shoulder	Diagnosis	ICD-10-CM
M08.919	Juvenile arthritis, unspecified, unspecified shoulder	Diagnosis	ICD-10-CM
M08.921	Juvenile arthritis, unspecified, right elbow	Diagnosis	ICD-10-CM
M08.922	Juvenile arthritis, unspecified, left elbow	Diagnosis	ICD-10-CM
M08.929	Juvenile arthritis, unspecified, unspecified elbow	Diagnosis	ICD-10-CM
M08.931	Juvenile arthritis, unspecified, right wrist	Diagnosis	ICD-10-CM
M08.932	Juvenile arthritis, unspecified, left wrist	Diagnosis	ICD-10-CM
M08.939	Juvenile arthritis, unspecified, unspecified wrist	Diagnosis	ICD-10-CM
M08.941	Juvenile arthritis, unspecified, right hand	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M08.942	Juvenile arthritis, unspecified, left hand	Diagnosis	ICD-10-CM
M08.949	Juvenile arthritis, unspecified, unspecified hand	Diagnosis	ICD-10-CM
M08.951	Juvenile arthritis, unspecified, right hip	Diagnosis	ICD-10-CM
M08.952	Juvenile arthritis, unspecified, left hip	Diagnosis	ICD-10-CM
M08.959	Juvenile arthritis, unspecified, unspecified hip	Diagnosis	ICD-10-CM
M08.961	Juvenile arthritis, unspecified, right knee	Diagnosis	ICD-10-CM
M08.962	Juvenile arthritis, unspecified, left knee	Diagnosis	ICD-10-CM
M08.969	Juvenile arthritis, unspecified, unspecified knee	Diagnosis	ICD-10-CM
M08.971	Juvenile arthritis, unspecified, right ankle and foot	Diagnosis	ICD-10-CM
M08.972	Juvenile arthritis, unspecified, left ankle and foot	Diagnosis	ICD-10-CM
M08.979	Juvenile arthritis, unspecified, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.98	Juvenile arthritis, unspecified, vertebrae	Diagnosis	ICD-10-CM
M08.99	Juvenile arthritis, unspecified, multiple sites	Diagnosis	ICD-10-CM
M08.9A	Juvenile arthritis, unspecified, other specified site	Diagnosis	ICD-10-CM
M15.0	Primary generalized (osteo)arthritis	Diagnosis	ICD-10-CM
M15.1	Heberden's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.2	Bouchard's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.3	Secondary multiple arthritis	Diagnosis	ICD-10-CM
M15.4	Erosive (osteo)arthritis	Diagnosis	ICD-10-CM
M15.8	Other polyosteoarthritis	Diagnosis	ICD-10-CM
M15.9	Polyosteoarthritis, unspecified	Diagnosis	ICD-10-CM
M16.0	Bilateral primary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.10	Unilateral primary osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.11	Unilateral primary osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.12	Unilateral primary osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.2	Bilateral osteoarthritis resulting from hip dysplasia	Diagnosis	ICD-10-CM
M16.30	Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip	Diagnosis	ICD-10-CM
M16.31	Unilateral osteoarthritis resulting from hip dysplasia, right hip	Diagnosis	ICD-10-CM
M16.32	Unilateral osteoarthritis resulting from hip dysplasia, left hip	Diagnosis	ICD-10-CM
M16.4	Bilateral post-traumatic osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.50	Unilateral post-traumatic osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.51	Unilateral post-traumatic osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.52	Unilateral post-traumatic osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.6	Other bilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
M16.7	Other unilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.9	Osteoarthritis of hip, unspecified	Diagnosis	ICD-10-CM
M17.0	Bilateral primary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.10	Unilateral primary osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.11	Unilateral primary osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.12	Unilateral primary osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.2	Bilateral post-traumatic osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.31	Unilateral post-traumatic osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.32	Unilateral post-traumatic osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.4	Other bilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.5	Other unilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.9	Osteoarthritis of knee, unspecified	Diagnosis	ICD-10-CM
M18.0	Bilateral primary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.10	Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.11	Unilateral primary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.12	Unilateral primary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.2	Bilateral post-traumatic osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.30	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.31	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.32	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.4	Other bilateral secondary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.50	Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.51	Other unilateral secondary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.52	Other unilateral secondary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.9	Osteoarthritis of first carpometacarpal joint, unspecified	Diagnosis	ICD-10-CM
M19.011	Primary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.012	Primary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.019	Primary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.021	Primary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.022	Primary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.029	Primary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.031	Primary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.032	Primary osteoarthritis, left wrist	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
M19.039	Primary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.041	Primary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.042	Primary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.049	Primary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.071	Primary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.072	Primary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.079	Primary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.09	Primary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.111	Post-traumatic osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.112	Post-traumatic osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.119	Post-traumatic osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.121	Post-traumatic osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.122	Post-traumatic osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.129	Post-traumatic osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.131	Post-traumatic osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.132	Post-traumatic osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.139	Post-traumatic osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.141	Post-traumatic osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.142	Post-traumatic osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.149	Post-traumatic osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.171	Post-traumatic osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.172	Post-traumatic osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.179	Post-traumatic osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.19	Post-traumatic osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.211	Secondary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.212	Secondary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.219	Secondary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.221	Secondary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.222	Secondary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.229	Secondary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.231	Secondary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.232	Secondary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.239	Secondary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.241	Secondary osteoarthritis, right hand	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M19.242	Secondary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.249	Secondary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.271	Secondary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.272	Secondary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.279	Secondary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.29	Secondary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.90	Unspecified osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.91	Primary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.92	Post-traumatic osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.93	Secondary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M45.0	Ankylosing spondylitis of multiple sites in spine	Diagnosis	ICD-10-CM
M45.1	Ankylosing spondylitis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.2	Ankylosing spondylitis of cervical region	Diagnosis	ICD-10-CM
M45.3	Ankylosing spondylitis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.4	Ankylosing spondylitis of thoracic region	Diagnosis	ICD-10-CM
M45.5	Ankylosing spondylitis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.6	Ankylosing spondylitis lumbar region	Diagnosis	ICD-10-CM
M45.7	Ankylosing spondylitis of lumbosacral region	Diagnosis	ICD-10-CM
M45.8	Ankylosing spondylitis sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.9	Ankylosing spondylitis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A0	Non-radiographic axial spondyloarthritis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A1	Non-radiographic axial spondyloarthritis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.A2	Non-radiographic axial spondyloarthritis of cervical region	Diagnosis	ICD-10-CM
M45.A3	Non-radiographic axial spondyloarthritis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.A4	Non-radiographic axial spondyloarthritis of thoracic region	Diagnosis	ICD-10-CM
M45.A5	Non-radiographic axial spondyloarthritis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.A6	Non-radiographic axial spondyloarthritis of lumbar region	Diagnosis	ICD-10-CM
M45.A7	Non-radiographic axial spondyloarthritis of lumbosacral region	Diagnosis	ICD-10-CM
M45.A8	Non-radiographic axial spondyloarthritis of sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.AB	Non-radiographic axial spondyloarthritis of multiple sites in spine	Diagnosis	ICD-10-CM
M46.80	Other specified inflammatory spondylopathies, site unspecified	Diagnosis	ICD-10-CM
M46.81	Other specified inflammatory spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.82	Other specified inflammatory spondylopathies, cervical region	Diagnosis	ICD-10-CM
M46.83	Other specified inflammatory spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M46.84	Other specified inflammatory spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M46.85	Other specified inflammatory spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M46.86	Other specified inflammatory spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M46.87	Other specified inflammatory spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M46.88	Other specified inflammatory spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.89	Other specified inflammatory spondylopathies, multiple sites in spine	Diagnosis	ICD-10-CM
M46.90	Unspecified inflammatory spondylopathy, site unspecified	Diagnosis	ICD-10-CM
M46.91	Unspecified inflammatory spondylopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.92	Unspecified inflammatory spondylopathy, cervical region	Diagnosis	ICD-10-CM
M46.93	Unspecified inflammatory spondylopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M46.94	Unspecified inflammatory spondylopathy, thoracic region	Diagnosis	ICD-10-CM
M46.95	Unspecified inflammatory spondylopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M46.96	Unspecified inflammatory spondylopathy, lumbar region	Diagnosis	ICD-10-CM
M46.97	Unspecified inflammatory spondylopathy, lumbosacral region	Diagnosis	ICD-10-CM
M46.98	Unspecified inflammatory spondylopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.99	Unspecified inflammatory spondylopathy, multiple sites in spine	Diagnosis	ICD-10-CM
M47.011	Anterior spinal artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.012	Anterior spinal artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.013	Anterior spinal artery compression syndromes, cervicothoracic region	Diagnosis	ICD-10-CM
M47.014	Anterior spinal artery compression syndromes, thoracic region	Diagnosis	ICD-10-CM
M47.015	Anterior spinal artery compression syndromes, thoracolumbar region	Diagnosis	ICD-10-CM
M47.016	Anterior spinal artery compression syndromes, lumbar region	Diagnosis	ICD-10-CM
M47.019	Anterior spinal artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.021	Vertebral artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.022	Vertebral artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.029	Vertebral artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.10	Other spondylosis with myelopathy, site unspecified	Diagnosis	ICD-10-CM
M47.11	Other spondylosis with myelopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.12	Other spondylosis with myelopathy, cervical region	Diagnosis	ICD-10-CM
M47.13	Other spondylosis with myelopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.14	Other spondylosis with myelopathy, thoracic region	Diagnosis	ICD-10-CM
M47.15	Other spondylosis with myelopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.16	Other spondylosis with myelopathy, lumbar region	Diagnosis	ICD-10-CM
M47.20	Other spondylosis with radiculopathy, site unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M47.21	Other spondylosis with radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.22	Other spondylosis with radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.23	Other spondylosis with radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.24	Other spondylosis with radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.25	Other spondylosis with radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.26	Other spondylosis with radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.27	Other spondylosis with radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.28	Other spondylosis with radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.811	Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.812	Spondylosis without myelopathy or radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.813	Spondylosis without myelopathy or radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.814	Spondylosis without myelopathy or radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.815	Spondylosis without myelopathy or radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.816	Spondylosis without myelopathy or radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.817	Spondylosis without myelopathy or radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.818	Spondylosis without myelopathy or radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.819	Spondylosis without myelopathy or radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.891	Other spondylosis, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.892	Other spondylosis, cervical region	Diagnosis	ICD-10-CM
M47.893	Other spondylosis, cervicothoracic region	Diagnosis	ICD-10-CM
M47.894	Other spondylosis, thoracic region	Diagnosis	ICD-10-CM
M47.895	Other spondylosis, thoracolumbar region	Diagnosis	ICD-10-CM
M47.896	Other spondylosis, lumbar region	Diagnosis	ICD-10-CM
M47.897	Other spondylosis, lumbosacral region	Diagnosis	ICD-10-CM
M47.898	Other spondylosis, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.899	Other spondylosis, site unspecified	Diagnosis	ICD-10-CM
M47.9	Spondylosis, unspecified	Diagnosis	ICD-10-CM
M48.8X1	Other specified spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M48.8X2	Other specified spondylopathies, cervical region	Diagnosis	ICD-10-CM
M48.8X3	Other specified spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M48.8X4	Other specified spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M48.8X5	Other specified spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M48.8X6	Other specified spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M48.8X7	Other specified spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M48.8X8	Other specified spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M48.8X9	Other specified spondylopathies, site unspecified	Diagnosis	ICD-10-CM
Stroke/ TIA			
G45.0	Vertebro-basilar artery syndrome	Diagnosis	ICD-10-CM
G45.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
G45.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM
G45.3	Amaurosis fugax	Diagnosis	ICD-10-CM
G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.3	Brain stem stroke syndrome	Diagnosis	ICD-10-CM
G46.4	Cerebellar stroke syndrome	Diagnosis	ICD-10-CM
G46.5	Pure motor lacunar syndrome	Diagnosis	ICD-10-CM
G46.6	Pure sensory lacunar syndrome	Diagnosis	ICD-10-CM
G46.7	Other lacunar syndromes	Diagnosis	ICD-10-CM
G46.8	Other vascular syndromes of brain in cerebrovascular diseases	Diagnosis	ICD-10-CM
G97.31	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating a nervous system procedure	Diagnosis	ICD-10-CM
G97.32	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating other procedure	Diagnosis	ICD-10-CM
I60.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I60.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
I60.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM
I60.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery	Diagnosis	ICD-10-CM
I60.20	Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating artery	Diagnosis	ICD-10-CM
I60.21	Nontraumatic subarachnoid hemorrhage from right anterior communicating artery	Diagnosis	ICD-10-CM
I60.22	Nontraumatic subarachnoid hemorrhage from left anterior communicating artery	Diagnosis	ICD-10-CM
I60.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery	Diagnosis	ICD-10-CM
I60.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I60.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM
I60.4	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
I60.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery	Diagnosis	ICD-10-CM
I60.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM
I60.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
I60.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM
I60.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery	Diagnosis	ICD-10-CM
I60.8	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I60.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM
I61.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
I61.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
I61.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
I61.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
I61.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
I61.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
I61.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
I61.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM
I61.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.00	Nontraumatic subdural hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.01	Nontraumatic acute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.02	Nontraumatic subacute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.9	Nontraumatic intracranial hemorrhage, unspecified	Diagnosis	ICD-10-CM
I63.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
I63.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
I63.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
I63.033	Cerebral infarction due to thrombosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM
I63.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I63.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
I63.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
I63.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
I63.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
I63.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
I63.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
I63.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral	Diagnosis	ICD-10-CM
I63.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral arteries	Diagnosis	ICD-10-CM
I63.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
I63.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
I63.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM
I63.233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid arteries	Diagnosis	ICD-10-CM
I63.29	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
I63.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.311	Cerebral infarction due to thrombosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.312	Cerebral infarction due to thrombosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.321	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.322	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.333	Cerebral infarction to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I63.341	Cerebral infarction due to thrombosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.342	Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.343	Cerebral infarction to thrombosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.39	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.40	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.411	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.412	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.419	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.421	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.422	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.429	Cerebral infarction due to embolism of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.431	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.432	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.441	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM
I63.442	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM
I63.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
I63.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral	Diagnosis	ICD-10-CM
I63.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral	Diagnosis	ICD-10-CM
I63.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral	Diagnosis	ICD-10-CM
I63.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral	Diagnosis	ICD-10-CM
I63.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I63.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral	Diagnosis	ICD-10-CM
I63.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
I63.8	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.81	Other cerebral infarction due to occlusion or stenosis of small artery	Diagnosis	ICD-10-CM
I63.89	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
I66.01	Occlusion and stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I66.02	Occlusion and stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I66.03	Occlusion and stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I66.09	Occlusion and stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I66.11	Occlusion and stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I66.12	Occlusion and stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I66.13	Occlusion and stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I66.19	Occlusion and stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I66.21	Occlusion and stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I66.22	Occlusion and stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I66.23	Occlusion and stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I66.29	Occlusion and stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I66.3	Occlusion and stenosis of cerebellar arteries	Diagnosis	ICD-10-CM
I66.8	Occlusion and stenosis of other cerebral arteries	Diagnosis	ICD-10-CM
I66.9	Occlusion and stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I67.841	Reversible cerebrovascular vasoconstriction syndrome	Diagnosis	ICD-10-CM
I67.848	Other cerebrovascular vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
I67.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM
I97.810	Intraoperative cerebrovascular infarction during cardiac surgery	Diagnosis	ICD-10-CM
I97.811	Intraoperative cerebrovascular infarction during other surgery	Diagnosis	ICD-10-CM
I97.820	Postprocedural cerebrovascular infarction following cardiac surgery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
I97.821	Postprocedural cerebrovascular infarction following other surgery	Diagnosis	ICD-10-CM
Breast Cancer			
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM
C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
C50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
C50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
C50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
C50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
C50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CM
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CM
C50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM
C50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CM
C50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CM
C50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CM
C50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CM
C50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CM
D05.00	Lobular carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.01	Lobular carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.02	Lobular carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.10	Intraductal carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.11	Intraductal carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.12	Intraductal carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.80	Other specified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.81	Other specified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.82	Other specified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.90	Unspecified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.91	Unspecified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.92	Unspecified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
Z17.0	Estrogen receptor positive status [ER+]	Diagnosis	ICD-10-CM
Z17.1	Estrogen receptor negative status [ER-]	Diagnosis	ICD-10-CM
Z19.1	Hormone sensitive malignancy status	Diagnosis	ICD-10-CM
Z19.2	Hormone resistant malignancy status	Diagnosis	ICD-10-CM
Z85.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-10-CM
Z86.000	Personal history of in-situ neoplasm of breast	Diagnosis	ICD-10-CM
Colorectal Cancer			
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
C49.A4	Gastrointestinal stromal tumor of large intestine	Diagnosis	ICD-10-CM
C49.A5	Gastrointestinal stromal tumor of rectum	Diagnosis	ICD-10-CM
D01.0	Carcinoma in situ of colon	Diagnosis	ICD-10-CM
D01.1	Carcinoma in situ of rectosigmoid junction	Diagnosis	ICD-10-CM
D01.2	Carcinoma in situ of rectum	Diagnosis	ICD-10-CM
Z85.030	Personal history of malignant carcinoid tumor of large intestine	Diagnosis	ICD-10-CM
Z85.038	Personal history of other malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.040	Personal history of malignant carcinoid tumor of rectum	Diagnosis	ICD-10-CM
Z85.048	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM
Prostate Cancer			
C61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CM
D07.5	Carcinoma in situ of prostate	Diagnosis	ICD-10-CM
Z85.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-10-CM
Lung Cancer			
C34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
D02.20	Carcinoma in situ of unspecified bronchus and lung	Diagnosis	ICD-10-CM
D02.21	Carcinoma in situ of right bronchus and lung	Diagnosis	ICD-10-CM
D02.22	Carcinoma in situ of left bronchus and lung	Diagnosis	ICD-10-CM
Z85.110	Personal history of malignant carcinoid tumor of bronchus and lung	Diagnosis	ICD-10-CM
Z85.118	Personal history of other malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM
Endometrial Cancer			
C54.0	Malignant neoplasm of isthmus uteri	Diagnosis	ICD-10-CM
C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM
C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
D07.0	Carcinoma in situ of endometrium	Diagnosis	ICD-10-CM
Z85.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-10-CM
Acquired Hypothyroidism			
E00.0	Congenital iodine-deficiency syndrome, neurological type	Diagnosis	ICD-10-CM
E00.1	Congenital iodine-deficiency syndrome, myxedematous type	Diagnosis	ICD-10-CM
E00.2	Congenital iodine-deficiency syndrome, mixed type	Diagnosis	ICD-10-CM
E00.9	Congenital iodine-deficiency syndrome, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E01.8	Other iodine-deficiency related thyroid disorders and allied conditions	Diagnosis	ICD-10-CM
E02	Subclinical iodine-deficiency hypothyroidism	Diagnosis	ICD-10-CM
E03.0	Congenital hypothyroidism with diffuse goiter	Diagnosis	ICD-10-CM
E03.1	Congenital hypothyroidism without goiter	Diagnosis	ICD-10-CM
E03.2	Hypothyroidism due to medicaments and other exogenous substances	Diagnosis	ICD-10-CM
E03.3	Postinfectious hypothyroidism	Diagnosis	ICD-10-CM
E03.4	Atrophy of thyroid (acquired)	Diagnosis	ICD-10-CM
E03.8	Other specified hypothyroidism	Diagnosis	ICD-10-CM
E03.9	Hypothyroidism, unspecified	Diagnosis	ICD-10-CM
E89.0	Postprocedural hypothyroidism	Diagnosis	ICD-10-CM
Anemia			
C94.6	Myelodysplastic disease, not elsewhere classified	Diagnosis	ICD-10-CM
D46.0	Refractory anemia without ring sideroblasts, so stated	Diagnosis	ICD-10-CM
D46.1	Refractory anemia with ring sideroblasts	Diagnosis	ICD-10-CM
D46.20	Refractory anemia with excess of blasts, unspecified	Diagnosis	ICD-10-CM
D46.21	Refractory anemia with excess of blasts 1	Diagnosis	ICD-10-CM
D46.22	Refractory anemia with excess of blasts 2	Diagnosis	ICD-10-CM
D46.4	Refractory anemia, unspecified	Diagnosis	ICD-10-CM
D46.9	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-10-CM
D46.A	Refractory cytopenia with multilineage dysplasia	Diagnosis	ICD-10-CM
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts	Diagnosis	ICD-10-CM
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality	Diagnosis	ICD-10-CM
D46.Z	Other myelodysplastic syndromes	Diagnosis	ICD-10-CM
D47.4	Osteomyelofibrosis	Diagnosis	ICD-10-CM
D50.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-10-CM
D50.1	Sideropenic dysphagia	Diagnosis	ICD-10-CM
D50.8	Other iron deficiency anemias	Diagnosis	ICD-10-CM
D50.9	Iron deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D51.0	Vitamin B12 deficiency anemia due to intrinsic factor deficiency	Diagnosis	ICD-10-CM
D51.1	Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuria	Diagnosis	ICD-10-CM
D51.2	Transcobalamin II deficiency	Diagnosis	ICD-10-CM
D51.3	Other dietary vitamin B12 deficiency anemia	Diagnosis	ICD-10-CM
D51.8	Other vitamin B12 deficiency anemias	Diagnosis	ICD-10-CM
D51.9	Vitamin B12 deficiency anemia, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
D52.0	Dietary folate deficiency anemia	Diagnosis	ICD-10-CM
D52.1	Drug-induced folate deficiency anemia	Diagnosis	ICD-10-CM
D52.8	Other folate deficiency anemias	Diagnosis	ICD-10-CM
D52.9	Folate deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D53.0	Protein deficiency anemia	Diagnosis	ICD-10-CM
D53.1	Other megaloblastic anemias, not elsewhere classified	Diagnosis	ICD-10-CM
D53.2	Scorbutic anemia	Diagnosis	ICD-10-CM
D53.8	Other specified nutritional anemias	Diagnosis	ICD-10-CM
D53.9	Nutritional anemia, unspecified	Diagnosis	ICD-10-CM
D55.0	Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency	Diagnosis	ICD-10-CM
D55.1	Anemia due to other disorders of glutathione metabolism	Diagnosis	ICD-10-CM
D55.2	Anemia due to disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.21	Anemia due to pyruvate kinase deficiency	Diagnosis	ICD-10-CM
D55.29	Anemia due to other disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.3	Anemia due to disorders of nucleotide metabolism	Diagnosis	ICD-10-CM
D55.8	Other anemias due to enzyme disorders	Diagnosis	ICD-10-CM
D55.9	Anemia due to enzyme disorder, unspecified	Diagnosis	ICD-10-CM
D56.0	Alpha thalassemia	Diagnosis	ICD-10-CM
D56.1	Beta thalassemia	Diagnosis	ICD-10-CM
D56.2	Delta-beta thalassemia	Diagnosis	ICD-10-CM
D56.3	Thalassemia minor	Diagnosis	ICD-10-CM
D56.4	Hereditary persistence of fetal hemoglobin [HPFH]	Diagnosis	ICD-10-CM
D56.5	Hemoglobin E-beta thalassemia	Diagnosis	ICD-10-CM
D56.8	Other thalassemias	Diagnosis	ICD-10-CM
D56.9	Thalassemia, unspecified	Diagnosis	ICD-10-CM
D57.00	Hb-SS disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.01	Hb-SS disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.02	Hb-SS disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.03	Hb-SS disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.09	Hb-SS disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.1	Sickle-cell disease without crisis	Diagnosis	ICD-10-CM
D57.20	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-10-CM
D57.211	Sickle-cell/Hb-C disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.212	Sickle-cell/Hb-C disease with splenic sequestration	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
D57.213	Sickle-cell/Hb-C disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.218	Sickle-cell/Hb-C disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.219	Sickle-cell/Hb-C disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.3	Sickle-cell trait	Diagnosis	ICD-10-CM
D57.40	Sickle-cell thalassemia without crisis	Diagnosis	ICD-10-CM
D57.411	Sickle-cell thalassemia with acute chest syndrome	Diagnosis	ICD-10-CM
D57.412	Sickle-cell thalassemia with splenic sequestration	Diagnosis	ICD-10-CM
D57.413	Sickle-cell thalassemia, unspecified, with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.418	Sickle-cell thalassemia, unspecified, with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.419	Sickle-cell thalassemia with crisis, unspecified	Diagnosis	ICD-10-CM
D57.42	Sickle-cell thalassemia beta zero without crisis	Diagnosis	ICD-10-CM
D57.431	Sickle-cell thalassemia beta zero with acute chest syndrome	Diagnosis	ICD-10-CM
D57.432	Sickle-cell thalassemia beta zero with splenic sequestration	Diagnosis	ICD-10-CM
D57.433	Sickle-cell thalassemia beta zero with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.438	Sickle-cell thalassemia beta zero with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.439	Sickle-cell thalassemia beta zero with crisis, unspecified	Diagnosis	ICD-10-CM
D57.44	Sickle-cell thalassemia beta plus without crisis	Diagnosis	ICD-10-CM
D57.451	Sickle-cell thalassemia beta plus with acute chest syndrome	Diagnosis	ICD-10-CM
D57.452	Sickle-cell thalassemia beta plus with splenic sequestration	Diagnosis	ICD-10-CM
D57.453	Sickle-cell thalassemia beta plus with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.458	Sickle-cell thalassemia beta plus with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.459	Sickle-cell thalassemia beta plus with crisis, unspecified	Diagnosis	ICD-10-CM
D57.80	Other sickle-cell disorders without crisis	Diagnosis	ICD-10-CM
D57.811	Other sickle-cell disorders with acute chest syndrome	Diagnosis	ICD-10-CM
D57.812	Other sickle-cell disorders with splenic sequestration	Diagnosis	ICD-10-CM
D57.813	Other sickle-cell disorders with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.818	Other sickle-cell disorders with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.819	Other sickle-cell disorders with crisis, unspecified	Diagnosis	ICD-10-CM
D58.0	Hereditary spherocytosis	Diagnosis	ICD-10-CM
D58.1	Hereditary elliptocytosis	Diagnosis	ICD-10-CM
D58.2	Other hemoglobinopathies	Diagnosis	ICD-10-CM
D58.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-10-CM
D58.9	Hereditary hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.0	Drug-induced autoimmune hemolytic anemia	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
D59.1	Other autoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.10	Autoimmune hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.11	Warm autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.12	Cold autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.13	Mixed type autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.19	Other autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.2	Drug-induced nonautoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.4	Other nonautoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.5	Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]	Diagnosis	ICD-10-CM
D59.6	Hemoglobinuria due to hemolysis from other external causes	Diagnosis	ICD-10-CM
D59.8	Other acquired hemolytic anemias	Diagnosis	ICD-10-CM
D59.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D60.0	Chronic acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.1	Transient acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.8	Other acquired pure red cell aplasias	Diagnosis	ICD-10-CM
D60.9	Acquired pure red cell aplasia, unspecified	Diagnosis	ICD-10-CM
D61.01	Constitutional (pure) red blood cell aplasia	Diagnosis	ICD-10-CM
D61.09	Other constitutional aplastic anemia	Diagnosis	ICD-10-CM
D61.1	Drug-induced aplastic anemia	Diagnosis	ICD-10-CM
D61.2	Aplastic anemia due to other external agents	Diagnosis	ICD-10-CM
D61.3	Idiopathic aplastic anemia	Diagnosis	ICD-10-CM
D61.810	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-10-CM
D61.811	Other drug-induced pancytopenia	Diagnosis	ICD-10-CM
D61.818	Other pancytopenia	Diagnosis	ICD-10-CM
D61.82	Myelophthisis	Diagnosis	ICD-10-CM
D61.89	Other specified aplastic anemias and other bone marrow failure syndromes	Diagnosis	ICD-10-CM
D61.9	Aplastic anemia, unspecified	Diagnosis	ICD-10-CM
D62	Acute posthemorrhagic anemia	Diagnosis	ICD-10-CM
D63.0	Anemia in neoplastic disease	Diagnosis	ICD-10-CM
D63.1	Anemia in chronic kidney disease	Diagnosis	ICD-10-CM
D63.8	Anemia in other chronic diseases classified elsewhere	Diagnosis	ICD-10-CM
D64.0	Hereditary sideroblastic anemia	Diagnosis	ICD-10-CM
D64.1	Secondary sideroblastic anemia due to disease	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
D64.2	Secondary sideroblastic anemia due to drugs and toxins	Diagnosis	ICD-10-CM
D64.3	Other sideroblastic anemias	Diagnosis	ICD-10-CM
D64.4	Congenital dyserythropoietic anemia	Diagnosis	ICD-10-CM
D64.81	Anemia due to antineoplastic chemotherapy	Diagnosis	ICD-10-CM
D64.89	Other specified anemias	Diagnosis	ICD-10-CM
D64.9	Anemia, unspecified	Diagnosis	ICD-10-CM
D75.81	Myelofibrosis	Diagnosis	ICD-10-CM
Asthma			
J45.20	Mild intermittent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.21	Mild intermittent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.22	Mild intermittent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.30	Mild persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.31	Mild persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.32	Mild persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.40	Moderate persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.41	Moderate persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.42	Moderate persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.50	Severe persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.51	Severe persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.52	Severe persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.901	Unspecified asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.902	Unspecified asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.909	Unspecified asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.990	Exercise induced bronchospasm	Diagnosis	ICD-10-CM
J45.991	Cough variant asthma	Diagnosis	ICD-10-CM
J45.998	Other asthma	Diagnosis	ICD-10-CM
J82.83	Eosinophilic asthma	Diagnosis	ICD-10-CM
Benign Prostatic Hyperplasia			
N40.0	Benign prostatic hyperplasia without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.1	Benign prostatic hyperplasia with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.2	Nodular prostate without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.3	Nodular prostate with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N42.83	Cyst of prostate	Diagnosis	ICD-10-CM
Chronic Kidney Disease			

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
A18.11	Tuberculosis of kidney and ureter	Diagnosis	ICD-10-CM
A52.75	Syphilis of kidney and ureter	Diagnosis	ICD-10-CM
B52.0	Plasmodium malariae malaria with nephropathy	Diagnosis	ICD-10-CM
C64.1	Malignant neoplasm of right kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.2	Malignant neoplasm of left kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis	Diagnosis	ICD-10-CM
C68.9	Malignant neoplasm of urinary organ, unspecified	Diagnosis	ICD-10-CM
D30.00	Benign neoplasm of unspecified kidney	Diagnosis	ICD-10-CM
D30.01	Benign neoplasm of right kidney	Diagnosis	ICD-10-CM
D30.02	Benign neoplasm of left kidney	Diagnosis	ICD-10-CM
D41.00	Neoplasm of uncertain behavior of unspecified kidney	Diagnosis	ICD-10-CM
D41.01	Neoplasm of uncertain behavior of right kidney	Diagnosis	ICD-10-CM
D41.02	Neoplasm of uncertain behavior of left kidney	Diagnosis	ICD-10-CM
D41.10	Neoplasm of uncertain behavior of unspecified renal pelvis	Diagnosis	ICD-10-CM
D41.11	Neoplasm of uncertain behavior of right renal pelvis	Diagnosis	ICD-10-CM
D41.12	Neoplasm of uncertain behavior of left renal pelvis	Diagnosis	ICD-10-CM
D41.20	Neoplasm of uncertain behavior of unspecified ureter	Diagnosis	ICD-10-CM
D41.21	Neoplasm of uncertain behavior of right ureter	Diagnosis	ICD-10-CM
D41.22	Neoplasm of uncertain behavior of left ureter	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E74.8	Other specified disorders of carbohydrate metabolism	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I70.1	Atherosclerosis of renal artery	Diagnosis	ICD-10-CM
I72.2	Aneurysm of renal artery	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
M10.30	Gout due to renal impairment, unspecified site	Diagnosis	ICD-10-CM
M10.311	Gout due to renal impairment, right shoulder	Diagnosis	ICD-10-CM
M10.312	Gout due to renal impairment, left shoulder	Diagnosis	ICD-10-CM
M10.319	Gout due to renal impairment, unspecified shoulder	Diagnosis	ICD-10-CM
M10.321	Gout due to renal impairment, right elbow	Diagnosis	ICD-10-CM
M10.322	Gout due to renal impairment, left elbow	Diagnosis	ICD-10-CM
M10.329	Gout due to renal impairment, unspecified elbow	Diagnosis	ICD-10-CM
M10.331	Gout due to renal impairment, right wrist	Diagnosis	ICD-10-CM
M10.332	Gout due to renal impairment, left wrist	Diagnosis	ICD-10-CM
M10.339	Gout due to renal impairment, unspecified wrist	Diagnosis	ICD-10-CM
M10.341	Gout due to renal impairment, right hand	Diagnosis	ICD-10-CM
M10.342	Gout due to renal impairment, left hand	Diagnosis	ICD-10-CM
M10.349	Gout due to renal impairment, unspecified hand	Diagnosis	ICD-10-CM
M10.351	Gout due to renal impairment, right hip	Diagnosis	ICD-10-CM
M10.352	Gout due to renal impairment, left hip	Diagnosis	ICD-10-CM
M10.359	Gout due to renal impairment, unspecified hip	Diagnosis	ICD-10-CM
M10.361	Gout due to renal impairment, right knee	Diagnosis	ICD-10-CM
M10.362	Gout due to renal impairment, left knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M10.369	Gout due to renal impairment, unspecified knee	Diagnosis	ICD-10-CM
M10.371	Gout due to renal impairment, right ankle and foot	Diagnosis	ICD-10-CM
M10.372	Gout due to renal impairment, left ankle and foot	Diagnosis	ICD-10-CM
M10.379	Gout due to renal impairment, unspecified ankle and foot	Diagnosis	ICD-10-CM
M10.38	Gout due to renal impairment, vertebrae	Diagnosis	ICD-10-CM
M10.39	Gout due to renal impairment, multiple sites	Diagnosis	ICD-10-CM
M32.14	Glomerular disease in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M35.04	Sicca syndrome with tubulo-interstitial nephropathy	Diagnosis	ICD-10-CM
M35.0A	Sjogren syndrome with glomerular disease	Diagnosis	ICD-10-CM
N00.0	Acute nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N00.1	Acute nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N00.2	Acute nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N00.3	Acute nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.4	Acute nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N00.5	Acute nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N00.6	Acute nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N00.7	Acute nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N00.8	Acute nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N00.9	Acute nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N00.A	Acute nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N01.0	Rapidly progressive nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N01.1	Rapidly progressive nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N01.2	Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N01.3	Rapidly progressive nephritic syndrome with diffuse mesangial proliferative	Diagnosis	ICD-10-CM
N01.4	Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative	Diagnosis	ICD-10-CM
N01.5	Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N01.6	Rapidly progressive nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N01.7	Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N01.8	Rapidly progressive nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N01.9	Rapidly progressive nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N01.A	Rapidly progressive nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N02.0	Recurrent and persistent hematuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N02.1	Recurrent and persistent hematuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
N02.2	Recurrent and persistent hematuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N02.3	Recurrent and persistent hematuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.4	Recurrent and persistent hematuria with diffuse endocapillary proliferative	Diagnosis	ICD-10-CM
N02.5	Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.6	Recurrent and persistent hematuria with dense deposit disease	Diagnosis	ICD-10-CM
N02.7	Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N02.8	Recurrent and persistent hematuria with other morphologic changes	Diagnosis	ICD-10-CM
N02.9	Recurrent and persistent hematuria with unspecified morphologic changes	Diagnosis	ICD-10-CM
N02.A	Recurrent and persistent hematuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N03.0	Chronic nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N03.1	Chronic nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N03.2	Chronic nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N03.3	Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.4	Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.5	Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N03.6	Chronic nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N03.7	Chronic nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N03.8	Chronic nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N03.9	Chronic nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N03.A	Chronic nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N04.0	Nephrotic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N04.2	Nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.3	Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.4	Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.5	Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N04.6	Nephrotic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N04.7	Nephrotic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N04.8	Nephrotic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N04.9	Nephrotic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N04.A	Nephrotic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N05.0	Unspecified nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N05.1	Unspecified nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N05.2	Unspecified nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
N05.3	Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.4	Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.5	Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N05.6	Unspecified nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N05.7	Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N05.8	Unspecified nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N05.9	Unspecified nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N05.A	Unspecified nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N06.0	Isolated proteinuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N06.1	Isolated proteinuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N06.2	Isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.3	Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.4	Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.5	Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N06.6	Isolated proteinuria with dense deposit disease	Diagnosis	ICD-10-CM
N06.7	Isolated proteinuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N06.8	Isolated proteinuria with other morphologic lesion	Diagnosis	ICD-10-CM
N06.9	Isolated proteinuria with unspecified morphologic lesion	Diagnosis	ICD-10-CM
N06.A	Isolated proteinuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N07.0	Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality	Diagnosis	ICD-10-CM
N07.1	Hereditary nephropathy, not elsewhere classified with focal and segmental glomerular	Diagnosis	ICD-10-CM
N07.2	Hereditary nephropathy, not elsewhere classified with diffuse membranous	Diagnosis	ICD-10-CM
N07.3	Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.4	Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.5	Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N07.6	Hereditary nephropathy, not elsewhere classified with dense deposit disease	Diagnosis	ICD-10-CM
N07.7	Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N07.8	Hereditary nephropathy, not elsewhere classified with other morphologic lesions	Diagnosis	ICD-10-CM
N07.9	Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions	Diagnosis	ICD-10-CM
N07.A	Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N08	Glomerular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
N13.1	Hydronephrosis with ureteral stricture, not elsewhere classified	Diagnosis	ICD-10-CM
N13.2	Hydronephrosis with renal and ureteral calculous obstruction	Diagnosis	ICD-10-CM
N13.30	Unspecified hydronephrosis	Diagnosis	ICD-10-CM
N13.39	Other hydronephrosis	Diagnosis	ICD-10-CM
N14.0	Analgesic nephropathy	Diagnosis	ICD-10-CM
N14.1	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.2	Nephropathy induced by unspecified drug, medicament or biological substance	Diagnosis	ICD-10-CM
N14.3	Nephropathy induced by heavy metals	Diagnosis	ICD-10-CM
N14.4	Toxic nephropathy, not elsewhere classified	Diagnosis	ICD-10-CM
N15.0	Balkan nephropathy	Diagnosis	ICD-10-CM
N15.8	Other specified renal tubulo-interstitial diseases	Diagnosis	ICD-10-CM
N15.9	Renal tubulo-interstitial disease, unspecified	Diagnosis	ICD-10-CM
N16	Renal tubulo-interstitial disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N17.0	Acute kidney failure with tubular necrosis	Diagnosis	ICD-10-CM
N17.1	Acute kidney failure with acute cortical necrosis	Diagnosis	ICD-10-CM
N17.2	Acute kidney failure with medullary necrosis	Diagnosis	ICD-10-CM
N17.8	Other acute kidney failure	Diagnosis	ICD-10-CM
N17.9	Acute kidney failure, unspecified	Diagnosis	ICD-10-CM
N18.1	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM
N18.2	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM
N18.3	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM
N18.30	Chronic kidney disease, stage 3 unspecified	Diagnosis	ICD-10-CM
N18.31	Chronic kidney disease, stage 3a	Diagnosis	ICD-10-CM
N18.32	Chronic kidney disease, stage 3b	Diagnosis	ICD-10-CM
N18.4	Chronic kidney disease, stage 4 (severe)	Diagnosis	ICD-10-CM
N18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM
N18.6	End stage renal disease	Diagnosis	ICD-10-CM
N18.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM
N19	Unspecified kidney failure	Diagnosis	ICD-10-CM
N25.0	Renal osteodystrophy	Diagnosis	ICD-10-CM
N25.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-10-CM
N25.81	Secondary hyperparathyroidism of renal origin	Diagnosis	ICD-10-CM
N25.89	Other disorders resulting from impaired renal tubular function	Diagnosis	ICD-10-CM
N25.9	Disorder resulting from impaired renal tubular function, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
N26.1	Atrophy of kidney (terminal)	Diagnosis	ICD-10-CM
N26.9	Renal sclerosis, unspecified	Diagnosis	ICD-10-CM
N99.0	Postprocedural (acute) (chronic) kidney failure	Diagnosis	ICD-10-CM
Q61.02	Congenital multiple renal cysts	Diagnosis	ICD-10-CM
Q61.11	Cystic dilatation of collecting ducts	Diagnosis	ICD-10-CM
Q61.19	Other polycystic kidney, infantile type	Diagnosis	ICD-10-CM
Q61.2	Polycystic kidney, adult type	Diagnosis	ICD-10-CM
Q61.3	Polycystic kidney, unspecified	Diagnosis	ICD-10-CM
Q61.4	Renal dysplasia	Diagnosis	ICD-10-CM
Q61.5	Medullary cystic kidney	Diagnosis	ICD-10-CM
Q61.8	Other cystic kidney diseases	Diagnosis	ICD-10-CM
Q62.0	Congenital hydronephrosis	Diagnosis	ICD-10-CM
Q62.10	Congenital occlusion of ureter, unspecified	Diagnosis	ICD-10-CM
Q62.11	Congenital occlusion of ureteropelvic junction	Diagnosis	ICD-10-CM
Q62.12	Congenital occlusion of ureterovesical orifice	Diagnosis	ICD-10-CM
Q62.2	Congenital megaureter	Diagnosis	ICD-10-CM
Q62.31	Congenital ureterocele, orthotopic	Diagnosis	ICD-10-CM
Q62.32	Cecoureterocele	Diagnosis	ICD-10-CM
Q62.39	Other obstructive defects of renal pelvis and ureter	Diagnosis	ICD-10-CM
R94.4	Abnormal results of kidney function studies	Diagnosis	ICD-10-CM
COPD and Bronchiectasis			
J40	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-10-CM
J41.0	Simple chronic bronchitis	Diagnosis	ICD-10-CM
J41.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J41.8	Mixed simple and mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J42	Unspecified chronic bronchitis	Diagnosis	ICD-10-CM
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	Diagnosis	ICD-10-CM
J43.1	Panlobular emphysema	Diagnosis	ICD-10-CM
J43.2	Centrilobular emphysema	Diagnosis	ICD-10-CM
J43.8	Other emphysema	Diagnosis	ICD-10-CM
J43.9	Emphysema, unspecified	Diagnosis	ICD-10-CM
J44.0	Chronic obstructive pulmonary disease with acute lower respiratory infection	Diagnosis	ICD-10-CM
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis	ICD-10-CM
J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
J47.0	Bronchiectasis with acute lower respiratory infection	Diagnosis	ICD-10-CM
J47.1	Bronchiectasis with (acute) exacerbation	Diagnosis	ICD-10-CM
J47.9	Bronchiectasis, uncomplicated	Diagnosis	ICD-10-CM
J98.2	Interstitial emphysema	Diagnosis	ICD-10-CM
J98.3	Compensatory emphysema	Diagnosis	ICD-10-CM
Glaucoma			
H40.001	Preglaucoma, unspecified, right eye	Diagnosis	ICD-10-CM
H40.002	Preglaucoma, unspecified, left eye	Diagnosis	ICD-10-CM
H40.003	Preglaucoma, unspecified, bilateral	Diagnosis	ICD-10-CM
H40.009	Preglaucoma, unspecified, unspecified eye	Diagnosis	ICD-10-CM
H40.011	Open angle with borderline findings, low risk, right eye	Diagnosis	ICD-10-CM
H40.012	Open angle with borderline findings, low risk, left eye	Diagnosis	ICD-10-CM
H40.013	Open angle with borderline findings, low risk, bilateral	Diagnosis	ICD-10-CM
H40.019	Open angle with borderline findings, low risk, unspecified eye	Diagnosis	ICD-10-CM
H40.021	Open angle with borderline findings, high risk, right eye	Diagnosis	ICD-10-CM
H40.022	Open angle with borderline findings, high risk, left eye	Diagnosis	ICD-10-CM
H40.023	Open angle with borderline findings, high risk, bilateral	Diagnosis	ICD-10-CM
H40.029	Open angle with borderline findings, high risk, unspecified eye	Diagnosis	ICD-10-CM
H40.031	Anatomical narrow angle, right eye	Diagnosis	ICD-10-CM
H40.032	Anatomical narrow angle, left eye	Diagnosis	ICD-10-CM
H40.033	Anatomical narrow angle, bilateral	Diagnosis	ICD-10-CM
H40.039	Anatomical narrow angle, unspecified eye	Diagnosis	ICD-10-CM
H40.041	Steroid responder, right eye	Diagnosis	ICD-10-CM
H40.042	Steroid responder, left eye	Diagnosis	ICD-10-CM
H40.043	Steroid responder, bilateral	Diagnosis	ICD-10-CM
H40.049	Steroid responder, unspecified eye	Diagnosis	ICD-10-CM
H40.051	Ocular hypertension, right eye	Diagnosis	ICD-10-CM
H40.052	Ocular hypertension, left eye	Diagnosis	ICD-10-CM
H40.053	Ocular hypertension, bilateral	Diagnosis	ICD-10-CM
H40.059	Ocular hypertension, unspecified eye	Diagnosis	ICD-10-CM
H40.10X0	Unspecified open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.10X1	Unspecified open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.10X2	Unspecified open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.10X3	Unspecified open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
H40.10X4	Unspecified open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1110	Primary open-angle glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1111	Primary open-angle glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1112	Primary open-angle glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1113	Primary open-angle glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1114	Primary open-angle glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1120	Primary open-angle glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1121	Primary open-angle glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1122	Primary open-angle glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1123	Primary open-angle glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1124	Primary open-angle glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1130	Primary open-angle glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1131	Primary open-angle glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1132	Primary open-angle glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1133	Primary open-angle glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1134	Primary open-angle glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1190	Primary open-angle glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1191	Primary open-angle glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1192	Primary open-angle glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1193	Primary open-angle glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1194	Primary open-angle glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.11X0	Primary open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.11X1	Primary open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.11X2	Primary open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.11X3	Primary open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.11X4	Primary open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1210	Low-tension glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1211	Low-tension glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1212	Low-tension glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1213	Low-tension glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1214	Low-tension glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1220	Low-tension glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1221	Low-tension glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1222	Low-tension glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
H40.1223	Low-tension glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1224	Low-tension glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1230	Low-tension glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1231	Low-tension glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1232	Low-tension glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1233	Low-tension glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1234	Low-tension glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1290	Low-tension glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1291	Low-tension glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1292	Low-tension glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1293	Low-tension glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1294	Low-tension glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1310	Pigmentary glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1311	Pigmentary glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1312	Pigmentary glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1313	Pigmentary glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1314	Pigmentary glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1320	Pigmentary glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1321	Pigmentary glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1322	Pigmentary glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1323	Pigmentary glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1324	Pigmentary glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1330	Pigmentary glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1331	Pigmentary glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1332	Pigmentary glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1333	Pigmentary glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1334	Pigmentary glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1390	Pigmentary glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1391	Pigmentary glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1392	Pigmentary glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1393	Pigmentary glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1394	Pigmentary glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1410	Capsular glaucoma with pseudoexfoliation of lens, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1411	Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
H40.1412	Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1413	Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1414	Capsular glaucoma with pseudoexfoliation of lens, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1420	Capsular glaucoma with pseudoexfoliation of lens, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1421	Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1422	Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1423	Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1424	Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1430	Capsular glaucoma with pseudoexfoliation of lens, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1431	Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1432	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1433	Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1434	Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1490	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1491	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1492	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1493	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1494	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.151	Residual stage of open-angle glaucoma, right eye	Diagnosis	ICD-10-CM
H40.152	Residual stage of open-angle glaucoma, left eye	Diagnosis	ICD-10-CM
H40.153	Residual stage of open-angle glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.159	Residual stage of open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.20X0	Unspecified primary angle-closure glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.20X1	Unspecified primary angle-closure glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.20X2	Unspecified primary angle-closure glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.20X3	Unspecified primary angle-closure glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.20X4	Unspecified primary angle-closure glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.211	Acute angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.212	Acute angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.213	Acute angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.219	Acute angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.2210	Chronic angle-closure glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2211	Chronic angle-closure glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.2212	Chronic angle-closure glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
H40.2213	Chronic angle-closure glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.2214	Chronic angle-closure glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2220	Chronic angle-closure glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2221	Chronic angle-closure glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.2222	Chronic angle-closure glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.2223	Chronic angle-closure glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.2224	Chronic angle-closure glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2230	Chronic angle-closure glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.2231	Chronic angle-closure glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.2232	Chronic angle-closure glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.2233	Chronic angle-closure glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.2234	Chronic angle-closure glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.2290	Chronic angle-closure glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2291	Chronic angle-closure glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.2292	Chronic angle-closure glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.2293	Chronic angle-closure glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.2294	Chronic angle-closure glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.231	Intermittent angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.232	Intermittent angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.233	Intermittent angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.239	Intermittent angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.241	Residual stage of angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.242	Residual stage of angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.243	Residual stage of angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.249	Residual stage of angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.30X0	Glaucoma secondary to eye trauma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.30X1	Glaucoma secondary to eye trauma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.30X2	Glaucoma secondary to eye trauma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.30X3	Glaucoma secondary to eye trauma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.30X4	Glaucoma secondary to eye trauma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.31X0	Glaucoma secondary to eye trauma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.31X1	Glaucoma secondary to eye trauma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.31X2	Glaucoma secondary to eye trauma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.31X3	Glaucoma secondary to eye trauma, right eye, severe stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
H40.31X4	Glaucoma secondary to eye trauma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.32X0	Glaucoma secondary to eye trauma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.32X1	Glaucoma secondary to eye trauma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.32X2	Glaucoma secondary to eye trauma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.32X3	Glaucoma secondary to eye trauma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.32X4	Glaucoma secondary to eye trauma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.33X0	Glaucoma secondary to eye trauma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.33X1	Glaucoma secondary to eye trauma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.33X2	Glaucoma secondary to eye trauma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.33X3	Glaucoma secondary to eye trauma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.33X4	Glaucoma secondary to eye trauma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.40X0	Glaucoma secondary to eye inflammation, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.40X1	Glaucoma secondary to eye inflammation, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.40X2	Glaucoma secondary to eye inflammation, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.40X3	Glaucoma secondary to eye inflammation, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.40X4	Glaucoma secondary to eye inflammation, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.41X0	Glaucoma secondary to eye inflammation, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.41X1	Glaucoma secondary to eye inflammation, right eye, mild stage	Diagnosis	ICD-10-CM
H40.41X2	Glaucoma secondary to eye inflammation, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.41X3	Glaucoma secondary to eye inflammation, right eye, severe stage	Diagnosis	ICD-10-CM
H40.41X4	Glaucoma secondary to eye inflammation, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.42X0	Glaucoma secondary to eye inflammation, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.42X1	Glaucoma secondary to eye inflammation, left eye, mild stage	Diagnosis	ICD-10-CM
H40.42X2	Glaucoma secondary to eye inflammation, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.42X3	Glaucoma secondary to eye inflammation, left eye, severe stage	Diagnosis	ICD-10-CM
H40.42X4	Glaucoma secondary to eye inflammation, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.43X0	Glaucoma secondary to eye inflammation, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.43X1	Glaucoma secondary to eye inflammation, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.43X2	Glaucoma secondary to eye inflammation, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.43X3	Glaucoma secondary to eye inflammation, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.43X4	Glaucoma secondary to eye inflammation, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.50X0	Glaucoma secondary to other eye disorders, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.50X1	Glaucoma secondary to other eye disorders, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.50X2	Glaucoma secondary to other eye disorders, unspecified eye, moderate stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
H40.50X3	Glaucoma secondary to other eye disorders, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.50X4	Glaucoma secondary to other eye disorders, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.51X0	Glaucoma secondary to other eye disorders, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.51X1	Glaucoma secondary to other eye disorders, right eye, mild stage	Diagnosis	ICD-10-CM
H40.51X2	Glaucoma secondary to other eye disorders, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.51X3	Glaucoma secondary to other eye disorders, right eye, severe stage	Diagnosis	ICD-10-CM
H40.51X4	Glaucoma secondary to other eye disorders, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.52X0	Glaucoma secondary to other eye disorders, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.52X1	Glaucoma secondary to other eye disorders, left eye, mild stage	Diagnosis	ICD-10-CM
H40.52X2	Glaucoma secondary to other eye disorders, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.52X3	Glaucoma secondary to other eye disorders, left eye, severe stage	Diagnosis	ICD-10-CM
H40.52X4	Glaucoma secondary to other eye disorders, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.53X0	Glaucoma secondary to other eye disorders, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.53X1	Glaucoma secondary to other eye disorders, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.53X2	Glaucoma secondary to other eye disorders, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.53X3	Glaucoma secondary to other eye disorders, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.53X4	Glaucoma secondary to other eye disorders, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.60X0	Glaucoma secondary to drugs, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.60X1	Glaucoma secondary to drugs, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.60X2	Glaucoma secondary to drugs, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.60X3	Glaucoma secondary to drugs, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.60X4	Glaucoma secondary to drugs, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.61X0	Glaucoma secondary to drugs, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.61X1	Glaucoma secondary to drugs, right eye, mild stage	Diagnosis	ICD-10-CM
H40.61X2	Glaucoma secondary to drugs, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.61X3	Glaucoma secondary to drugs, right eye, severe stage	Diagnosis	ICD-10-CM
H40.61X4	Glaucoma secondary to drugs, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.62X0	Glaucoma secondary to drugs, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.62X1	Glaucoma secondary to drugs, left eye, mild stage	Diagnosis	ICD-10-CM
H40.62X2	Glaucoma secondary to drugs, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.62X3	Glaucoma secondary to drugs, left eye, severe stage	Diagnosis	ICD-10-CM
H40.62X4	Glaucoma secondary to drugs, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.63X0	Glaucoma secondary to drugs, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.63X1	Glaucoma secondary to drugs, bilateral, mild stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
H40.63X2	Glaucoma secondary to drugs, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.63X3	Glaucoma secondary to drugs, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.63X4	Glaucoma secondary to drugs, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.811	Glaucoma with increased episcleral venous pressure, right eye	Diagnosis	ICD-10-CM
H40.812	Glaucoma with increased episcleral venous pressure, left eye	Diagnosis	ICD-10-CM
H40.813	Glaucoma with increased episcleral venous pressure, bilateral	Diagnosis	ICD-10-CM
H40.819	Glaucoma with increased episcleral venous pressure, unspecified eye	Diagnosis	ICD-10-CM
H40.821	Hypersecretion glaucoma, right eye	Diagnosis	ICD-10-CM
H40.822	Hypersecretion glaucoma, left eye	Diagnosis	ICD-10-CM
H40.823	Hypersecretion glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.829	Hypersecretion glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.831	Aqueous misdirection, right eye	Diagnosis	ICD-10-CM
H40.832	Aqueous misdirection, left eye	Diagnosis	ICD-10-CM
H40.833	Aqueous misdirection, bilateral	Diagnosis	ICD-10-CM
H40.839	Aqueous misdirection, unspecified eye	Diagnosis	ICD-10-CM
H40.89	Other specified glaucoma	Diagnosis	ICD-10-CM
H40.9	Unspecified glaucoma	Diagnosis	ICD-10-CM
H42	Glaucoma in diseases classified elsewhere	Diagnosis	ICD-10-CM
H44.511	Absolute glaucoma, right eye	Diagnosis	ICD-10-CM
H44.512	Absolute glaucoma, left eye	Diagnosis	ICD-10-CM
H44.513	Absolute glaucoma, bilateral	Diagnosis	ICD-10-CM
H44.519	Absolute glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H47.231	Glaucomatous optic atrophy, right eye	Diagnosis	ICD-10-CM
H47.232	Glaucomatous optic atrophy, left eye	Diagnosis	ICD-10-CM
H47.233	Glaucomatous optic atrophy, bilateral	Diagnosis	ICD-10-CM
H47.239	Glaucomatous optic atrophy, unspecified eye	Diagnosis	ICD-10-CM
Q15.0	Congenital glaucoma	Diagnosis	ICD-10-CM
Osteoporosis			
M80.00XA	Age-related osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.011A	Age-related osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.012A	Age-related osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M80.019A	Age-related osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.021A	Age-related osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.022A	Age-related osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.029A	Age-related osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.031A	Age-related osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.032A	Age-related osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.039A	Age-related osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.041A	Age-related osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.042A	Age-related osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.049A	Age-related osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.051A	Age-related osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.052A	Age-related osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.059A	Age-related osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.061A	Age-related osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.062A	Age-related osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.069A	Age-related osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.071A	Age-related osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M80.072A	Age-related osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.079A	Age-related osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.08XA	Age-related osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0AXA	Age-related osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.80XA	Other osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.811A	Other osteoporosis with current pathological fracture, right shoulder, initial encounter for	Diagnosis	ICD-10-CM
M80.812A	Other osteoporosis with current pathological fracture, left shoulder, initial encounter for	Diagnosis	ICD-10-CM
M80.819A	Other osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.821A	Other osteoporosis with current pathological fracture, right humerus, initial encounter for	Diagnosis	ICD-10-CM
M80.822A	Other osteoporosis with current pathological fracture, left humerus, initial encounter for	Diagnosis	ICD-10-CM
M80.829A	Other osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.831A	Other osteoporosis with current pathological fracture, right forearm, initial encounter for	Diagnosis	ICD-10-CM
M80.832A	Other osteoporosis with current pathological fracture, left forearm, initial encounter for	Diagnosis	ICD-10-CM
M80.839A	Other osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.841A	Other osteoporosis with current pathological fracture, right hand, initial encounter for	Diagnosis	ICD-10-CM
M80.842A	Other osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.849A	Other osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.851A	Other osteoporosis with current pathological fracture, right femur, initial encounter for	Diagnosis	ICD-10-CM
M80.852A	Other osteoporosis with current pathological fracture, left femur, initial encounter for	Diagnosis	ICD-10-CM
M80.859A	Other osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.861A	Other osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.862A	Other osteoporosis with current pathological fracture, left lower leg, initial encounter for	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
M80.869A	Other osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.871A	Other osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.872A	Other osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.879A	Other osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.88XA	Other osteoporosis with current pathological fracture, vertebra(e), initial encounter for	Diagnosis	ICD-10-CM
M80.8AXA	Other osteoporosis with current pathological fracture, other site, initial encounter for	Diagnosis	ICD-10-CM
M81.0	Age-related osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
M81.6	Localized osteoporosis [Lequesne]	Diagnosis	ICD-10-CM
M81.8	Other osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
Drug Abuse or Dependence			
F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM
F11.11	Opioid abuse, in remission	Diagnosis	ICD-10-CM
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.13	Opioid abuse with withdrawal	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM
F11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F12.10	Cannabis abuse, uncomplicated	Diagnosis	ICD-10-CM
F12.11	Cannabis abuse, in remission	Diagnosis	ICD-10-CM
F12.120	Cannabis abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.121	Cannabis abuse with intoxication delirium	Diagnosis	ICD-10-CM
F12.122	Cannabis abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.129	Cannabis abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.13	Cannabis abuse with withdrawal	Diagnosis	ICD-10-CM
F12.150	Cannabis abuse with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.151	Cannabis abuse with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.159	Cannabis abuse with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.180	Cannabis abuse with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F12.188	Cannabis abuse with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.19	Cannabis abuse with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.20	Cannabis dependence, uncomplicated	Diagnosis	ICD-10-CM
F12.220	Cannabis dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.221	Cannabis dependence with intoxication delirium	Diagnosis	ICD-10-CM
F12.222	Cannabis dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.229	Cannabis dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.250	Cannabis dependence with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.251	Cannabis dependence with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.259	Cannabis dependence with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.280	Cannabis dependence with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.288	Cannabis dependence with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.29	Cannabis dependence with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.90	Cannabis use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F12.920	Cannabis use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.921	Cannabis use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F12.922	Cannabis use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.929	Cannabis use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.950	Cannabis use, unspecified with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.951	Cannabis use, unspecified with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.959	Cannabis use, unspecified with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.980	Cannabis use, unspecified with anxiety disorder	Diagnosis	ICD-10-CM
F12.988	Cannabis use, unspecified with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.99	Cannabis use, unspecified with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F13.10	Sedative, hypnotic or anxiolytic abuse, uncomplicated	Diagnosis	ICD-10-CM
F13.11	Sedative, hypnotic or anxiolytic abuse, in remission	Diagnosis	ICD-10-CM
F13.120	Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.121	Sedative, hypnotic or anxiolytic abuse with intoxication delirium	Diagnosis	ICD-10-CM
F13.129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.130	Sedative, hypnotic or anxiolytic abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.131	Sedative, hypnotic or anxiolytic abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F13.132	Sedative, hypnotic or anxiolytic abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.139	Sedative, hypnotic or anxiolytic abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.14	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F13.150	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.151	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.159	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.180	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.181	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.182	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep	Diagnosis	ICD-10-CM
F13.188	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced	Diagnosis	ICD-10-CM
F13.19	Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.20	Sedative, hypnotic or anxiolytic dependence, uncomplicated	Diagnosis	ICD-10-CM
F13.220	Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium	Diagnosis	ICD-10-CM
F13.229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.230	Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.231	Sedative, hypnotic or anxiolytic dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F13.232	Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.239	Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.24	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.250	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.251	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.259	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.26	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F13.27	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F13.280	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.281	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.282	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.288	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.29	Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.90	Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F13.920	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.921	Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F13.929	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.930	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.931	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F13.932	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual	Diagnosis	ICD-10-CM
F13.939	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.94	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.950	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.951	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.959	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.96	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F13.97	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.980	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.981	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F13.982	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.988	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.99	Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F14.10	Cocaine abuse, uncomplicated	Diagnosis	ICD-10-CM
F14.11	Cocaine abuse, in remission	Diagnosis	ICD-10-CM
F14.120	Cocaine abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.121	Cocaine abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F14.122	Cocaine abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.129	Cocaine abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.13	Cocaine abuse, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.14	Cocaine abuse with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.150	Cocaine abuse with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.151	Cocaine abuse with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.159	Cocaine abuse with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.180	Cocaine abuse with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.181	Cocaine abuse with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.182	Cocaine abuse with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.188	Cocaine abuse with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.19	Cocaine abuse with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.20	Cocaine dependence, uncomplicated	Diagnosis	ICD-10-CM
F14.220	Cocaine dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.221	Cocaine dependence with intoxication delirium	Diagnosis	ICD-10-CM
F14.222	Cocaine dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.229	Cocaine dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.23	Cocaine dependence with withdrawal	Diagnosis	ICD-10-CM
F14.24	Cocaine dependence with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.250	Cocaine dependence with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.251	Cocaine dependence with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.259	Cocaine dependence with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.280	Cocaine dependence with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.281	Cocaine dependence with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F14.282	Cocaine dependence with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.288	Cocaine dependence with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.29	Cocaine dependence with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.90	Cocaine use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F14.920	Cocaine use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.921	Cocaine use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F14.922	Cocaine use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.929	Cocaine use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.93	Cocaine use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.94	Cocaine use, unspecified with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.950	Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.951	Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.959	Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.980	Cocaine use, unspecified with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.981	Cocaine use, unspecified with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.982	Cocaine use, unspecified with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.988	Cocaine use, unspecified with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.99	Cocaine use, unspecified with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F15.10	Other stimulant abuse, uncomplicated	Diagnosis	ICD-10-CM
F15.11	Other stimulant abuse, in remission	Diagnosis	ICD-10-CM
F15.120	Other stimulant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.121	Other stimulant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F15.122	Other stimulant abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.129	Other stimulant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.13	Other stimulant abuse with withdrawal	Diagnosis	ICD-10-CM
F15.14	Other stimulant abuse with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.150	Other stimulant abuse with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.151	Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.159	Other stimulant abuse with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.180	Other stimulant abuse with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.181	Other stimulant abuse with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.182	Other stimulant abuse with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.188	Other stimulant abuse with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.19	Other stimulant abuse with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F15.20	Other stimulant dependence, uncomplicated	Diagnosis	ICD-10-CM
F15.220	Other stimulant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.221	Other stimulant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F15.222	Other stimulant dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.229	Other stimulant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.23	Other stimulant dependence with withdrawal	Diagnosis	ICD-10-CM
F15.24	Other stimulant dependence with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.250	Other stimulant dependence with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.251	Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.259	Other stimulant dependence with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.280	Other stimulant dependence with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.281	Other stimulant dependence with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.282	Other stimulant dependence with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.288	Other stimulant dependence with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.29	Other stimulant dependence with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.90	Other stimulant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F15.920	Other stimulant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.921	Other stimulant use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F15.922	Other stimulant use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.929	Other stimulant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.93	Other stimulant use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F15.94	Other stimulant use, unspecified with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.950	Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.951	Other stimulant use, unspecified with stimulant-induced psychotic disorder with	Diagnosis	ICD-10-CM
F15.959	Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.980	Other stimulant use, unspecified with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.981	Other stimulant use, unspecified with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.982	Other stimulant use, unspecified with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.988	Other stimulant use, unspecified with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.99	Other stimulant use, unspecified with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F16.10	Hallucinogen abuse, uncomplicated	Diagnosis	ICD-10-CM
F16.11	Hallucinogen abuse, in remission	Diagnosis	ICD-10-CM
F16.120	Hallucinogen abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.121	Hallucinogen abuse with intoxication with delirium	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F16.122	Hallucinogen abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F16.129	Hallucinogen abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.14	Hallucinogen abuse with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.150	Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.151	Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.159	Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.180	Hallucinogen abuse with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.183	Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.188	Hallucinogen abuse with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.19	Hallucinogen abuse with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.20	Hallucinogen dependence, uncomplicated	Diagnosis	ICD-10-CM
F16.220	Hallucinogen dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.221	Hallucinogen dependence with intoxication with delirium	Diagnosis	ICD-10-CM
F16.229	Hallucinogen dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.24	Hallucinogen dependence with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.250	Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.251	Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.259	Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.280	Hallucinogen dependence with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.283	Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.288	Hallucinogen dependence with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.29	Hallucinogen dependence with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.90	Hallucinogen use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F16.920	Hallucinogen use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.921	Hallucinogen use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F16.929	Hallucinogen use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.94	Hallucinogen use, unspecified with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.950	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.951	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with	Diagnosis	ICD-10-CM
F16.959	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.980	Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.983	Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.988	Hallucinogen use, unspecified with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.99	Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F18.10	Inhalant abuse, uncomplicated	Diagnosis	ICD-10-CM
F18.11	Inhalant abuse, in remission	Diagnosis	ICD-10-CM
F18.120	Inhalant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.121	Inhalant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F18.129	Inhalant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.14	Inhalant abuse with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.150	Inhalant abuse with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.151	Inhalant abuse with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.159	Inhalant abuse with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.17	Inhalant abuse with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.180	Inhalant abuse with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.188	Inhalant abuse with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.19	Inhalant abuse with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.20	Inhalant dependence, uncomplicated	Diagnosis	ICD-10-CM
F18.220	Inhalant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.221	Inhalant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F18.229	Inhalant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.24	Inhalant dependence with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.250	Inhalant dependence with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.251	Inhalant dependence with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.259	Inhalant dependence with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.27	Inhalant dependence with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.280	Inhalant dependence with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.288	Inhalant dependence with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.29	Inhalant dependence with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.90	Inhalant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F18.920	Inhalant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.921	Inhalant use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F18.929	Inhalant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.94	Inhalant use, unspecified with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.950	Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.951	Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.959	Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.97	Inhalant use, unspecified with inhalant-induced persisting dementia	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F18.980	Inhalant use, unspecified with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.988	Inhalant use, unspecified with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.99	Inhalant use, unspecified with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F19.10	Other psychoactive substance abuse, uncomplicated	Diagnosis	ICD-10-CM
F19.11	Other psychoactive substance abuse, in remission	Diagnosis	ICD-10-CM
F19.120	Other psychoactive substance abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.121	Other psychoactive substance abuse with intoxication delirium	Diagnosis	ICD-10-CM
F19.122	Other psychoactive substance abuse with intoxication with perceptual disturbances	Diagnosis	ICD-10-CM
F19.129	Other psychoactive substance abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.130	Other psychoactive substance abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.131	Other psychoactive substance abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F19.132	Other psychoactive substance abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.139	Other psychoactive substance abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.14	Other psychoactive substance abuse with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.150	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.151	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.159	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.16	Other psychoactive substance abuse with psychoactive substance-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F19.17	Other psychoactive substance abuse with psychoactive substance-induced persisting	Diagnosis	ICD-10-CM
F19.180	Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.181	Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.182	Other psychoactive substance abuse with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.188	Other psychoactive substance abuse with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.19	Other psychoactive substance abuse with unspecified psychoactive substance-induced	Diagnosis	ICD-10-CM
F19.20	Other psychoactive substance dependence, uncomplicated	Diagnosis	ICD-10-CM
F19.21	Other psychoactive substance dependence, in remission	Diagnosis	ICD-10-CM
F19.220	Other psychoactive substance dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.221	Other psychoactive substance dependence with intoxication delirium	Diagnosis	ICD-10-CM
F19.222	Other psychoactive substance dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.229	Other psychoactive substance dependence with intoxication, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F19.230	Other psychoactive substance dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.231	Other psychoactive substance dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F19.232	Other psychoactive substance dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.239	Other psychoactive substance dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.24	Other psychoactive substance dependence with psychoactive substance-induced mood	Diagnosis	ICD-10-CM
F19.250	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.251	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.259	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.26	Other psychoactive substance dependence with psychoactive substance-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F19.27	Other psychoactive substance dependence with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.280	Other psychoactive substance dependence with psychoactive substance-induced anxiety	Diagnosis	ICD-10-CM
F19.281	Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.282	Other psychoactive substance dependence with psychoactive substance-induced sleep	Diagnosis	ICD-10-CM
F19.288	Other psychoactive substance dependence with other psychoactive substance-induced	Diagnosis	ICD-10-CM
F19.29	Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.90	Other psychoactive substance use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F19.920	Other psychoactive substance use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.921	Other psychoactive substance use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F19.922	Other psychoactive substance use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.929	Other psychoactive substance use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.930	Other psychoactive substance use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.931	Other psychoactive substance use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F19.932	Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.939	Other psychoactive substance use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.94	Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F19.950	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.951	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.959	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.96	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F19.97	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.980	Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.981	Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.982	Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.988	Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.99	Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ41ZZZ	Group Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
HZ42ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ43ZZZ	Group Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ44ZZZ	Group Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ45ZZZ	Group Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ46ZZZ	Group Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ47ZZZ	Group Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ48ZZZ	Group Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ49ZZZ	Group Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ4BZZZ	Group Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ50ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ51ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ52ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ53ZZZ	Individual Psychotherapy for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ54ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ55ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interactive	Procedure	ICD-10-PCS
HZ56ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ57ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ58ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ59ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Supportive	Procedure	ICD-10-PCS
HZ5BZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoanalysis	Procedure	ICD-10-PCS
HZ5CZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychodynamic	Procedure	ICD-10-PCS
HZ5DZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychophysiological	Procedure	ICD-10-PCS
HZ63ZZZ	Family Counseling for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ83ZZZ	Medication Management for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ86ZZZ	Medication Management for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ88ZZZ	Medication Management for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ89ZZZ	Medication Management for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ98ZZZ	Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ99ZZZ	Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
O35.5XX0	Maternal care for (suspected) damage to fetus by drugs, not applicable or unspecified	Diagnosis	ICD-10-CM
O35.5XX1	Maternal care for (suspected) damage to fetus by drugs, fetus 1	Diagnosis	ICD-10-CM
O35.5XX2	Maternal care for (suspected) damage to fetus by drugs, fetus 2	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
O35.5XX3	Maternal care for (suspected) damage to fetus by drugs, fetus 3	Diagnosis	ICD-10-CM
O35.5XX4	Maternal care for (suspected) damage to fetus by drugs, fetus 4	Diagnosis	ICD-10-CM
O35.5XX5	Maternal care for (suspected) damage to fetus by drugs, fetus 5	Diagnosis	ICD-10-CM
O35.5XX9	Maternal care for (suspected) damage to fetus by drugs, other fetus	Diagnosis	ICD-10-CM
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.0X3A	Poisoning by opium, assault, initial encounter	Diagnosis	ICD-10-CM
T40.0X4A	Poisoning by opium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.0X5A	Adverse effect of opium, initial encounter	Diagnosis	ICD-10-CM
T40.0X5S	Adverse effect of opium, sequela	Diagnosis	ICD-10-CM
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X3A	Poisoning by heroin, assault, initial encounter	Diagnosis	ICD-10-CM
T40.1X4A	Poisoning by heroin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X3A	Poisoning by other opioids, assault, initial encounter	Diagnosis	ICD-10-CM
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.3X3A	Poisoning by methadone, assault, initial encounter	Diagnosis	ICD-10-CM
T40.3X4A	Poisoning by methadone, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X5A	Adverse effect of methadone, initial encounter	Diagnosis	ICD-10-CM
T40.3X5S	Adverse effect of methadone, sequela	Diagnosis	ICD-10-CM
T40.411A	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.412A	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.413A	Poisoning by fentanyl or fentanyl analogs, assault, initial encounter	Diagnosis	ICD-10-CM
T40.414A	Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.415A	Adverse effect of fentanyl or fentanyl analogs, initial encounter	Diagnosis	ICD-10-CM
T40.421A	Poisoning by tramadol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.423A	Poisoning by tramadol, assault, initial encounter	Diagnosis	ICD-10-CM
T40.424A	Poisoning by tramadol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.425A	Adverse effect of tramadol, initial encounter	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
T40.491A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.492A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.493A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.494A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.495A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.693A	Poisoning by other narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.694A	Poisoning by other narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.711A	Poisoning by cannabis, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.721A	Poisoning by synthetic cannabinoids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.7X1A	Poisoning by cannabis (derivatives), accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.8X1A	Poisoning by lysergide [LSD], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.901A	Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.991A	Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial	Diagnosis	ICD-10-CM
Z71.51	Drug abuse counseling and surveillance of drug abuser	Diagnosis	ICD-10-CM
Obesity (diagnosis/procedure)			
0D16079	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160J9	Bypass Stomach to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JA	Bypass Stomach to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JB	Bypass Stomach to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
0D160K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160Z9	Bypass Stomach to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D160ZA	Bypass Stomach to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D160ZB	Bypass Stomach to Ileum, Open Approach	Procedure	ICD-10-PCS
0D160ZL	Bypass Stomach to Transverse Colon, Open Approach	Procedure	ICD-10-PCS
0D16479	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0D1647L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164J9	Bypass Stomach to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JA	Bypass Stomach to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JB	Bypass Stomach to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164Z9	Bypass Stomach to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZA	Bypass Stomach to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZB	Bypass Stomach to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZL	Bypass Stomach to Transverse Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D16879	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0D1687A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168J9	Bypass Stomach to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JA	Bypass Stomach to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0D168JB	Bypass Stomach to Ileum with Synthetic Substitute, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0D168JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168Z9	Bypass Stomach to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZA	Bypass Stomach to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZB	Bypass Stomach to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZL	Bypass Stomach to Transverse Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D19079	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JB	Bypass Duodenum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190Z9	Bypass Duodenum to Duodenum, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
0D190ZA	Bypass Duodenum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D190ZB	Bypass Duodenum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D19479	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0D194JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JB	Bypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194Z9	Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZA	Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZB	Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D19879	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JB	Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0D198K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
0D198KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198Z9	Bypass Duodenum to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZA	Bypass Duodenum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZB	Bypass Duodenum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A07A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A07B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JB	Bypass Jejunum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0ZA	Bypass Jejunum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D1A0ZB	Bypass Jejunum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1A47A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A47B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0D1A4JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JB	Bypass Jejunum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZA	Bypass Jejunum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZB	Bypass Jejunum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A87A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A87B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0D1A8JB	Bypass Jejunum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0D1A8KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
0D1A8KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZA	Bypass Jejunum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZB	Bypass Jejunum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZH	Bypass Jejunum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B07B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0JB	Bypass Ileum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0ZB	Bypass Ileum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1B47B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4JB	Bypass Ileum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic	Procedure	ICD-10-PCS
0D1B4ZB	Bypass Ileum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B87B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8JB	Bypass Ileum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZB	Bypass Ileum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZH	Bypass Ileum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DB60Z3	Excision of Stomach, Open Approach, Vertical	Procedure	ICD-10-PCS
0DB60ZZ	Excision of Stomach, Open Approach	Procedure	ICD-10-PCS
0DB63Z3	Excision of Stomach, Percutaneous Approach, Vertical	Procedure	ICD-10-PCS
0DB63ZZ	Excision of Stomach, Percutaneous Approach	Procedure	ICD-10-PCS
0DB67Z3	Excision of Stomach, Via Natural or Artificial Opening, Vertical	Procedure	ICD-10-PCS
0DB67ZZ	Excision of Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB68Z3	Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Vertical	Procedure	ICD-10-PCS
0DB80ZZ	Excision of Small Intestine, Open Approach	Procedure	ICD-10-PCS
0DB90ZZ	Excision of Duodenum, Open Approach	Procedure	ICD-10-PCS
0DBB0ZZ	Excision of Ileum, Open Approach	Procedure	ICD-10-PCS
0DQ64ZZ	Repair Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DV64CZ	Restriction of Stomach with Extraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0F190Z3	Bypass Common Bile Duct to Duodenum, Open Approach	Procedure	ICD-10-PCS
0TRB07Z	Replacement of Bladder with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)	Procedure	CPT-4
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption	Procedure	CPT-4
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)	Procedure	CPT-4
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty	Procedure	CPT-4
43843	Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty	Procedure	CPT-4
43845	Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)	Procedure	CPT-4
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy	Procedure	CPT-4
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption	Procedure	CPT-4
E66.01	Morbid (severe) obesity due to excess calories	Diagnosis	ICD-10-CM
E66.09	Other obesity due to excess calories	Diagnosis	ICD-10-CM
E66.1	Drug-induced obesity	Diagnosis	ICD-10-CM
E66.2	Morbid (severe) obesity with alveolar hypoventilation	Diagnosis	ICD-10-CM
E66.8	Other obesity	Diagnosis	ICD-10-CM
E66.9	Obesity, unspecified	Diagnosis	ICD-10-CM
K95.01	Infection due to gastric band procedure	Diagnosis	ICD-10-CM
K95.09	Other complications of gastric band procedure	Diagnosis	ICD-10-CM
K95.81	Infection due to other bariatric procedure	Diagnosis	ICD-10-CM
K95.89	Other complications of other bariatric procedure	Diagnosis	ICD-10-CM
O99.210	Obesity complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.211	Obesity complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.212	Obesity complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.213	Obesity complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.214	Obesity complicating childbirth	Diagnosis	ICD-10-CM
O99.215	Obesity complicating the puerperium	Diagnosis	ICD-10-CM
O99.840	Bariatric surgery status complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
O99.841	Bariatric surgery status complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.842	Bariatric surgery status complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.843	Bariatric surgery status complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
O99.845	Bariatric surgery status complicating the puerperium	Diagnosis	ICD-10-CM
Z68.30	Body mass index (BMI) 30.0-30.9, adult	Diagnosis	ICD-10-CM
Z68.31	Body mass index (BMI) 31.0-31.9, adult	Diagnosis	ICD-10-CM
Z68.32	Body mass index (BMI) 32.0-32.9, adult	Diagnosis	ICD-10-CM
Z68.33	Body mass index (BMI) 33.0-33.9, adult	Diagnosis	ICD-10-CM
Z68.34	Body mass index (BMI) 34.0-34.9, adult	Diagnosis	ICD-10-CM
Z68.35	Body mass index (BMI) 35.0-35.9, adult	Diagnosis	ICD-10-CM
Z68.36	Body mass index (BMI) 36.0-36.9, adult	Diagnosis	ICD-10-CM
Z68.37	Body mass index (BMI) 37.0-37.9, adult	Diagnosis	ICD-10-CM
Z68.38	Body mass index (BMI) 38.0-38.9, adult	Diagnosis	ICD-10-CM
Z68.39	Body mass index (BMI) 39.0-39.9, adult	Diagnosis	ICD-10-CM
Z68.41	Body mass index (BMI) 40.0-44.9, adult	Diagnosis	ICD-10-CM
Z68.42	Body mass index (BMI) 45.0-49.9, adult	Diagnosis	ICD-10-CM
Z68.43	Body mass index (BMI) 50-59.9, adult	Diagnosis	ICD-10-CM
Z68.44	Body mass index (BMI) 60.0-69.9, adult	Diagnosis	ICD-10-CM
Z68.45	Body mass index (BMI) 70 or greater, adult	Diagnosis	ICD-10-CM
Overweight			
E66.3	Overweight	Diagnosis	ICD-10-CM
Z68.25	Body mass index (BMI) 25.0-25.9, adult	Diagnosis	ICD-10-CM
Z68.26	Body mass index (BMI) 26.0-26.9, adult	Diagnosis	ICD-10-CM
Z68.27	Body mass index (BMI) 27.0-27.9, adult	Diagnosis	ICD-10-CM
Z68.28	Body mass index (BMI) 28.0-28.9, adult	Diagnosis	ICD-10-CM
Z68.29	Body mass index (BMI) 29.0-29.9, adult	Diagnosis	ICD-10-CM
Smoking (diagnosis/procedure)			
1034F	Current tobacco smoker (CAD, CAP, COPD, PV) (DM)	Procedure	CPT-2
4001F	Tobacco use cessation intervention, pharmacologic therapy (COPD, CAD, CAP, PV, Asthma) (DM) (PV)	Procedure	CPT-2
4004F	Patient screened for tobacco use and received tobacco cessation intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user (PV, CAD)	Procedure	CPT-2

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
99406	Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes	Procedure	CPT-4
99407	Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes	Procedure	CPT-4
F17.200	Nicotine dependence, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F17.201	Nicotine dependence, unspecified, in remission	Diagnosis	ICD-10-CM
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.210	Nicotine dependence, cigarettes, uncomplicated	Diagnosis	ICD-10-CM
F17.211	Nicotine dependence, cigarettes, in remission	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.290	Nicotine dependence, other tobacco product, uncomplicated	Diagnosis	ICD-10-CM
F17.291	Nicotine dependence, other tobacco product, in remission	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
G0436	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes	Procedure	HCPCS
G0437	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes	Procedure	HCPCS
G9016	Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only]	Procedure	HCPCS
G9276	Documentation that patient is a current tobacco user	Procedure	HCPCS
G9458	Patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, counseling on the benefits of quitting smoking or tobacco use, assistance with or referral to external smoking or tobacco cessation support programs, or current enrollment in smoking or tobacco use cessation program) if identified as a tobacco user	Procedure	HCPCS
O99.330	Smoking (tobacco) complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
O99.331	Smoking (tobacco) complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.332	Smoking (tobacco) complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.333	Smoking (tobacco) complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.334	Smoking (tobacco) complicating childbirth	Diagnosis	ICD-10-CM
O99.335	Smoking (tobacco) complicating the puerperium	Diagnosis	ICD-10-CM
S4995	Smoking cessation gum	Procedure	HCPCS
S9075	Smoking cessation treatment	Procedure	HCPCS
S9453	Smoking cessation classes, nonphysician provider, per session	Procedure	HCPCS
T65.221A	Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.223A	Toxic effect of tobacco cigarettes, assault, initial encounter	Diagnosis	ICD-10-CM
T65.224A	Toxic effect of tobacco cigarettes, undetermined, initial encounter	Diagnosis	ICD-10-CM
Z71.6	Tobacco abuse counseling	Diagnosis	ICD-10-CM
Alcohol Abuse or Dependence			
F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.11	Alcohol abuse, in remission	Diagnosis	ICD-10-CM
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.130	Alcohol abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.131	Alcohol abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F10.132	Alcohol abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.139	Alcohol abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.21	Alcohol dependence, in remission	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.930	Alcohol use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.931	Alcohol use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F10.932	Alcohol use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.939	Alcohol use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
R78.0	Finding of alcohol in blood	Diagnosis	ICD-10-CM
Z65.8	Other specified problems related to psychosocial circumstances	Diagnosis	ICD-10-CM
Z71.41	Alcohol abuse counseling and surveillance of alcoholic	Diagnosis	ICD-10-CM
History of Cardiac Arrest			
Z86.74	Personal history of sudden cardiac arrest	Diagnosis	ICD-10-CM
History of Coronary Angioplasty or Bypass			
Z95.1	Presence of aortocoronary bypass graft	Diagnosis	ICD-10-CM
Z95.5	Presence of coronary angioplasty implant and graft	Diagnosis	ICD-10-CM
Z98.61	Coronary angioplasty status	Diagnosis	ICD-10-CM

Appendix E. List of Non-Proprietary and Proprietary Names of Medical Products Used to Define Baseline Characteristics in this Request

Non-Proprietary Name	Proprietary Name
Obesity	
amino acids/multivit-minerals/dietary supplement/protein	Optifast 70
benzphetamine HCl	benzphetamine
diethylpropion HCl	diethylpropion
diethylpropion HCl	diethylpropion HCl (bulk)
liraglutide	Saxenda
liraglutide	Victoza 2-Pak
liraglutide	Victoza 3-Pak
lorcaserin HCl	Belviq
lorcaserin HCl	Belviq XR
naltrexone HCl/bupropion HCl	Contrave
orlistat	Alli
orlistat	Xenical
phendimetrazine tartrate	phendimetrazine tartrate
phentermine HCl	Adipex-P
phentermine HCl	Lomaira
phentermine HCl	phentermine
phentermine HCl	phentermine HCl (bulk)
phentermine HCl/topiramate	Qsymia
resveratrol/chromium pico/green	Resveratrol Diet
Smoking	
nicotine	Nicoderm CQ
nicotine	Nicotrol
nicotine	Nicotrol NS
nicotine	nicotine
nicotine bitartrate	Nicotine Tartrate
nicotine polacrilex	Nicorette
nicotine polacrilex	Quit 2
nicotine polacrilex	Quit 4
nicotine polacrilex	Stop Smoking Aid
nicotine polacrilex	nicotine (polacrilex)
nicotine polacrilex	nicotine polacrilex (bulk)
varenicline tartrate	Chantix
varenicline tartrate	Chantix Continuing Month Box
varenicline tartrate	Chantix Starting Month Box
varenicline tartrate	Tyrvaya
varenicline tartrate	varenicline

Appendix F. Specifications Defining Parameters for this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool, version 12.1.2, to assess utilization and uptake of the 2021, part 2 (Approved July 2021 - December 2021) New Molecular Entities (NMEs) to inform FDA in the Sentinel Distributed Database (SDD).

Query year: 01/01/2021 - Most recent available data
Coverage requirement: Medical and Drug Coverage
Pre-index enrollment requirement: 183 days
Post-index requirement: 0 days
Enrollment gap: 45 days
Age groups: 0-17, 18-24, 25-40, 41-64, 65+ years
Stratifications: Age group, Sex, Calendar Month
Restrictions: Male and Female
Distribution of index-defining codes: No
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Freeze data: No

Exposure

Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout year	Exclude evidence of days supply if exposure washout includes dispensing	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
1	Finerenone	Include all valid exposure episodes during query year; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters for this Request										
Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout year	Exclude evidence of days supply if exposure washout includes dispensing	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
2	Fexinidazole	Include all valid exposure episodes during query year; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
3	Belumosudil	Include all valid exposure episodes during query year; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
4	Odevixibat	Include all valid exposure episodes during query year; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
5	Anifrolumab-Fnia	Include all valid exposure episodes during query year; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters for this Request										
Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout year	Exclude evidence of days supply if exposure washout includes dispensing	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
6	Avalglucosidase Alfa-Ngpt	Include all valid exposure episodes during query year; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
7	Belzutifan	Include all valid exposure episodes during query year; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
8	Difelikefalin	Include all valid exposure episodes during query year; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
9	Lonapegsomatro pin-Tcgd	Include all valid exposure episodes during query year; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters for this Request										
Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout year	Exclude evidence of days supply if exposure washout includes dispensing	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
10	Mobocertinib	Include all valid exposure episodes during query year; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
11	Tisotumab Vedotin-Tftv	Include all valid exposure episodes during query year; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
12	Atogepant	Include all valid exposure episodes during query year; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
13	Maralixibat	Include all valid exposure episodes during query year; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters for this Request										
Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout year	Exclude evidence of days supply if exposure washout includes dispensing	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
14	Avacopan	Include all valid exposure episodes during query year; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
15	Asciminib	Include all valid exposure episodes during query year; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
16	Ropeginterferon Alfa-2b-Njft	Include all valid exposure episodes during query year; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
17	Vosoritide	Include all valid exposure episodes during query year; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters for this Request										
Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout year	Exclude evidence of days supply if exposure washout includes dispensing	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
18	Maribavir	Include all valid exposure episodes during query year; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
19	Pafolacianine	Include all valid exposure episodes during query year; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
20	Tezepelumab-Ekko	Include all valid exposure episodes during query year; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
21	Efgartigimod Alfa-Fcab	Include all valid exposure episodes during query year; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Specifications Defining Parameters for this Request

Scenario	Index Exposure/ Event	Cohort definition	Incident exposure washout year	Exclude evidence of days supply if exposure washout includes dispensing	Treatment episode gap	Treatment episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:
22	Inclisiran	Include all valid exposure episodes during query year; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
23	Tralokinumab-Ldrm	Include all valid exposure episodes during query year; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A	0 days	0 days	Any care setting	Any	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

ICD-9, ICD-10, HCPCS, and CPT codes are provided by Optum360.
 NDC codes are checked against First Data Bank's FDB MedKnowledge®.
 N/A: Not Applicable

Appendix G. Specifications Defining Parameters for Baseline Characteristics in this Request

Baseline Characteristic	Characteristic Number	Care setting/ Principal diagnosis ¹	Evaluation year start	Evaluation year end	Exclude evidence of days supply if characteristic includes dispensing	Number of instances the characteristic should be found in evaluation year	Forced supply to attach to dispensing
<i>Chronic Conditions Data Warehouse</i>							
Acute Myocardial Infarction (AMI)	1	IPP, IPS	-183	-1	n/a	1	N/A
Alzheimer's Disease and related conditions	2	Any	-183	-1	n/a	1	N/A
Atrial Fibrillation	3	IPP, IPS	-183	-1	n/a	1	N/A
	4	AV*, ED*, OA*	-183	-1	n/a	2	N/A
	5	IPP, IPS OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
Diabetes	6	IP*, IS*	-183	-1	n/a	1	N/A
	7	AV*, ED*, OA*	-183	-1	n/a	2	N/A
	8	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
Heart Failure	9	IP*, AV*, ED*, OA*	-183	-1	n/a	1	N/A
Hyperlipidemia	10	IP*, IS*	-183	-1	n/a	1	N/A
	11	AV*, ED*, OA*	-183	-1	n/a	2	N/A
	12	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A

Appendix G. Specifications Defining Parameters for Baseline Characteristics in this Request

Baseline Characteristic	Characteristic Number	Care setting/ Principal diagnosis ¹	Evaluation year start	Evaluation year end	Exclude evidence of days supply if characteristic includes dispensing	Number of instances the characteristic should be found in evaluation year	Forced supply to attach to dispensing
Hypertension	13	IP*, IS*	-183	-1	n/a	1	N/A
	14	AV*, ED*, OA*	-183	-1	n/a	2	N/A
	15	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
Depression	16	Any	-183	-1	n/a	1	N/A
Ischemic Heart Disease	17	Any	-183	-1	n/a	1	N/A
Rheumatoid Arthritis/Osteoarthritis	18	Any	-183	-1	n/a	2	N/A
Stroke/Transient Ischemic Attack (TIA)	19	IP*	-183	-1	n/a	1	N/A
	20	AV*, ED*, OA*	-183	-1	n/a	2	N/A
	21	IP* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
Breast Cancer	22	IP*, IS*	-183	-1	n/a	1	N/A
	23	AV*, ED* OA*	-183	-1	n/a	2	N/A
	24	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A

Appendix G. Specifications Defining Parameters for Baseline Characteristics in this Request

Baseline Characteristic	Characteristic Number	Care setting/ Principal diagnosis ¹	Evaluation year start	Evaluation year end	Exclude evidence of days supply if characteristic includes dispensing	Number of instances the characteristic should be found in evaluation year	Forced supply to attach to dispensing
Colorectal Cancer	25	IP*, IS*	-183	-1	n/a	1	N/A
	26	AV*, ED* OA*	-183	-1	n/a	2	N/A
	27	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
Prostate Cancer	28	IP*, IS*	-183	-1	n/a	1	N/A
	29	AV*, ED* OA*	-183	-1	n/a	2	N/A
	30	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
Lung Cancer	31	IP*, IS*	-183	-1	n/a	1	N/A
	32	AV*, ED* OA*	-183	-1	n/a	2	N/A
	33	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
Endometrial Cancer	34	IP*, IS*	-183	-1	n/a	1	N/A
	35	AV*, ED* OA*	-183	-1	n/a	2	N/A
	36	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A

Appendix G. Specifications Defining Parameters for Baseline Characteristics in this Request

Baseline Characteristic	Characteristic Number	Care setting/ Principal diagnosis ¹	Evaluation year start	Evaluation year end	Exclude evidence of days supply if characteristic includes dispensing	Number of instances the characteristic should be found in evaluation year	Forced supply to attach to dispensing
Acquired Hypothyroidism	37	IP*, IS*	-183	-1	n/a	1	N/A
	38	AV*, ED* OA*	-183	-1	n/a	2	N/A
	39	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
Anemia	40	Any	-183	-1	n/a	1	N/A
Asthma	41	IP*, IS*	-183	-1	n/a	1	N/A
	42	AV*, ED* OA*	-183	-1	n/a	2	N/A
	43	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
Benign Prostatic Hyperplasia	44	IP*, IS*	-183	-1	n/a	1	N/A
	45	AV*, ED* OA*	-183	-1	n/a	2	N/A
	46	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
Chronic Kidney Disease	47	IP*, IS*	-183	-1	n/a	1	N/A
	48	AV*, ED* OA*	-183	-1	n/a	2	N/A

Appendix G. Specifications Defining Parameters for Baseline Characteristics in this Request

Baseline Characteristic	Characteristic Number	Care setting/ Principal diagnosis ¹	Evaluation year start	Evaluation year end	Exclude evidence of days supply if characteristic includes dispensing	Number of instances the characteristic should be found in evaluation year	Forced supply to attach to dispensing
	49	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
COPD and Bronchiectasis	50	IP*, IS*	-183	-1	n/a	1	N/A
	51	AV*, ED* OA*	-183	-1	n/a	2	N/A
	52	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
Glaucoma	53	AV*, ED*, OA*	-183	-1	n/a	1	N/A
Osteoporosis	54	IP*, IS*	-183	-1	n/a	1	N/A
	55	AV*, ED* OA*	-183	-1	n/a	2	N/A
	56	IP*, IS* OR AV*, ED*, OA*	-183	-1	n/a	N/A	N/A
<i>Other</i>							
Obesity: diagnosed or identified by weight management procedures	57	Any	-183	-1	n/a	1	N/A
Obesity: identified by weight management-related prescriptions	58	Any	-183	-1	Evaluation year should search for evidence of days supply	1	N/A

Appendix G. Specifications Defining Parameters for Baseline Characteristics in this Request

Baseline Characteristic	Characteristic Number	Care setting/ Principal diagnosis ¹	Evaluation year start	Evaluation year end	Exclude evidence of days supply if characteristic includes dispensing	Number of instances the characteristic should be found in evaluation year	Forced supply to attach to dispensing
Overweight	59	Any	-183	-1	n/a	1	N/A
Smoking: diagnosed or identified by smoking cessation procedures	60	Any	-183	-1	n/a	1	N/A
Smoking: identified by smoking-related prescriptions	61	Any	-183	-1	Evaluation year should search for evidence of days supply	1	N/A
Alcohol Abuse or Dependence	62	Any	-183	-1	n/a	1	N/A
Drug Abuse or Dependence	63	Any	-183	-1	n/a	1	N/A
History of Cardiac Arrest	64	Any	-183	-1	n/a	1	N/A
History of Coronary Angioplasty or Bypass	65	Any	-183	-1	n/a	1	N/A

The wildcard symbol () can be used to represent 'any' values of either the care setting or principal discharge diagnosis flag. Wildcard does not restrict a specific principal diagnosis position. The principal discharge diagnosis flag is only relevant for diagnosis codes.

The (P) at the end of the care setting refers to the primary diagnosis position, while the (S) refers to the secondary diagnosis position. This indicates that only the first or second diagnosis on the claims should be used for specified codes. For example, IPP (Inpatient Primary) uses the first diagnosis position, and IPS (Inpatient Scodary) uses the second diagnosis position.

N/A: Not Applicable

¹Caresetting/ Principal Diagnosis

Appendix G. Specifications Defining Parameters for Baseline Characteristics in this Request

Baseline Characteristic	Characteristic Number	Care setting/ Principal diagnosis ¹	Evaluation year start	Evaluation year end	Exclude evidence of days supply if characteristic includes dispensing	Number of instances the characteristic should be found in evaluation year	Forced supply to attach to dispensing
-------------------------	-----------------------	--	-----------------------	---------------------	---	---	---------------------------------------

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.


Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.

Appendix H. Query Design Diagram for this Request



¹ Includes all valid exposure during the query period; only the first valid episode's incidence is assessed using the washout period.

² 23 scenarios defined on initiation of NMEs approved in 2021 part 2 (one scenario per NME); Cohort entry date = first dispensing date for qualifying NME.

³ Baseline characteristics:

Window I: Age, Sex, Year

Window II: Chronic conditions warehouse (CCW), alcohol abuse or dependence, drug abuse or dependence, history of cardiac arrest, history of coronary angioplasty or bypass, obesity, overweight, and smoking

⁴ Censoring: earliest of death, disenrollment, data partner data end date, query end date